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ABSTRACT
This thesis describes investigations towards the self-assembly of heterocyclic amino
acids to form cyclopeptides, including the natural products dendroamide A and
nostacyclamide.
The Introduction highlights a variety of different natural products including the
lissoclinum cyclopeptides and other oxazole and thiazole based natural products. The
conformation of the lissoc1inumcyclopeptides and the affect different substituents have
on their conformation is explored. The ability of a variety of natural products to chelate
metal ions and the evidence for metal ion chelation within the lissoclinum cyclopeptides
is also discussed. The Introduction is concluded with a statement of the aims and
objectives of our research.
The Results and Discussion section of the thesis details the development of a novel
cyc1ooligomerisation reaction of heterocyclic amino acids. This cyc1ooligomerisation is
applied to the self-assembly of thiazole and oxazole amino acids to form analogues of
naturally occurring cyc1opeptides. The protocol is then extended to the self-assembly
of the natural products dendroamide A and nostacyclamide. Additionally the ability of
metal ions to act as templates and promote the formation of particular products is
illustrated throughout these studies. Detailed discussions are also presented within this
section into the methods for thiazole and oxazole formation.
The third part of the thesis is the Experimental section containing full details of the
preparative work completed and listing spectroscopic and analytical data on all new
compounds synthesised during this study.
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INTRODUCTION
1.1 Marine and Terrestrial Secondary Metabolites
The marine environment is a treasury of fascinating and brightly coloured organisms
such as sea squirts, sponges, soft corals and molluscs (Figure 1). These organisms are a
source of a great wealth of novel and unusual secondary metabolites which exhibit a
unique molecular architecture. However, despite the apparent wealth of carbon in the
marine environment few organisms can exploit this source photosynthetically. It is not
then surprising that while marine organisms can produce these tremendously complex
organic extracts, each component is present in only trace quantities. A remarkable
preference for nitrogenous metabolites derived from amino acids is a characteristic
feature of natural products isolated from ascidians. The isolation and structural
elucidation of such compounds has only become relatively straightforward since the
advent of modern separation and spectroscopic techniques.
Not only do some of these compounds possess a magnificent molecular architecture but
they often exhibit a broad range of bioactivities, such as cytotoxicity, tumour
promotion, anticancer, antiviral, and anti-inflamatory activities. The immense challenge
associated with the total synthesis of such formidable targets, in addition to the problem
of isolating pure metabolites in suitable quantities to study their biological activity have,
together, long stimulated synthetic chemists. Indeed almost since the discovery of
aspirin, and its application in medical practice in the 18908, natural products have been
regarded as an excellent starting point in the search for lead compounds for drug
development. Arguably few discoveries of the twentieth century can claim higher
notoriety than that of penicillin 1 which was introduced as a drug during World War II
and saved countless lives. However, although Alexander Fleming! discovered penicillin
in 1928 from the secretion of the mold Pencillium notatum, its molecular structure which
contained the unique and strained fJ-Iactam ring was not confirmed until 1949 by
Dorothy Crowfoot Ho dg k in- by X-ray crystallography.
2
Figure 1 The marine environment displaying its rich source of fascinating organisms (top).
An example of a sea squirt from which so many cyclic peptides have been isolated (bottom).
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Eight years later Sheehan and Henery-Legan- completed the first ever total synthesis.
In complete contrast to penicillin, Taxol® 2, is a further celebrated natural product
which was isolated from the pacific yew tree, Taxus brevi/alia, and its structure
reported in 1971.4 Twenty one years later it was approved by the Food and Drug
Administration for the treatment of ovarian cancer.> and in 1994 two simultaneous
reports by Nicolaou'' and Holton? described two distinctly different total syntheses.
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In the marine environment one of the major chemical structural classes isolated from
ascidians are cyclopeptides. One of the most significant cyclopeptide metabolites
isolated is didemnin B 3 which was isolated from the Caribbean tunicate Trididemnum
solidum in 1981.8 Didernnin B was the first marine natural product to enter clinical
trials as a potential anticancer agent. It has also been reported to be extremely active as
an immunosuppressive agent, in addition to inhibiting herpes simplex virus types Iand
II and other lethal RNA viruses. The first total synthesis of didemnin B was reported
in 1987 by Rinehart et al.9
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Mollamide 4, which is a cyclic heptapeptide, was isolated in 1994 from the ascidian
Didemnum molle and shows cytotoxicity against a range of cell lines. It belongs to a
rare family of cyclic peptides where the structure has been modified by the inclusion of
a reverse prenyl unit associated as a serine ether residue.!? Another interesting member
of this family is the doubly prenylated compound, trunkamide A 5 isolated from the
ascidian Lissoclinum patella in 1996.11 A total synthesis of mollamide was reported in
1999 by McKeever and Pattenden.J? Pattenden and Wipf and their respective
colleagues then simultaneously synthesised trunkamide A 5 in 2000 with a revised
stereochemistry. 13
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Didemid ascidians, especially of the Lissoclinum species isolated from the Great Barrier
Reef, have been prolific sources of new classes of biologically active cyclopeptides.
The patellamides, lissoclinamides and patellazoles have all been isolated from
Lissoclinum patella and the bistratamides and bistratenes were isolated from
Lissoclinum bistratum. Their complex 18 to 24 membered hexa-, hepta-, and
octapeptide macrocycles are characterised by the presence of highly modified amino
acid residues: thiazoles, thiazolines, oxazoles, and oxazolines. Some of these
metabolites are potent cytotoxins, for example ulithiacyclamide 8 and lissoclinamide 7
(9g), while others such as the bistratenes cause human cells to differentiate.
5
1.2 The Lissoclinum Cyclopeptides
The most widely investigated tunicates are those of the genus Lissoclinum patella, the
metabolites of which differ with geographical location. The largest group of compounds
consists of a range of cyclic hepta- and octapeptides distinguished by the presence of
thiazole (or thiazoline) and oxazoline rings in the macrocyclic periphery.
The patellamides A-F (6a-f),14 ulithiacyclamide 8,15 and the Cy-symmetr!c
ascidiacyclamide 716 make up the group of cyclic octapeptides. The similarities within
the octapeptides are very marked; they all possess two oxazoline, and two thiazole
moieties which are alternatively linked to form the core macrocycle. Unlike the
patellamides, ulithiacyclamide 8 incorporates a disulfide bridge forming a strap across its
slightly convex surface which is thought to contribute to making it the most potent
cytotoxin in this group.!?
6a
6b
X RI Rz R3 R4
H (R)-Val (S)-Ile (R)-Val (S)-Ile
Me (R)-Ala (S)-Leu (R)-Phe (S)-I1e
Me (R)-Ala (S)-Val (R)-Phe (S)-I1e
Me (R)-Ala (S)-Ile (R)-Phe (S)-Ile
Me (R)-Val (S)-Val (R)-Phe (S)-Ile
Me (R)-Val (S)-Val (R)-Phe (R)-Val
Me (R)-Vat (S)-Ile (R)-Vat (S)-Ile
6c
7
6
The heptapeptides isolated from the aplousobranch ascidian Lissoclinurn patel/a lS
include lissoclinamides 1-8 (9a-h) and ulicyc1amide 10.16 They conform to a common
macrocycle disposition, which includes one oxazoline ring and two thiazole or thiazoline
derived amino acids.
RI R2 A B
9a (S)-Val (R)-lIe thiazole thiazoleV- RI
o ~~~
9b (R)-lIe (R)-Ala thiazoline thiazole
9c (R)-lIe (S)-Ala thiazoline thiazoleet N 0 9d (S)-Val (R)-Phe thiazoline thiazoleHN ge (S)-Val (R)-Phe thiazole thiazole
N~R2 9f (R)-Val (R)-Phe thiazoline thiazoleo)-~~s 9g Val (R)-Phe thiazoline thiazoline
9h Val (R)-Phe thiazoline thiazolePh
10 (S)-lIe (R)-Ala thiazole thiazole
The bistratamides A-D (11-13) are cyclic hexapeptides isolated from Lissoclinum
bistraturn in Australia, 19 and the Philippines,20 and are characterised by the presence of
one oxazoline or oxazole derived amino acid and two thiazoline or thiazole derived
amino acids.
11 (A = Thiazoline)
12 (A = Thiazole)
13
Another interesting hexapeptide is the Cj-symmetric cyclo-oxazoline westiellamide 17,
isolated from both an ascidian Lissoclinurn btstratuml) and a terrestrial blue-green algae
Westiellopsis prolijica.22 In addition to marine ascidians terrestrial freshwater and
marine cyanobacterial species have been shown to be prolific sources of secondary
metabolites including cyclic peptides and depsipeptides. More recently terrestrial blue-
7
green algae have provided several 'bistratamide type' cyclic hexapeptides. Thus,
dendroamides A-C e.g. dendroamide A 14 were isolated in 1996 from the
cyanobacterium, Stigonema dendroideum-l and raocyclamide A 15 and nostacyclamide
16 were obtained from the cyanobacterium Oscillatoria raoi25 and Nostoc sp.24
respectively.
aY
'r-=!-N~)0-:( H N.f
\"., NH HN a
N. J.
a Y""
S
14
aY
~N~)
~N H N.f
NH HN ao~r
a~
,..;----? ~ I)....
"r" N1
--r:~~
,.' a
",
16 17
Interestingly all of these natural products contain at least one unnatural D-amino acid
residue. Indeed all the amino acid residues in dendroamide A 14 are derived from D-
amino acids! This intriguing property of the lissoclinamide cyclopeptides prompts
chemists to ask why does nature incorporate these unnatural residues? Are they
incorporated early on in the biosynthesis, or does epimerisation take place late on in the
biosynthesis? These are some questions which will be explored later in this Thesis.
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1.3 Azole Containing Natural Products
Oxazole-containing natural products often possess significant biological activities,
including antifungal, cytotoxic, and tumour promoting properties. A large proportion of
these secondary metabolites incorporate isolated oxazole rings, e.g. phenoxan 19. More
recently interest has grown in natural products containing two or three contiguously
linked oxazoles. Of the vast array of oxazole containing natural products now isolated a
select number have stimulated particular interest due to their unique molecular
architecture and biological activity, and a few of these are highlighted below.
Calyculin A 18 was isolated from the marine sponge, Discodermi calyx in 1986.26
Calyculin A is a novel spiro-ketal with an unprecedented skeleton containing a 2, 4-
disubstituted oxazole moiety amongst a wide array of functionality which includes a
phosphate and cyanotetraene. Calyculin A has generated considerable interest owing to
its ability to inhibit protein phosphatases I and 2a, two of the four major protein-
serine/threonine phosphatases. The total synthesis of calyculin A has been reported by
the research groups of Evans,27Masamune, 28 and Smith.J?
OH OH OMe
18
One of the simplest oxazole containing natural products is phenoxan 19. Phenoxan was
isolated in 1991 from a soil micro-organism and was shown to exhibit anti-HfV
activity.w The structure of phenoxan is characterised by the pyran-4-one ring fused to
the oxazole in the 4-position, a structural feature analogous to the oxazole-pyran sub-
9
unit contained within the phorboxazoles (A and B) 20 and 21. To date there have been
two published syntheses of phenoxan 19.3 I
19
The phorboxazoles were isolated from the Indian Ocean marine sponge Phorbas sp. in
1995 by Molinski and Searle.I? Their gross structure is based upon a 21-membered
macrolactone ring and embodies three tetrahydropyran rings, four oxetane rings and two
2, 4-disubstituted oxazole rings. The phorboxazoles also possess exceptional biological
activity, exhibiting cytotoxic, cytostatic and antifungal properties. A total synthesis of
phorboxazole A was completed in 1998 by Forsyth et al.33 and then by Evans et al. in
2000.34
20 RI = H, R2 = OH
21 RI =OH, R2 = H
One of the first families of oxazole containing natural products to be characterised were
the group A virginiamycins family of antibiotics.J> The group A virginiamycins are all
based on a common 23-membered macrolactone core incorporating a variety of
functionality including a 2, 4-disubstituted oxazole, a 1, 3-diene, an acrylamide unit and
an amino acid residue. Both virginiamycin M222 and 14, 15-anhydropristinamycin lIB
10
23 act as cholecystokinin antagonist for treating panic and anxiety. 36 A total synthesis
of virginiamycin M2 22 was finally reported in 1996 by Schlessinger et ai. some 30
years after its isolation)? The total synthesis of madumycin II 24, by Meyers et al. ,38
and of the related antibiotic 14, 15-anpydropristinamycin lis 23, by Pattenden et al.,39
were reported simultaneously.
b N
b
N IH 0 H 0
111,. ","
0 0 0 0
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o~~ -r" °15A(_~
22 23
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H OH
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Natural products possessing two or three contiguously linked oxazole rings have also
been isolated. Hennoxazole A 25, a bis-oxazole containing natural product was isolated
from the marine sponge Poiyfibrospongia sp.40 and is highly active against the herpes
simplex virus. The diverse structure of hennoxazole A 25 incorporates a 2, 4-
disubstituted bis-oxazole, a pyranoid glycoside and an unusual skipped triene unit.
Wipf et ai. reported the total synthesis of the unnatural enantiomer ofhennoxazole A 25
in 1995,41 and this was followed in 1999 by the total synthesis of hennoxazole A by
Williams et al..42
OH
("lOMe
M;tO-t'~~~N.,o '-0
25
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Muscoride A 26 is another novel bis-oxazole based peptidic alkaloid isolated from the
freshwater cyanobacterium Nostoc muscarum in 1995.43 It has weak antibacterial
activity and is related structurally to hennoxazole A 25. The bis-oxazole core of
muscoride A 26 is formally derived from two threonine residues, which is rather
remarkable since even isolated oxazoles derived from threonine are rare. The total
synthesis of muscoride A 26 was reported by Wipf et al. in 1996,44 and in 1998 by
Pattenden et al.45
A family of marine metabolites known as the ulapualides which include the
halichondramides,46 the kabiramides+? and the mycalolides+f have structures based on
three contiguously linked 2, 4-disubstituted oxazole rings. The ulapualides were first
isolated from the egg masses of the nudibranch Hexabranchus sanguineus and some
members of the family possess an interesting biological profile including antifungal, anti-
leukaemic and ichthyotoxic activity.t? A total synthesis of ulapualide A 27 was
completed by Chattopadhyay and Pattenden in 1998.50 However, the isolation of the
halishigamides in which one oxazole ring of the tris-oxazole backbone is incomplete, e.g.
halishigamide D 28, has stimulated much speculation about the possible biosynthesis of
these compounds. It would be quite reasonable to suggest that oxazole formation may
take place late on in the biosynthesis, maybe even as the last step. This postulation
paved the way for a new synthetic approach to ulapualide A in which the middle
oxazole of the tris-oxazole backbone is formed during the last step in the synthesis. 51
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Similarly interesting compounds possessing contiguously linked sulfur containing azoles
have also been isolated. The mirabazoles are a unique family of thiazole/thiazoline
based cytotoxic alkaloids isolated from the blue-green algae Scytonema mirabile.52 Their
structures, including didehydromirabazole A 29 together with the related tantazoles,
(e.g. thiangazole 30, isolated in 1992 from the bacterium Polyangium sp. )53 have
aroused considerable interest amongst synthetic chemists as a result of their novel
biological properties. Total syntheses of didehydromirabazole and thiangazole were
completed by Pattenden et al. in 199454 and 199555 respectively. In addition Ehrler
and Farooq56 reported a total synthesis of thiangazole 30 in 1994 utilising Heathcock's
TiCl4 protocol for the cyclodehydration of a series of cysteine amides.S? Within the
same year Heathcock and Parsons reported the total synthesis of thiangazole,58 and just
a year later Wipf and Venkatraman completed a total synthesis. 59
13
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1.4 Conformations of Cyclopeptides
Several aspects of the diverse structure and properties of marine metabolites render
them particularly interesting to synthetic and medicinal chemists alike. While their
varied and intriguing architecture initially attracts the synthetic chemist, questions
relating to their conformation, biological activity and possible metal ion chelation
attracts the medicinal chemist. The structural variety of oxazole and thiazole containing
alkaloids that have recently been isolated from both marine and terrestrial micro-
organisms is astounding. The key questions are: a) what is the relationship between
chemical structure and molecular conformation, and b) how is their biological activity
dependant on their conformation? Cyclic peptides exhibiting potent cytotoxic activity
share a common ring structure and it has long been postulated that this may be the key
feature in promoting their cytotoxic activity.
The formation of the macrocycle from the linear oligomer restricts Wlnformational
freedom of the polypeptide backbone with respect to the open chain, but as the cycle
increases in size additional constraints become necessary to control conformation.
Nature utilises a number of devices to restrict conformational freedom in peptides,
including disulfide bonds (ulithiacyclamide 8), H-bonds, salt bridges, and metal ions,
but the most common devices are molecular constraints. These constraints come in the
14
form of azole heterocycles namely oxazoles, oxazolines, thiazoles, and thiazolines.
Indeed, a study carried out by Fairlie et al.60 demonstrates the conformational control
induced by the formation of azole heterocycles. These authors studied the octapeptides
31 and 32. Comparison of NMR data for the cyclic peptide 31 containing no azole
heterocycles with that for the cyclic peptide 32 in which two thiazole rings are present
did indeed show a reduction in flexibility.
31
The increase in rigidity of the molecule by the introduction of the two thiazoles is
thought to induce clefts and unusual shapes within the molecule which may provide
sites for metal chelation and be a major factor contributing to the bioactivity of some
metabolites. In an attempt to further elucidate the relationship between chemical
structure, conformation and biological activity, Schmitz et al.61 analysed the
conformations of the cyclic hexapeptides; ascidiacyclamide 7, patellamide A 6a,
patellamide D 6d, and ulithiacyclamide 8.
15
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The molecular conformations of these cyclic hexapeptides were found to be closely
related to their chemical structures, and were found to be especially dependent on the
degree of asymmetry induced in the molecule by the side chains tethered to either half of
the C2-symmetric backbone. It was deduced that molecules possessing Crsymmetry
(e.g. ascidiacyclamide 7, and ulithiacyc1amide 8) adopted a 'type l' conformation
(Figure 2). Indeed a small deviation from the Crsymmetry as present in patellamide A
6a at the oxazoline methyl group was not sufficient to deform the conformation from
that of 'type 1'. However, the less subtle deviations from C2-symmetry in patellamide
B 6b, C 6c, and D 6d resulted in a twisted, figure of eight conformation as indicated by
'type 4', stabilised by four intra-molecular hydrogen bonds (Figure 2).
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Figure 2: Molecular Conformations of Cyclic Octapeptides
Ulithiacyclamide is locked conformationally by the disulfide linkage into a 'type I'
conformation, and as it is the most potent cytotoxic compound among the related
peptides the 'type I' conformation was proposed to exert the greatest biological
activity.
1.5 Biosynthesis of Cyclopeptides
The marine environment is relatively rich in carbon, buffered by carbonate and
bicarbonate to pH 8.2-8.5, but few organisms other than algae can exploit this carbon
source photosynthetically. Important building blocks such as amino acids and sugars
are available at only parts per billion levels, while nitrogen which is principally available
as the ammonium or nitrate ion is generally the limiting nutrient. It is not then
surprising that although the marine environment is rich in life forms the formidable
compounds it produces are formed very slowly and in only trace amounts. It has
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generally been assumed that the pathways involved in the formation of marine
metabolites do not differ substantially from those that have been established for
metabolites in terrestrial animals and plants. However, consideration of the variations in
terrestrial and marine metabolism uncovers some striking differences. For example,
halogens and isocyanide groups appear frequently as substituents in marine metabolites,
yet they are rarely observed in products of terrestrial metabolism.
The biosynthesis of the thiopeptide antibiotic thiostrepton 33 has been investigated by
administration of isotopically labelled precursors to cultures of Streptomyces azureus
and Streptomyces laurentii and the amino acid origin of all components of the antibiotic
were determined. The four thiazoles, as well as the thiazoline ring and their attached
carboxy groups, each arise from the condensation of a molecule of cysteine and the
carboxyl group of the adjacent amino acid.62 However, this study does not provide any
information about the order of assembly of the amino acids. This raises the question of
whether thiazole/oxazole based marine cyclopeptides in particular, the lissoclinum
cyclopeptides are formed by the assembly of preformed oxazole/thiazole based amino
acids residues or whether the heterocyclic rings are elaborated late on in the biosynthesis
following macrocyclisation to form the cyclopeptide core.
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A large number of cyclic peptides isolated from both marine and terrestrial organisms
exhibit quite an unusual, and as yet unexplainable trait where thiazole and
dihydrothiazole amino acids exist in both (L) and (D) forms with the latter
predominating. It is not clear whether differences such as these reflect the individuality
of the producer organism or are more fundamentally important, possibly of
evolutionary significance. Is this feature associated with some specific folding of a
peptide chain prior to macrocycle formation? The origin of optical activity is not clear.
Some reports have suggested that it may be related to the difference in catalytic activity
of (L)- and (D)-amino acids which permit the selection of optically active catalysts at
early stages in development. In a study, (L)-cysteine was oxidised with iron over a
wide range of pH values (6-11.5) in the presence of complexes of (D)- and (L )-alanine.
At pH 7 the catalytic activity of the (D)-alanine iron complex was seven times greater
than the (L)-alanine complex.v- Although it is only speculated that such processes
could be responsible for the unusual distribution of chirality in the marine environment
it raises the question yet again, do metals playa part in marine metabolism?
1.6 Metal Chelation of Natural Products
Metal ions are essential to the proper functioning of all living cells, and it is critical that
the minute amounts of ions required be delivered to the right compartments and that
they be present in the correct oxidation state and co-ordination geometry to carry out
selective functions. In fact each organism could be considered as a highly tuned multi-
metal, multi-ligand system capable of both controlling the amounts of each of these
elements delivered and distinguishing between them. All of these requirements can be
and are achieved by selective chelation. Indeed without chelation as a control any free
transition metal ions would bind indiscriminately to a range of biological molecules with
concomitant physiological disorders.
19
It is believed that chelation could have played a role in early protein nucleation and in
the development of stereoselectivity in biological molecules. Indeed evidence that
complex ligands were formed early on in the stages of biological evolution was found in
the discovery of metal-porphyrin complexes in the biolithosphere. Porphyrins are
widely found in nature as metal complexes; as magnesium complexes in the
chlorophylls, for example chlorophyl A 34; as cobalt complexes in the corrinoids, for
example vitamin B12 35, and in the haem groups of many iron proteins. Iron-porphyrin
proteins share a general structure 36 and differ from one another by the nature of the
pyrrole substituents.
34
NH2
PhytYl"
o
35
36
The seas and oceans contain substantial amounts of dissolved inorganic salts, common
metal cations such as sodium, potassium, magnesium, and calcium are present in
concentrations often in excess of 10-3 M, while important trace elements such as
vanadium, manganese. cobalt. copper. zinc and molybdenum often reach concentrations
as high as 10-6 M.64 It would be quite amazing if this wealth of metal ions was
20
insignificant in the modes of formation and origins of the marine metabolites. Indeed the
organisms that produce these metabolites concentrate metal ions, including copper to
10,000 times that found in the local marine environment. This provides further evidence
that these metabolites do sequester metals. Furthermore the ability of terrestrial
metabolites to act as ionophores provides a premise for the possible involvement of
metal ions in marine metabolism. Can marine metabolites sequester and transport metal
ions in vivo? Do metal ions provide a convenient template for biological assembly of
the metabolites? Could metal-ligand complexation playa part in the pronounced
biological activity of many of these compounds?
Many marine natural products have structural features which would make them ideal for
interacting with metals, for example the presence of macrocylic cavities and polar
functional groups in chelating positions with the potential for wrapping around metal
ions, however, as yet few examples exist in the literature. A novel boron containing
antibacterial metabolite was isolated from the cultured marine microorganism
Streptomyces griseus in which boron is encapsulated into the macrocyclic cavity as a
tetracoordinate borate 37.65 In addition a novel mixed polyketide-depsipeptide,
jasplakinolide isolated from a marine sponge was found to form a complex with
Iithium.v'' More recently Schmitz et al. isolated two zinc complexes derived from
isonamidine Band D 38 and 39, from a pacific sponge, Leucettasl
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The lissoclinum cyclopeptides have an almost symmetrical array of oxazolines,
oxazoles, thiazolines, and thiazoles which is reminiscent of ring-extended porphyrins
and aza-crown ethers, but the role of these cyclopeptides as ligands in metal ion
complexation and transport within their environment has not yet been fully elucidated.
The cyclic octapeptides posses a 24-aza-crown-8 structure which is ideally set up for
chelating a metal, but as yet only a handful of metal complexes have been isolated.
Fairlie et al. uncovered a number of copper complexes with the cyclic octapeptide,
patellamide D 6d. Patellamide D 6d was found to form multiple mononuclear
copper(II) complexes in which there are three ligating nitrogen atoms coordinated to the
copper(U) ion and the fourth binding site is occupied by a chloride ion, water or
carbonate. Three binuclear copper (II) complexes, [Cu2(pat.H2)]2+,[Cu2(pat.H2)(OH)]+
and [Cu2(Pat.H2)(C03)]40 were also isolated.sf
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Fairlie et al. also isolated blue crystals of a bis-copper(II) complex of ascidiacyc1amide 7
in which the copper ion is coordinated by three nitrogen donors, one each from an
oxazoline, a thiazole, and a deprotonated amide. A water molecule and the oxygen atom
of a bridging carbonate anion complete the coordination sphere 41.69 The formation of
three complexes of ascidiacyc1amide 7 with zinc have also been reported,70 along with a
novel potassium binding hydrolysis product of ascidiacyclamide."! In addition, work
within our own group has shown the ability of the patellamides, A, B and E 6a, b and e
to bind one or two copper or zinc ions.72
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Biological activity and metal binding properties are also said to be critically dependent
upon the presence of oxazoline rings which are shown to induce a boat shaped cleft ideal
for encapsulating a metal. A prime example of the ability of oxazoline containing natural
products to complex metals is the silver complex of the highly modified cyclic peptide,
westiellamide 17.22 Wipf et al. isolated a novel [Ag4(17)2J complex in which all N-H
bonds and the lone pairs of the oxazoline nitrogen atoms are directed towards the
interior of the I8-membered macrocycle.U This complexation induced drastic changes
in the geometry of the macrocycle with a previously 'flat' macrocycle being turned
'inside out.' The amide carbonyls rotated from pointing out of the ring to pointing
inwards and the oxazolines adopted a position orthogonal to the macrocycle. This
allowed the oxazoline nitrogen atoms and the amide carbonyl oxygen atoms to complex
to silver.
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Recent work by Jolliffe and Pattenden using analogues of naturally occurring cyclic
peptides 42 culminated in the isolation of a cyclic peptide sandwich in which five silver
atoms were bound between two cyclic peptide rings.74
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1.7 Aims and Objectives
Nature has delivered a plethora of structurally novel and unusual peptidic alkaloids.
One group of peptidic alkaloids, the lissoclinum cyclopeptides possess macrocyc1ic
structures accommodating thiazole and oxazole rings. Little is known about the order of
the assembly of the constituent amino acids to form these metabolites. Is the
macrocyclic core formed at an early stage in the biosynthesis and the heterocyclic rings
elaborated later on in vivo to form the cyclopeptide? or are these cyclopeptides formed
via the self-assembly of preformed oxazole/thiazole based amino acids residues?
These ring systems are clearly reminiscent of macrocyc1ic ligands such as aza-crown
ethers and extended porphyrins. There has therefore been much speculation about the
possible role of metal ions as convenient templates for the biological assembly of these
cyclopeptide metabolites.
The aim of this research is to attempt to find some answers to these questions:-
Are the lissoclinum cyclopeptides elaborated in vivo by the self-assembly of
preformed oxazole/thiazole based amino acid residues?
•
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• Could metal ions be used as templates to tailor the distribution of products
formed from a self-assembly reaction of azole heterocycles?
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RESULTS AND DISCUSSION
2.1 The Questions Inspired by Nature
Returning to the lissoclinum cyclic peptides, when considering the biosynthesis of these
types of compounds, two main pathways can be envisaged for their formation from
constituent amino acids:- Firstly the macrocyclic core could be formed early on in the
biosynthesis, via a series of peptide coupling reactions from the constituent amino
acids. The natural product could then be elaborated from the cyclic core via a series of
cyclodehydration reactions to form the heterocycles late on in the biosynthesis (route
1). Alternatively, the heterocyclic components of the cyclopeptide could be formed
early on in the biosynthesis. The heterocycles could then self-assemble, and, following
a series of peptide coupling reactions, form the macrocycle core, possibly as the final
step in the biosynthesis (route 2) (Scheme 1).
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There is another question which must be addressed. Thus, if the organisms that
produce these metabolites can concentrate metal ions to 10, 000 times that found in the
local marine environment, do these ions play a role in the formation of the cyclic
compounds? Could they provide a convenient template for the biological assembly of
these metabolites? Perhaps metal ions are responsible for bringing together heterocyclic
amino acids and holding them in the required conformation and proximity to one another
to facilitate macrocylisation (Figure 3). This is not such an outrageous idea, since the
cyclic octapeptides possess a 24-aza-crown-8 structure which is perfectly set up for
chelating a metal and examples of such complexes already exist in the literature icf
section 1.6, p 19-24).
Figure 3
At the outset of this project our goal was to tackle the question of how nature
constructs such heterocyclic-based cyclopeptides. To this end we decided to
investigate the self-assembly of thiazole and oxazole heterocycles to form analogues of
naturally occurring cyclopeptides.
2.2 Thiazole Ring Formation
Thiazolines and thiazoles are important building blocks in pharmaceutical agents and in
biologically active natural products. They are characteristic structural segments of
cyclopeptide alkaloids such as lissoclinamides, patellins and bistramides, as previously
described. The multitudinous synthetic stratagems employed by researchers to produce
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thiazolines and thiazoles can be divided into two main classes, i. e. condensation
reactions and cyclodehydration reactions.
2.2.1 Condensation Reactions
Condensation reactions leading to thiazoles can themselves be divided into two sub-
classes, i.e. [3+2] and [4+1] atom cyclisations. The Hantzsch reaction involves a [3+2]
atom cyclisation between a thioamide 44, and a a-halo-carbonyl compound 43, and this
is one of the most direct routes to thiazoles viz 45.
o
E'o~:f
Br
43 44 45
The reaction conditions reported by Pettit and Holzapfel'[> simply involve stirring the
thioamide and the bromopyruvate together at room temperature in a solvent, and lead to
amino acid thiazoles in excellent yields. However, these conditions do result in
complete racemisation of the amino-substituted chiral centre 47. Pettit suggested that
the racemisation took place at the intermediate thiazoline 46 stage, mediated by acidic
hydrobromic acid, a by-product of the reaction (Scbeme 2).
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Hemichart later published a synthesis of a number of thiazoles under very similar
condensation conditions i.e. stirring the thioamide and bromopyruvate together for two
days at room temperature.I'' He claimed that the production of homochiral thiazoles
was due to the improved procedure for the conversion of amides to thioamides using
Lawesson's reagent,"? but no optical rotations were published. Attempts by Schmidt et
al. to reproduce Hemichart's work met with failure_78 Schmidt decided to limit the
exposure time of the thiazoline to the racemising effect of hydrobromic acid by adding
the dehydrating agent, trifluroacetic anhydride, in order to increase the rate of
conversion of the intermediate thiazoline to the thiazole. In addition, the reaction was
carried out at -10 QC. The combined effect of these modifications was the production of
thiazoles with enantiomeric excesses of up to 90 %. In 1986 Kelly et al. published
work in which calcium carbonate was used to mop up the unwanted hydrobromic
acid.Z? These two modifications were combined by Holzapfel et al. in work published
between 1990 and 1992 which forms the basis of the widely utilised modified Hantzsch
condensation for the formation of thiazoles.sv Sodium hydrogen carbonate or
potassium hydrogen carbonate is stirred in an aprotic solvent, such as DME, along with
the thioamide 44, and the solution is then treated with ethyl bromopyruvate. When the
reaction mixture contains significant amounts of thiazoline 46, trifluoroacetic anhydride
is added to produce the thiazole 45 (Scheme 3).
HO
NH2 Et02Ct N ii Et02C'!i-N
s~NHBOC ---- ~ .NHBoc -_ (s ~ "~NHBoc
RI H S.... X / X
44 46 RI H 4S RI H
Reagents: i, Et02CCOCH2Br, KHC03, DME, -10°C; ii, (CF3COhO, pyridine, DME,-lO°C.
Scheme 3
This method was successful in producing a wide range of optically pure thiazoles,
however, with some amino acids a small amount of racemisation was still observed.
Meyers et al., in 1994, reported that by using the same conditions at -15 QCrather than
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-10°C these problems could be eliminated.U This subsequently allowed Meyers to
complete a total synthesis of bistratamide C.82
Biosynthetic investigations on molecules containing the thiazole moiety, such as
nosiheptidets and thiostrepton.H show that they result from a condensation reaction
between the carboxyl of an amino acid 49 and cysteine 50.
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While procedures that furnish thiazoles in one pot from simple starting materials are
very valuable, thiazolines occur very frequently in nature; thus routes to form thiazoles
via thiazoline formation are equally valuable. Amino acids can be converted into imino
ethers, and these can then undergo condensation with cysteine to form a thiazoline. In
early experiments carried out by Hirotsu, Kaneka, and Shiba85 thiazolines were formed,
but only as racemic compounds. It wasn't for another twenty years when Pattenden
and North86 published the synthesis of a number of thiazoles via the imino ether route
that the procedure was finally adapted to the synthesis of optically pure compounds.
In this work, an imino ether 52 was formed by treating the corresponding amide 51 with
triethyloxonium hexafluorophosphate. A solution of the imino ether 52 and cysteine
methyl ester 53 in ethanol was then stirred at room temperature until thiazoline 54
formation was detected by tlc. The reaction mixture was then immediately worked up
to avoid any racemisation of the thiazoline (Scheme 4).
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Reagents: i, (EthOPF6, EtOH; ii, EtOH
Scheme 4
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Pattenden and Boyce later employed an imino ether to form one of the thiazoline units
in their total synthesis of didehydromirabazole 29.87 Thus, manipulation of the
tetrapeptide 55 to the imino ether 56 and subsequent condensation with cysteine
methyl ester installed the third azole heterocycle in 57. Repetition of this sequence,
followed by oxidation of the terminal thiazoline then gave didehydromirabazole 29
(Scheme 5).
1, 11
HN)-OEt
N~
-Is-t.s
55 56
Reagents: i, EtOH / aq.NH3; ii, Et30+PF6-, OeM.
Scheme 5
There are many methods available for the oxidation of thiazolines to thiazoles in the
literature, and a few of these will be highlighted later on in this Thesis.
A very similar [4+1] atom cyclisation is that involving amino nitriles 58 and cysteine
methyl ester 53. These reactions are carried out in alcoholic solutions in which an imino
ether is generated in situ (Scheme 6). This method has an advantage over the usual
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imino ether procedure as a common problem with imino ethers is their conversion into
methyl esters before they have chance to react with cysteine,
Me02yNH2
H '":--SH
53 58
Scheme 6
Pattenden and colleagues used these thiazoline forming conditions in the total synthesis
of the tris-thiazoline containing metabolite, thiangazole 30,88 Thus condensation of the
thiazoline 59 with cysteine methyl ester 53 in an alcoholic solution first yielded the bis-
thiazoline 60, which was then manipulated to the amino nitrile 61. Further
condensation with a cysteine residue attached to an oxazole led to the tris-thiazoline
oxazole backbone 62 which on treatment with methylamine followed by crystallisation
finally led to thiangazole 30 (Scheme 7),
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62 cR=OMe
30 R=NHMe
Reagents: i, Et3N, MeOH, A
Scheme 7
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Finally, thiazolidine containing amino acids, viz 64, can be obtained when cysteine
methyl ester 53 is condensed with an a-amino aldehyde 63. Oxidation of the
thiazolidine 64 with manganese dioxide then furnishes the corresponding thiazole
(Scheme 8).89
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2.2.2 Cyclodehydration Reactions
In general cyclodehydration reactions leading to thiazolines require the formation of a
dipeptide 67 from one amino acid possessing the desired chiral centre 65 and another
amino acid 66 containing a hydroxy moiety such as serine (R3=H) or threonine
(R3=CH3). The dipeptide 67a can then be manipulated to form a thioamide 67b, most
commonly using Lawesson's reagent, and all that is then required is activation of the
hydroxyl to promote a cyclodehydration to form the thiazoline 68 (Scheme 9).
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Some of the simplest reagents available for activating alcohols include tosyl chloride and
thionyl chloride. Over fifty years ago Attenburrow, Elliott, and Penny discovered that
tosyl chloride in the presence of triethylamine induced cyclodehydration of dipeptides
to form oxazolines.P'' Just a year later Elliott discovered the effectiveness of thionyl
chloride as a cyclodehydrating agent.''! In an attempt to pinpoint the cyclodehydration
method which produced thiazolines in the highest yield and with the least amount of
epimerisation, Wipf and Fritch investigated a number of alternative methods. However,
they found that upon subjecting an N-protected thiopeptide methyl ester 69 to either of
the conditions described above, a rather disappointing 40-50 % yield of racemic
thiazoline 70 and 71 was obtained (entries 1 and 2, Table 1). Thiazolines, oxazolines
and aziridines have also been formed from J3-hydroxy-a-amino acids92,93 using the
Mitsunobu conditions'[+ but side chain epimerisations have not been reported.
Cyclodehydrations under Mitsunobu conditions occur at low temperature, and thus,
when N-protected thiopeptide methyl ester 69 was exposed to triphenylphosphine and
diisopropylazodicarboxylate, a 4 : 1 ratio of 70 : 71 was formed in an overall 80 % yield
(entry 3, Table 1). Burgess' reagent (Me02CNS02NEt3)95 is nothing more than a
fancy equivalent to thionyl chloride but has an added advantage, not only does it
activate the hydroxyl but it also acts as an intramolecular base to facilitate the
cyclisation process. The use of Burgess' reagent'" to effect the cyclodehydration of
thiopeptides was found to be superior to other procedures, with the thiazolines being
produced in yields up to 96 %, in greater than 97: 3 ratio of70 : 71 (entry 4, Table 1).
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Entry Method Yield (%) Ratio 70:71
1 TsCI, Et3N, DCM, 42°C, 1h 40 1: 1
2 1. SOCI2, OoC, 2h; 2. Pyridine, THF, 0 °C, lSmin 49 1: 1
3 Ph3P, DIAD, DCM, -78°C to 22°C, 30min 80 78:22
4 Burgess' Reagent 96 >97:3
Table 1
Pattenden and Boden have utilised Burgess' reagent to effect a double cyclodehydration
of the cyclopeptide 72 to install both the oxazoline and thiazoline rings simultaneously
as the final step in their total synthesis oflissoclinamide 4 (9d) (Scheme 10).96
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Lellouche reported the use of DAST (diethylaminosulfur trifluoride) in 1995 as a
powerful hydroxyl activating agent towards 1, 2-thioamido alcohols.?? This reagent
induces a fast «lh) and stereoselective cyclisation at -78°C to afford the corresponding
2-thiazolines. Pattenden and Rutt found that DAST was highly efficient in producing
thiazolines with good retention of chirality. In particular, the phenylalanine derived
thiazoline 73 was formed in >99 % ee as shown by chiral HPLC.98
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Heathcock and Walker employed a different strategy to activate the hydroxyl to
cyclodehydration in their total synthesis of (-)-mirabazole C 76.57 The peptidic
backbone 74 was synthesised via a series of peptide coupling/deprotection steps, which
upon exposure to titanium tetrachloride in dichloromethane afforded the tetra-thiazoline
75 in a 63 % yield. The terminal thiazoline was oxidised using nickel peroxide in 60 %
yield to give (-)-mirabazole C 76 (Scheme 11).99
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Scheme 11
In total contrast to all the methods already described for the formation of thiazolines, it
is possible to directly convert an oxazoline into a thiazoline.l 00 The advantage of such a
transformation arises from the fact that oxazolines are synthetically more accessible
than the corresponding thiazolines. Thus, treatment of the oxazoline 77 with a
saturated solution of hydrogen sulfide in methanol at room temperature leads to the
formation of the thioamide 79, probably via reversible formation of the orthoamide
intermediate 78. Subsequent cyclodehydration of 79 with Burgess' reagent then
provides the thiazoline 80 in 89 % yield (Scheme 12).
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Scheme 12
2.2.3 Oxidations of Thiazollnes
The oxidation of thiazolines to thiazoles has been developed extensively over recent
years and most methods proceed either by a radical pathway or via an addition-
elimination sequence. In order to effect these transformations in good yield an
enolisable group at the 4-position in the thiazoline seems necessary. A few of the
methods available for the oxidation of oxazolines involve the use of copper(I) and
copper(II) salts. A modification of the Kharasch-Sosnovsky reaction, 101 by the
Meyers group 102 involves treatment of thiazolines with a cocktail of copper(II)
acetate, copper(I) bromide and tert-butyl hydroperoxide to give thiazoles in high
yields. More recently Williams et al. have developed a mild, addition-elimination
'oxidation' method using BrCCl3 and DBU. Thus, when a solution of the thiazoline
81 in dichloromethane is treated with DBU and BrCC13, at 0 °C for six hours, a 95
% yield of the thiazole 82 is obtained (Scheme 13).
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Comparisons to other oxidation techniques have shown that this procedure is
cleaner and higher yielding, and as a consequence this protocol is becoming
increasingly popular in organic synthesis.' 03 Jung et al. have developed a very
similar oxidation to Williams, using DBU, CCl4 in pyridine and acetonitrile.104
Oxidation of thiazolines to thiazoles can also be effected under radical conditions.
Meyers has shown the utility of Ni02 in oxidising both oxazolines and thiazolines
to the corresponding azole heterocycles in good yields.99 The mild and selective
nature of this oxidation is illustrated by the successful conversion of phleomycin
A2 83a to bleomycin A2 83b.105
83a CA=thiazoline
83b A=thiazole
Our goal was to explore the cyclooligomerisation reactions of thiazoles with side
chains of varying size, particularly those thiazoles found in natural products. We
decided that a good starting point was the thiazole 88a derived from (D)-alanine,
and that we would employ the modified Holzapfel-Hantzsch procedure in its
formation. Thus, exposure of Boc-(D)-alanine 84a to ammonia gas in the presence
of N-methylmorpholine and isobutylchloroformate first gave rise to the amide 85a,
which upon treatment with Lawesson's reagent afforded the thioamide 86a.
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Condensation of the thioamide 86a with ethyl bromopyruvate then smoothly led to
the thiazole 87a in a pleasing 71 % yield. Subsequent saponification of the thiazole
87a and Boc-deprotection finally gave the totally deprotected thiazole 88a in 71 %
yield over the two steps (Scheme 14).
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To our delight Moshers amide formation 90a106 from the free amine 89a and
subsequent analysis of the 19F NMR spectrum indicated that the acid 88a had an ee
~95 % (SF 71.64 «-)-Moshers amide), SF 72.12 «+)-Moshers amide) (Scheme
15).
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Having successfully synthesised the alanine derived thiazole 88a we then set about
the synthesis of the thiazole derived from phenylalanine i.e. 88b in the same manner
(Scheme 14). Once we had material in hand we performed a Boc-deprotection of
the protected thiazole 87b and prepared Moshers amides 90b from the free amine
89b (Scheme 15). To our surprise the synthetic phenylalanine derived thiazole
had an enantiomeric excess of only 60%. We were able to improve this marginally
to 70% by performing the condensation/dehydration steps at -20°C, but further
attempts at -78°C lead only to the recovery of starting material. However, not
wanting to loose sight of our aim, i.e. to attempt cyclooligomerisation reactions of
these thiazoles, we decided to proceed with the 70 % enantiomerically enriched
thiazole 88b.
2.3 Cyctooligomerisation Reactions
Preliminary experiments were performed in our laboratories by Jeffrey Hannam,
using the thiazole 91 derived from (D)-valine. Cyclooligomerisation reactions were
attempted using a number of peptide coupling reagents (Table 2), of which
pentafluorophenyl diphenylphosphinate (FDPP) was found to give consistently
high yields (80-90 %) of cyclic products. The optimum concentration for the
cyclooligomerisation of the valine thiazole was found to be in the range 10-50 mM
(Table 2),107 and under these conditions two major products were isolated, i.e. the
cyclic trimer 42 and the cyclic tetramer 92, in a 5 : 2 ratio (Scheme 16). The X-ray
structure of 42 indicated that it is Cj-symmetric with a rigid structure in which all
the amide protons are directed towards the centre of the macrocycle and with all of
the valine side chains lying on the same face, adopting axial positions.
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Coupling Reagent Concentration Yield Of Cyclic
Products
DPPAa 0.05 M 47%
DPPClb 0.05 M 55%
EDCc 0.05 M 43%
FDPpd 0.5M 60%
FDPP 0.1 M 62%
FDPP 0.05 M 91 %
FDPP 0.01 M 93%
FDPP 0.005 M 60%
a) diphenyl phosphoraziridate; b) diphenylphosphinyl
chloride; c) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride; d) pentafluorophenyl diphenylphosphinate.
Table 2
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2.3.1 Cyctooligomerisations of (D)-Alanine Thiazole
The (D )-alanine derived thiazole 88a was exposed to the optimum
cyclooligomerisation conditions of FDPP and DIPEA in anhydrous acetonitrile,
with the solution being stirred at room temperature under an atmosphere of nitrogen
for 3 days. Upon work-up an overall 55 % yield of cyclic products were isolated;
the slight decrease in yield can be attributed to the very poor solubility of 88a in
acetonitrile. Interestingly, the ratio of cyclic trimer 93 to cyclic tetramer 94 was
found to vary compared with the valine derived thiazole, i.e. a 9 : 2 ratio of 93 : 94
was now obtained (Scheme 17).
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HPLC was used to determine the ratio of cyclic products formed in all the
experiments performed during this research. A refractive index detector was used to
determine the ratio of cyclic products formed as the cyclopeptides all have different
AMax values. A C 18 column was used with an acetonitrile/water solvent system.
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Scheme 17
The cyclic trimer 93 and cyclic tetramer 94 are C3 and C4 symmetric respectively
as deduced from 1H NMR spectra of the separated cyclopeptides in CDCl3 at 21
CC. With the exception of the signals attributable to the amide protons, the PMR
spectra were very similar. The amide protons in the trimer 93, however, appeared
0.7 ppm further downfield from those in the tetramer 94, suggesting that
intramolecular H-bonding is probably more significant in the trimer (see
experimental section pages 96-98).
2.3.2 Cyclooligomerisations of (D)-Phenylalanine Thiazote
Cyclooligomerisation reactions of the enantiomerically enriched (D)-phenylalanine
thiazole 88b with the coupling reagent FDPP proceeded smoothly to give an overall
63% yield of cyclic products. Interestingly, none of the expected Cr-symmetric
cyclic trimer 98 was produced in any of these cyclisations. In this instance the
cyclic products included a mixture of the trimer 95 and the isomeric tetramers, 96
and 97 in a 2 : 6 ratio of cyclic trimer to cyclic tetramers (Scheme 18)(Appendix
4.1) .107
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The 'unsymmetrical' cyclic trimer isolated viz 95 contains one benzyl group on the
opposite face to the other two, and most probably arises as a result of the
incorporation of a small amount of the (L)-phenylalanine thiazole present (ee 70%)
in the starting material (Appendix 4.1). Molecular modelling studies oftrimers 95
and 98 found the trimer 95 to be energetically more favourable than trimer 98.
When the three benzyl groups lie on the same face, as in trimer 98, the energy
minimum is 264 klmol! compared with 242 kJrnol-1 for trimer 95 in which one
benzyl group is on the opposite face. Indeed this is evident when visually
comparing the lowest energy conformations of 95 and 98. It is, however,
interesting to note the presence of n-n interactions between two of the phenyl rings
in both of these compounds (Figure 4).
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Figure 4 : Cyclic peptide 95 energy minimised (top LHS); Cyclic peptide 95 - a space
filling representation of the benzyl side chains (top RHS); Cyclic peptide 98 energy
minimised (bottom LHS); Cyclic peptide 98 - a space filling representation of the
benzyl side chains (bottom RHS).
In addition it is very interesting to note the marked difference in the ratio of trimer
to tetramer to that observed in the valine and alanine thiazole cyclooligomerisations
(Table 3). There is an obvious trend in the ratio of cyclic products formed which is
dependent upon the nature of the alkyl side chain. As the size of the alkyl side
chain is decreased, the amount of cyclic trimer produced in the cyc1ooligomerisation
process increases. In the case where R=CH2Ph, almost three times as much cyclic
tetramer is formed compared with cyclic trimer. By changing the benzyl side chain
for a methyl group, the thiazole derived from alanine, sees nearly five times as much
cyclic trimer than cyclic tetramer formed. Indeed molecular modelling of the trimer
93 found the compound to adopt an energy minimum of just 212 klmol}, thus
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confirming that an increase in the size of the alkyl side chain increases the
minimised energy of the cyclic trimer and therefore disfavours its formation cfthe
tetramer (Figure 5).
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r=1N~)
S ,N H N i
R1NH HN 0 +
~/N. ).,
° 'L7 'R
S~Nly,~}=N H N
R""( °
0=t
NH
HN)""R
N H N={
YS~N~S
R 0
R Trimer: Tetramer
CH2Ph 1 : 2.8
CH(CH3h 3.5 : 1
CH3 4.3 : I
Table 3
Figure 5 : Cyclic peptide 93 energy minimised (LHS); Cyclic peptide 93 - a space
filling representation of the methyl side chains (RHS)
We postulated that the competition between the formation of the cyclic trimer and
the cyclic tetramer may depend on the difference in rates of the two competing
reactions. It is thought that during the cyclooligomerisation reactions a linear
precursor is formed which then macrocyclises to form the cyclic product.
However, the steric interactions between the benzyl groups in the linear trimer,
prior to macrocyclisation, may disfavour the linear trimer adopting the required
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conformation to cyclise. In an attempt to investigate this further, we wanted to
know whether it would be possible to synthesise the cyclic trimer in which the
benzyl groups all lay on the same face via a linear method. Is this compound too
hindered to form at all, or was the absence of this trimer in our cyclooligomerisation
products simply the result of a competitive tetramerisation with a more favoured
rate? We therefore decided to prepare the L, L, L-linear trimer 103 and examine its
cyclisation to 104. Thus, coupling of the thiazole acid 99 with the thiazole amine
100 using carbodiimide mediated conditions led smoothly to the dimer 101. Boc-
deprotection of this dimer 101 using 4M Hel in dioxane then gave the amine 102 in
a 96 % yield. Further coupling of 102 under carbodiimide mediated conditions with
the thiazole acid 99, followed by saponification, and Boc-deprotection finally gave
the macrocyclic precursor 103 (Scheme 19).
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Cyclisation of 103 with FDPP did indeed lead to the formation of the C3-
symmetric trimer 104 in which all side chains lie on the same face of the molecule
(Scheme 20). Clearly steric effects do not directly prevent the formation of this
'symmetrical' macrocyc1e in the cyc1ooligomerisation reactions. More likely, they
just slow down the rate of macrocyclisation of the linear trimer sufficiently, so that
the competing reaction, the formation of the linear tetramer 105 from the linear
trimer, predominates (i.e. '2>'/) (Scheme 20) .
FDPP
DIPEA
rj
~N<-)
S ,N H Ni
PhJNH HN 0
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104
Scheme 20
Macrocyclisation of a racemic mixture of the phenylalanine thiazole 93 was also
performed (Scheme 21), giving a different product ratio to that obtained using
enantiomerically enriched material. In this case, the product mixture contained,
'unsymmetrical' trimer 95 and a mixture of isomeric tetramers in approximately a 2 :
2.5 ratio. This increase in the formation of the cyclic trimer over cyclic tetramer
when cyclisation takes place from a racemic mixture, further supports our notion
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that the 'symmetrical trimer' 98 doesn't form due to steric hinderance, and thus a
higher energy minimum cfthe 'unsymmetrical trimer' 95.
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Scheme 21
At this stage in our research we had developed novel, high yielding
cyclooligomerisation reactions of amino-acid based thiazoles to selectively form
analogues of naturally occurring cyclopeptides in just one step from relatively
accessible starting materials. Contemporaneous work by Fairlie et al. reported
similar cyclooligomerisations but from an amino acid sequence, i.e 106 (Scheme
22).108
HOY 0NJ: 'r'
H2N ~ ~~ Ii OH
o / S
HO H
106
BOP
DIPEA
DMF
n = 2-19
Scheme 22
Cyclooligomerisation of this amino acid was much less selective compared to our
cyclooligomerisations with thiazole heterocycles. Exposure of 106 to the coupling
reagent BOP with DIPEA in DMF led to the isolation of 18 cyclopeptides
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(Scheme 22). The presence of unmodified amino acids, not in the form of azole
heterocycles, is the most likely cause of the decrease in selectivity. In light of the
efficiency and selectivity of our reactions leading to just two main products, we
feel we have provided some circumstantial evidence that naturally occurring
cyclopeptides could be formed from preformed heterocyclic amino acids as
opposed to free amino acids.
2.4 Metal Ions as Templates in Cyclooligomerisations
We now wished to challenge our cyclooligomerisation reactions even further and
assert an even greater control over them. Templates have already proved useful in
the promotion of cyclisation reactions and can often dramatically increase
yields. ID9 Most templation reactions are performed under kinetic control, with the
template being responsible for bringing the two ends of a particular intermediate
into close proximity, and thus promoting their reaction.Uv We were interested in
using a metal ion as a template under thermodynamic control to promote formation
of the product that it binds best. In this instance, using a single component
mixture, templating could potentially bias the reaction between different sized
cyclopeptides.
After considering the abundance of particular metal ions in the oceans and seas, we
decided to attempt templation of our cyclooligomerisation reactions initially using
the alkali metals, and then later with silver, cadmium and zinc. We decided to use
the tetrafluoroborate and chloride salts of these metals due to their good solubility
in organic solvents. Thus, a solution of the alanine derived thiazole 88a in
acetonitrile was stirred with DIPEA, and a metal salt, then, after stirring for 5
minutes the coupling reagent FDPP was added. This reaction mixture was stirred
for 3 days, the reaction worked up and the residue subjected to HPLC analysis.
Interestingly, we found that using lithium and cadmium as templates in the
cyclooligomerisation of the alanine derived thiazole 88a we promoted the formation
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of only the cyclic trimer 93 (Scheme 23)(Table 4). Using sodium as a template
also biased the reaction towards the formation of the cyclic trimer 93, increasing the
ratio from 9 : 2 without a metal to 12 : 2; potassium and silver were similarly found
to bias the distribution of products, but to a lesser extent.
p=(C02H
SXN
R NH2.HCl
FDPP
DIPEA
MX+
+
88a R=Me
88b R=CH2Ph
91 R=CH(CH3h
93 R=Me
95 R=CH2Ph
42 R=CH(CH3n
94R=Me
96 R=CH2Ph
92 R=CH(CH3n
Scheme 23
Metal Salt Ionis Radius /A Trimer: Tetramer
No Metal - 9:2
LiBF4 0.73 1:0
CdCl2 0.92 1:0
NaBF4 1.13 12:2
AgBF4 1.14 9:2
KBF4 1.51 10:2
Table 4
It is not possible to molecularly model metals encapsulated in the macroyclic
cavities of these cyclopeptides due to the highly complex nature of the calculations
required. It is, however, possible to generate a space filling representation of a
lithium ion encapsulated in the macrocyclic cavity of a cyclic trimer, this illustrates
just how tailor made these macrocylic cavities are for sequestering an ion (Figure
6). It is very difficult to postulate which properties of these metals render them
better templates than others. The size of the metal ion is probably very crucial; if
the metal is to template the monomer thiazoles to form, for example, a cyclic
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trimer then it must be able to chelate three monomers and hold them in favourable,
positions to promote cyclisation (Figure 6).
Figure 6 : Cyclic peptide 95 encapsulating a Li+ ion (LHS); Cyclic peptide 95
encapsulating a Li+ ion - a space filling representation (RHS).
Why does cadmium produce the same effect as lithium? What properties do these
metals share? Well they have very similar ionic radii. Interestingly, if we correlate
our templation results to the ionic radii of the metals (with a co-ordination number
of 4) we find that as the size of the ion increases the selection for the cyclic trimer
over the cyclic tetramer decreases (Table 4). It is very important to stress here,
that although, with the exception of potassium, this relationship holds, we don't
know what co-ordination number the ions adopt in these reactions (this would
affect their actual ionic radius), or what affect charge density may have.
We then went on to attempt the templation of the cyclooligomerisation of the
phenylalanine derived thiazole 88b (Table 5). Where, once again the results
displayed a similar correlation with the size of the metal ion. Moving down the
first group, the affects with lithium are negligible, but sodium and potassium appear
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to promote the formation of the tetramer 96. Alternatively, we could consider
sodium and potassium to be less effective templates for the formation of the cyclic
trimer 95. The strong selectivity for the phenylalanine derived thiazole 88b to form
the cyclic tetramer 96 in cyclooligomerisations without metal ions probably
decreases the possibility of templates promoting the formation of the cyclic trimer
95. This may, therefore, explain why the templation effects are not fantastically
large.
Metal Salt Ionis Radius /A Trimer: Tetramer
No Metal - 1:2.8
LiBF4 0.73 1:2.7
NaBF4 1.13 1:3
KBF4 1.51 1:3.5
Table 5
These trends are further supported by work carried out in our laboratories by my
colleagues Jolliffe and Hannam into the templation of the valine derived thiazole 91.
Lithium was found to increase the ratio of cyclic trimer 42 to cyclic tetramer 92
from 3 : 1 to 4 : 1; once more, as the metal ion was increased in size the formation
of the tetramer became more significant. 74 It was during concurrent studies of the
complexation behaviour of these cyclopeptides that the novel crystalline sandwich
complex of 42 was isolated (Section 1.6). Further studies will be described into
the use of metal ions as templates for natural products later on in this Thesis
(Section 2.7.2, and 2.8.1).
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2.5 Oxazole Ring Formation
The chemistry of oxazoles began in 1876 with the synthesis of 2-methyloxazole.
The development of penicillin as a drug during the World War ignited further
interest in this heterocycle as it was initially thought to feature in the overall
structure of penicillin. More recently, the isolation of many oxazole containing
natural products, many of them peptide alkaloids has renewed the interest in
oxazole chemistry, with many methods now available for their efficient
construction.
The most common type of oxazole found in natural products is a 2, 4-disubstituted
oxazole and the vast majority of research to date has been towards those
compounds possessing a 4-carboxyl group. One of the oldest methods available for
oxazole synthesis is the Robinson-Gabriel reaction. I I I This reaction involves
cyclodehydration of a-acylamino ketones 107 in the presence of dehydrating
agents such as PCIs, P20S, POCb, SOCh and polyphosphoric acid.
In 1947 Cornforth developed a synthesis of oxazoles starting from an imidate and
an amino acid.112 Thus condensation between ethyl acetimidate hydrochloride 108
and glycine ethyl ester hydrochloride 109 led to an imidate 110. The imidate was
next formylated to give 111, which was immediately cyclised to the oxazole ester
112, in good yields, by refluxing in acetic acid (Scbeme 24).
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a-Diazocarbonyl compounds 113 have also been shown to participate in oxazole
ring formation by undergoing reactions with nitriles 114.113 There are a variety of
conditions which induce these reactions, ranging from metal catalysis or Lewis acid
promoted reactions, to thermally or photochemically induced reactions. This
method is particularly useful in providing oxazoles functionalised at the 5-position
e.g. 115.
113 114
Konopelski et al. have utilised this reaction in their studies towards the natural
product, diazonamide A.114 Thus treatment of the a-diazo-J3-keto ester 116 in
acetonitrile under Lewis acid conditions led to the desired 2-methyl oxazole 117 in
64 % yield.
BF3.Et20.
CH3CN
116 117
55
Alternatively, condensation of an a-halo-keto ester 119 with an amide 118 under
the Hantzsch conditionsl l> gives rise to a 2, 4-disubstituted oxazole 120 after acid
mediated dehydration. The utility of this method has recently been demonstrated
by Panek et aI., in their synthesis of the tris-oxazole unit of ulapualide A 27.116
oBrJ
R2
118 119 120
2.5.1 Cyclodehydration Reactions
Probably the most widely used route towards oxazole ring formation in recent
years involves the formation of a dipeptide 123, followed either by, i) cyclisation
to an oxazoline 124 and subsequent oxidation to the oxazole 125, or ii) oxidation to
the 1, 4-dicarbonyl species 126 followed by cyclodehydration to yield the oxazole
125 (Scheme 25).
123
-, JO:(' -:
R3 N C02R2
H
126
Scheme 25
There are, however, a number of competing reactions which may take place during
the cyclodehydration of 123 to 124. Elimination of the activated hydroxyl group in
123 may occur to produce an alkene, such as 127. Alternatively, formation of an
aziridine 128, via direct attack by the amide nitrogen, is also a possibility (Scheme
26). A reaction which gives a multitude of products is highly undesirable.
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Researchers have therefore sought to activate the alcohol in a manner that will
induce the molecule to follow one of these pathways exclusively. An additional
proviso is that the reaction conditions do not induce racemisation of any chiral
centres.
JlHXRI
R3 N C02R2
H
123 124
1Jl -(RI
R3 N'-J
-.
C02R2
128
Scheme 26
A whole variety of reagents and conditions are currently available to effect these
transformations. As for thiazoles, the formation of the oxazoline can be achieved in
many ways from the corresponding dipeptide by activation of the hydroxyl amide
prior to cyclisation. The reagents employed for the activation of dipeptides
towards cyc1odehydration to form oxazolines are generally identical to those used
in thiazoline formation. Activation is achieved using thionyl chloride, followed by
treatment with silver triflate; 117 methane sulfonyl chloride and triethylamine; 118
triphenylphospine, CCl4 and DIPEA; 118 Mitsunobu conditions;92, 119
phosphorus oxychloride; 120 or the more commonly encountered Burgess' reagent95
or DAST.97, 121
Cyclodehydration of p-hydroxy amino acid peptides to produce oxazolines was
first observed by Nakajima et al. when their attempts to perform a /3-elimination on
a dipeptide of type 123 via an O-tosylated intermediate to afford the
corresponding alkene 127 met with only oxazoline 124 formation.122 Although the
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significance of this transformation was appreciated at this time, it was not until
1985 that it was fully utilised when Shioiri et al. applied it to the total synthesis of
ascidiacyclamide 7123 and later to patellamide B 6b.124 Thus two simultaneous
cyclodehydrations induced the formation of both oxazolines in one step by
treatment of the cyclic peptide 129 with thionyl chloride in THF, yielding
patellamide B 6b in 94 % yield.
soel2
THF
Some of the yields for similar cyclisations were poor, and in these instances the
addition of silver triflate was found to facilitate the reaction.U? All the reagents
listed above for the conversion of hydroxy amides into oxazolines do nothing more
than activate the hydroxyl group to induce cyc1odehydration. Care must, however,
be taken when choosing the best reagent for a given substrate to reduce side
reactions such as elimination, aziridine formation and epimerisation. Burgess
reagent is widely used in the formation of oxazolines in high yields and
enantiomeric purity. Pattenden and Freeman utilised Burgess' reagent to effect the
cyc1odehydration of 130 to form the oxazoline of raocyc1amide 15 as the final step
in the total synthesis.125
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In situations where the hydroxyl component is derived from threonine, e.g. 131, it
proves difficult to effect a cyc1odehydration and in many cases the main product
isolated is the corresponding alkene 132.
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An alternative pathway to oxazoles from /3-hydroxy amides has been developed by
Wipf et al. and has been shown to be extremely useful in oxazole formation en route
to natural products. Having encountered problems in the oxidation of oxazolines
substituted at the 5-position, Wipf pursued a Robinson-Gabriel type cyclisation of
a fJ-keto amide to furnish the corresponding oxazole.126 This method avoids the
problem of /3-elimination to form the alkene when attempting a cyclodehydration
on a dipeptide derived from threonine e.g. 131, as mentioned earlier. Thus
oxidation of a fJ-hydroxy amide 123 with Dess-Martin periodinane l-? and a
subsequent mild cyclodehydration of the fJ-keto amide 133 wi th
triphenylphosphine, iodine and triethylamine allowed for the rapid synthesis of
highly substituted and functionalised oxazoles 125 in good yields.
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Amino aldehydes derived from serine residues were found to cyclise to the oxazole
in a much less facile manner. This problem was overcome by using a bulky base,
i.e. 2, 6-di-tert-butyl-4-methylpyridine in place of triethylamine, with
dibromotetrachloroethane and triphenylphosphine. Under these conditions
elimination did not occur spontaneously but required subsequent treatment with
DBU to yield the oxazole.128 Wipf utilised the Robinson-Gabriel oxazole
synthesis to install the threonine derived bis-oxazole core of muscoride A 26.129
Thus, the dipeptide 134 was readily obtained from the condensation of Boc-(L)-
proline with threonine methyl ester hydrochloride in the presence of isobutyl
chloroformate. Oxidation and cyclodehydration of the threonine residue by side-
chain oxidation with Dess Martin periodinane followed by exposure to electrophilic
phosphorus reagent furnished the first oxazole 135 in 68 % yield. The oxazole 135
was next homologated by hydrolysis of the methyl ester and coupling with (L)-
threonine to give the tripeptide 136, which after oxidative cyc1odehydration ring -
closed to form the second oxazole 137 of muscoride A in 65 % yield (Scheme 27).
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Reagents: i, Dess-Martin periodinane; ii, Ph3P, 12, Et3N, DCM; iii, LiOH, H20, THF,
lh; iv, (L)-Thr-OMe, iBuOCOCl, NMM.
Scheme 27
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2.5.2 Oxidations oj Oxazolines
The oxidation techniques already discussed for the conversion of thiazolines into
thiazoles are generally quite versatile and the majority are also applicable to the
oxidation of oxazolines. A few examples of the oxidation techniques already
discussed (Section 2.2.3) will be highlighted here towards the construction of
oxazole containing natural products.
Williams employed a cyclodehydration of an amide using diethylaminosulfur
trifluoride (DAST)97 and further oxidised the oxazoline with BrCCbIDBU103 in his
total synthesis of hennoxazole A 25.130 Thus, cyclodehydration of 138 with
DAST at -78°C first led to the oxazoline 139, and subsequent oxidation with
BrCCl3 and DBU then cleanly effected dehydration to the oxazole 140.
Saponification of the ester in 140 and condensation of the resulting acid with serine
methyl ester hydrochloride led to 141. The cyclodehydration-oxidation protocol
was repeated to yield the bis-oxazole core 142 ofhennoxazole A 25 (Scheme 28).
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Reagents: i, OAST (leq.), OCM, -78 QC, lh; ii, K2C03, -78°C - O°C; iii, BrCCI3,
OBU; iv, LiOH (leq.), THF, H20; v, iBuOCOCI, Et3N, (2eq.), serine methyl
ester.HCI (2eq.), DCM, -20 QC.
Scheme 28
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A similar oxidation to that of Williams was developed by Jung et al. using DBU,
CCl4 in pyridine and acetonitrile, 104 and this method was utilised by Pattenden et
al. in their total synthesis of muscoride A (Scheme 29).131
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Reagents: i, OBU, CCI4, Pyridine, MeCN.
Scheme 29
In addition Bristol-Myers Squibb discovered a novel procedure using a mixture of
copper (II) bromide and DBU to effect the oxidation of 143 to 144.132
Reagents: i, CuBr2, OBU, HMTA, OCM
Scheme 30
In contrast to these oxidations Evans et al. formed a 5-seleno-oxazole and
performed an oxidative elimination to form an oxazole in their total synthesis of
calyculin 18.133 Enolisation of 145 with KHMDS followed by reaction with
phenylselenyl chloride and oxidative elimination of the resulting diastereomeric
selenides afforded the oxazole 146 in a 57 % overall yield (Scheme 31).
Me Me
BOC2N~). i. ii BOC2N~)
145 C02Me 146 C02Me
Reagents: i, KHMDS, THF, -78°C, PhSeCl; ii, 30 % aq. H202, DCM, pyridine, O°C
Scheme 31
62
Returning to our own work we first decided to synthesise the oxazole derived from
(D)-phenylalanine due to the high abundance of this type of substitued oxazole in
natural products. This would also allow us to compare the behaviour of oxazoles
with that of thiazoles. We synthesised the oxazole by cyclodehydration of the
relevent dipeptide to the oxazoline, followed by oxidation to the corresponding
oxazole using the mild Williams' oxidation protocol. The oxazole was produced as
an enantiomerically pure compound as shown in Scheme 32. Thus coupling of the
Boc-protected (D)-phenylalanine with (D, L)-serine methyl ester led to the
dipeptide 147 in good yield. Cyclodehydration of the dipeptide 147 using
DAST97, 121gave the oxazoline 148 in a respectable 76% yield, and oxidation with
BeCCl , and DBU103 then smoothly led to the oxazole 149. Saponification of
methyl ester 149 with lithium hydroxide afforded the acid 150, which was
subjected to Boc-deprotection with 4 M hydrochloric acid in dioxane to give the
oxazole 151 in a 93 % yield (Scheme 32).
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Scheme 32
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Muscoride 26, dendroamide A 14 and nostacyclamide 16, to name but a few,
incorporate oxazoles derived from threonine. In addition Wipf et al. looked at
cyclooligomerisation reactions of oxazolines derived from threonine within their
total synthesis ofwestiellamide 17.134 We therefore decided it would be interesting
to experiment with such oxazoles ourselves. However, although we had previously
synthesised the oxazoles by cyclodehydration of the relevant dipeptide 152 using
OAST, followed by mild dehydration using BrCC13 and OBU to furnish the
oxazole 153 in good yields (- 70 % over the two steps) (Scheme 33), other
workers in our research group had reported a difficulty when converting dipeptides
derived from threonine into oxazolines.
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Lellouche et al. 135encountered a limitation of cyclodehydrations using OAST when
applied to threonine containing dipeptides, treatment of the dipeptide 154 with
OAST gave rise to the corresponding E-dehydropeptide 15S (Scheme 34).
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In addition to Lellouche's attempts to cyclodehydrate threonine containing
dipeptides using DAST, Wipf and Miller had reported the cyclodehydration of
threonine containing dipeptides using Burgess' reagent''>. 136 and so we decided to
switch tactics. Unfortunately, attempts to form the oxazoline 156 from the
dipeptide 154 in reasonable yields failed, the main product obtained being the E-
dehydropeptide 155 (Scbeme 35). We attempted to increase the yield of
oxazoline by varying reaction times from l h to 7h, by changing the concentration
and also by attempting a one-pot cyclodehydration/oxidation reaction but all
attempts failed.
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On closer examination we noticed that both Wipf and Lellouche had only used
CbZ-protected amines in contrast to our Boc-protected dipeptides. Attempts
within our research group to form another oxazoline had also failed when the
dipeptide was Boc-protected, indeed simply swapping protecting groups for CbZ
saw an increase in the yield of oxazoline formed from ~10 % to nearly 30 %.
However, such a low yield would make a large scale synthesis quite laborious and
as a consequence we decided to switch tactics yet again. We decided to pursue a
Robinson-Gabriel type cyclisation as Wipf and Venkatraman had done in their total
synthesis of muscoride A 26.129 Thus, coupling of CbZ-protected (D)-alanine
with (D, L)-serine methyl ester hydrochloride using EDC and HOBt first gave the
dipeptide 157. Oxidation of the alcohol in 157 using Dess-Martin periodinanel-?
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next led to the {j-keto amide 158 in an 86 % yield. The {j-keto amide was then
exposed to Ph3P, Et3N and iodine at 0 QC and cyclised to the oxazole 159 in a
pleasing 84% yield. Saponification of the oxazole was carried out in ethanol using
sodium hydroxide and finally the CbZ group was removed using a 33% solution of
HBr in acetic acid to leave the oxazole 160 as a brown, highly hygroscopic powder
(Scheme 36).
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Scheme 36
It is important to note that in March 2000, after we had synthesised this oxazole,
Wipf and colleagues reported the use of bis-(2-methoxyethyl)-aminosulfur
trifluoride (Deoxo-Fluor), to effect cyclodehydrations of threonine containing
dipeptides to the corresponding oxazolines. Indeed, cyclodehydration of 161 to the
oxazoline 162 was achieved in a 72% yield compared with a 27 % yield when using
DAST.137
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2.6 Cyclooligomerisations of Oxazoles
Initial attempts to cyclise the oxazole 151 derived from (D)-phenylalanine using the
same conditions employed for the corresponding thiazoles gave a disappointing 12
% yield of cyclic trimer 163 and cyclic tetramer 164, even following optimisation
we were only able to increase this yield to 31 %. In an attempt to further optimise
this reaction, we swapped the coupling reagent FDPP for DPPA and managed to
increase the yield of cyclic products to 49 %. These lower yields in comparison
with thiazole cyclooligomerisations probably result from the poor solubility of the
oxazole in acetonitrile even after addition of base. Interestingly, the ratio of cyclic
trimer 163 : cyclic tetramer 164 varied drastically from those found when
performing cyclooligomerisations of the phenylalanine derived thiazoles. Unlike
the phenylalanine derived thiazole the cyclic trimer 163 was now the favourable
product (Scheme 37).
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Scheme 37
The differences in product ratios of the oxazole and thiazole derivatives may be as a
result of differences in their geometry, orientation of the alkyl side chains, or
concentration effects as a result of the differing solubility of oxazoles and thiazoles.
Molecular modelling of the cyclic trimer 163 reveals it to possess a minimum
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energy conformation of just 173 k.lmol'! compared with a minimum energy
conformation for the thiazole trimer 95 of 264 klmol+,
Subjection of the oxazole 165 derived from valine to our cyclooligomerisation
conditions led to a very disappointing 12 % yield of cyclic products. The valine
oxazole was significantly less soluble than the phenylalanine derived oxazole, thus
providing further credibility for our solubility argument. The ratio of cyclic trimer
166 : cyclic tetramer 167 is drastically different to that obtained for the analogous
thiazole. The cyclic trimer 166 and tetrarner 167 were isolated in a 1 : 1 ratio, cia 3
:1 ratio in the case of the thiazole (Scheme 38).
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Scheme 38
Attempts to perform a cyclooligomerisation reaction from the threonine/alanine
derived oxazole 160 were equally disappointing. Exposure of 160 to the optimised
coupling conditions led to only trace amounts of cyclic products. Indeed,
performing the reaction on alSO mg scale led only to the isolation of 2 mg of cyclic
products comprising approximately of a 1 : 1 ratio of cyclic trimer 168 : cyclic
tetramer 169 as determined by IH NMR (Scheme 39). The solubility of this
oxazole was very poor, with the compound appearing to be present mainly as a
suspension throughout the reaction. The oxazole based cyclooligomerisations now
await optimisation which may just involve identifying better solvents for the
reaction.
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2.7 Total Synthesis of Dendroamide A
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NH HN
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At the outset of our studies we had always been interested in applying our newly
established cyclooligomerisation methodology to natural product targets. Dendroamide
A 14 is a bistratamide type cyclic hexapeptide which exhibits multi drug resistance
reversing activity and was isolated from the cyanobacterium Stigonema dendroideum in
1996.22 Its structure is made up of three heterocyclic units, i.e. a thiazole derived from
(D)-valine and cysteine 91, a thiazole derived from (D)-alanine and cysteine 88a, and an
oxazole derived from (D)-alanine and threonine 160 .
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Our ultimate aim was to take a 1:1:1 mixture of these constituent heterocycles, and
attempt to 'self-assemble' them to form dendroamide A 14. This was not considered a
simple task, considering that a cyclooligomerisation reaction from the three heterocycles
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would lead to the formation of 49 possible cyclic trimers and tetramers! We did,
however, have something working in our favour, that is thiazole heterocycles with
smaller alkyl side chains did form cyclic trimers in preference to cyclic tetramers, but
there would still be a possibility of forming eleven cyclic trimers i.e. 14, 171, 93, 42,
168, 172, 173, 174, 175, 176, and 177. We decided the best way to move forwards was
to first synthesise dendroamide A 14 totally in a linear fashion. Once the natural
product was fully characterised we could then move on to our studies of the mixed
cyclooligomerisation of 160, 91, and 88a.
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Thus coupling of the oxazole amine 178 and the thiazole acid 177 under carbodiimide
mediated conditions first led to the linear tetrapeptide 179 in an 80 % yield.
Saponification of this tetrapeptide 179 followed by coupling with the (D)-valine derived
thiazole amine 181, next gave the linear hexapeptide 182 in good overall yield. The
macrocyclic precursor 183 was then obtained following saponification and Boc-
deprotection of 182 in an overall 94 % yield. Macrocyclisation of 183 was achieved
under our optimised coupling conditions, using a slightly higher dilution of O.OIM, to
finally provide dendroamide A 14 in a pleasing 91 % yield (Scheme 40).
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Scheme 40
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The synthetic material had chiroptical and NMR spectroscopic data which were found
to be identical to those reported for the natural product isolated from S. dendroideum
(Appendix 4.1, 4.2).138
2.7.1 Cycooligomerisation Reactions towards Dendroamide A
Having obtained spectroscopic and chromatographic data for the natural dendroamide A
it was now time to attempt the reaction which had provided the focus and the impetus
for the whole project. AI: 1:1mixture of the heterocyclic amino acids, 160,91, and 88a
in acetonitrile was treated with DIPEA and FDPP at room temperature and the reaction
was stirred for three days. Using conditions we had adapted during our earlier studies,
the reaction mixture was now subjected to hplc analysis using a reverse phase C18
column, and an acetonitrile/water solvent system. We prepared ourselves for what
could well be a very complicated hplc trace. To our delight chromatography led to the
isolation of dendroamide A 14 (23 %) together with its positional isomer 171 (22 %)
accompanied by only the products 93, 42, 172 and 173 resulting from homo-coupling of
the thiazole amino acids 88a and 91 in an overall 75 % yield (Scheme 41)(TabJe 6).
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Scheme 41
Interestingly no cyclic tetramers were detected by mass spectrometry or hplc. The
structures of these other cyclic compounds were determined following their independent
synthesis, using a linear approach similar to that shown in Scheme 40, viz experimental
pages 126 to132. In order to confirm the identity of these compounds in the hplc trace,
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small amounts of the crude mixture of cyclic products obtained from the 'mixed
cyclooligomerisation' were enriched in turn with each of these by-products and the
natural product. These spiked samples were injected onto the hplc column, resulting in
an enlargement of the peak corresponding to that product in the hplc trace of the
mixture.138
We have already shown that thiazole heterocycles undergo homo-cyclooligomeriation
reactions much more readily than their oxazole counterparts (Sections 2.3 and 2.6
respectively). Bearing this in mind we envisaged that the thiazole heterocycles would
be more competitive in this mixed cyclooligomerisation than the oxazole heterocycle in
forming peptide bonds. In an attempt to further tailor this 'self-assembly' reaction
towards the formation of dendroamide A 14 we decided to increase the amount of
oxazole in the starting mixture. By performing the reaction with a 1 : 1 : 2 ratio of 91 :
88a : 160 it was possible to increase the composition of dendroamide A 14 to 31 %
from 23 % of the cyclic products formed. Unfortunately, increasing the amount of
oxazole present three-fold and four-fold, with respect to the thiazoles, failed to further
increase the amount of dendroamide A 14 formed (Table 6).
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Heterocycles PercentageCompositionof CyclicProducts
--
-- --
91 :88a: 160 93 172 DendroamideA 171 168 173 42
14
1:1:1 14 37 23 26
1:1:2 16 29 31 15 4 4
1:1:3 18 23 30 21 5 2
1:1:4 10 27 23 14 13 5 6
Table 6
As discussed already, dendroamide A 14, unusually, contains three non-natural (D)-
amino acid residues. In light of the results we obtained for the cyclooligomerisations of
the enantiomerically enriched phenylalanine derived thiazole, in which the trimer with
one side chain on the opposite face was of lower energy (and thus was the predominant
product), we decided to attempt our mixed cyclooligomerisation reaction using the
thiazole derived from (L)-valine 184 in order to ascertain whether this subtle difference
affects the distribution of isomeric products. Could the results we obtain shed any light
on why nature is so keen on incorporating (D)-amino acids? Hence, a 1:1:1 mixture of
88a, 184, and 160 was therefore stirred under our standard reaction conditions for three
days (Scheme 42).
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Upon analysis of the crude mixture of cyclic products by hplc we found that the
amount of isomeric dendromide A 185 formed was 34 % compared to the 23 % of
dendroamide obtained in the analogous reaction. Molecular modelling of dendroamide A
14 and of the isomeric compound 185, incorporating the (I)-valine derived thiazole
showed the two compounds to adopt conformations with minimised energies of 178
k.lmol! and 179klmol! respectively, suggesting that the affects of steric interactions
with relatively small side chains is negligible (Figure 9).
Figure 9 : Dendroamide A - energy minimised
2.7.2 Metal Templation Reactions towards Dendroamide A
Does nature use metal ions as convenient biological templates in the formation of
peptidic metabolites? We have already investigated the ability of metal ions to act as
templates and alter the ratio of cyclic trimer and cyclic tetramer formed from a
homogenous mixture of heterocyclic amino acids (Sections 2.3 and 2.6). If a metal ion
is used as a template in a cyclooligomerisation reaction from a heterogeneous mixture of
heterocyclic amino acids, is it possible to not only increase the amount of cyclic trimer
formed, clcyclic tetramer, but also to bias the ratio of cyclic trimers towards a particular
product?
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When we reconsidered the metal templation experiments we had already carried out, we
decided to increase the time the metals had to template the heterocycles before the
coupling reagent was added. In previous experiments the heterocycles had been stirred
in the presence of the metal salts for just five minutes before the coupling reagent was
added. With hindsight this may not have been long enough for the metal to template the
most favourable compound. Thus a 1:1:1 mixture of the constituent heterocycles of
dendroamide A, 160, 91, and 88a, was stirred in acetonitrile with DIPEA at room
temperature. The appropriate metal salt was then added and the solution was stirred
for six hours. We believed six hours was ample time for any equilibrium to be reached
promoting the most favourable order of heterocycles to be chelated to the metal ion.
FDPP was then added and the reaction was stirred for a further three days. We initially
experimented with the alkali metals before moving onto the other abundant ions Cu2+,
Zn2+, Ag" and Ca2+ (Scheme 43).
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To our amazement the metal ions appeared to be extremely capable of altering the
distribution of cyclic products. Using lithium as a template the amount of the trimer
173 was increased from 29 % without a metal to 59 % in the presence of the metal. In
addition, other ions also increased the amount of 173 formed but to varying amounts.
As we had previously calculated we correlated the amount of 173 formed with the ionic
radii of the ions (co-ordination number = 4), and found that the trend was quite
77
remarkable. With the smallest ion, copper, the amount of 173 formed was
approximately double the amount formed without a metal As the radius of the ions
increase this affect drops off. Indeed using potassium, whose ionic radius is around
twice that of copper, there is no change in the distribution of products (Table 7).
PercentageCompositionof
Cyclic Products
MetalSalt IonicRadiusI A 173 DendroamideA
Cu(BF4h 0.71 61
LiBF4 0.73 59
Zn(BF4h 0.74 59
NaBF4 1.13 48
KBF4 1.51 29
No Metal
- 29
AgBF4 0.81 100
Ca(BF4h 1.14 23 52
Table 7
Unfortunately the yield of cyclic material obtained in these 'metal templated' reactions is
considerably lower than that obtained in the analogous cyclooligomerisations in the
absence of a metal. It is probable that this is a result of a decrease in the reaction rate
when the amino acids are chelated to a metal ion. At present these reactions await
optimisation, this could possibly be achieved by simply heating the reaction or changing
the solvent or reaction time.
The macrocyclic cavity of the cyclic hexapeptides we are dealing with is reported to be
in the range 5.2-5.6A,24 considering the case of copper(II) (d; = 1.42), and assuming the
metal ion sits within the proximity of the macrocyclic cavity, approximately 2 A is
available around the metal ion in which intramolecular interactions with the macrocycle
can take place (Figure 10). 2 A is the optimum distance for intramolecular interactions
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to take place. This therefore, provides further evidence that copper would be much
more liable to act as a template compared with, for example, potassium. Potassium
possesses twice the ionic diameter of copper, and thus would only allow approximately
1A space around the ion for intramolecular interactions to take place.
Macrocycle
-1.4 A
-5.2-5.6 A
Figure 10
It is important to stress that little is known about the qualities of ions that render them
good templates for certain compounds. The size of the ion is probably a major factor
but, we don't know what co-ordination number the metals adopt or exactly how they
interact with these heterocycles. In the case of silver and calcium the results obtained
do not fit into the simplistic size correlation argument. Indeed, using silver as a
template only 173 is formed. Silver is bigger than zinc and so if the size correlation was
to hold we would expect around a 50% yield of 173.
We have found a range of metals which can be used to tailor the distribution of products
towards 173. Indeed, we can form 173 exclusively using silver as a template, but our
interests were in finding a metal which would template the formation of dendroamide A
14. When calcium was used in the self-assembly 52 % of the cyclic products consisted
of dendroamide A 14, with the amount of 173 being reduced to just 23 % (Table 7).
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In conclusion we can deduce that silver(I) and copper(II) possess just the right
geometry and electronic properties to chelate two valine derived thiazoles and an alanine
derived thiazole, and thus facilitate the formation of 173. In addition calcium(II)
possesses the right properties to chelate each component of dendroamide A 14, and
thus facilitate its formation. It is not possible to generate a lowest energy conformation
of a chelated cyclopeptide as the calculations required are too complex. However it is
possible to insert a metal ion into the macrocyclic cavity to illustrate how well a calcium
ion fits into the macrocyclic cavity of dendroamide A(Figure 11).
Figure 11 :Dendroamide A containing a Ca2+ ion (LHS); Dendroamide A containing a
Ca2+ ion - a space filling representation (RHS)
In conclusion we have been able to tailor the mixed cyclooligomerisation reaction in
which a possible forty nine cyclic trimers and tetramers could be formed into a highly
selective reaction in which just one compound is produced. Furthermore, depending on
the metal ion we use as a template we can form 173 exclusively or greatly increase the
amount of dendroamide A 14 produced. Our next aim of our work was to attempt to
apply this methodology to the self-assembly of another natural product.
80
2.8 Total Synthesis of Nostacyclamide
Nostacyclamide 16 is a bistratamide type cyclic hexapeptide isolated from Nostoc Sp.24
Its structure consists of two thiazoles, one derived from (D)-valine and cysteine 91, and
the other from glycine and cysteine 185, and the macrocycle is completed using an
oxazole derived from (L)-alanine and threonine 186. Moody and Bagley published a
total synthesis of this cyclic hexapeptide in 1996 using their recently developed
rhodium(II) catalysed N-H insertion reactions of diazoketoesters to form the
oxazole.P? We now wished to apply our novel cyclooligomerisation reactions to 'self-
assemble' nostacyclamide from its constituent heterocycles (Figure 12).
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In a similar fashion to our approach with dendroamide A 14, we decided to firstly
synthesise nostacyclamide to aid the identification of the natural product amongst the
cyclic products obtained from a mixed cyc1ooligomerisation. Thus, coupling of the
oxazole acid 186 with the thiazole amine 187 under carbodiimide mediated conditions
first led to the formation of the tetrapeptide 188 in a 60 % yield. Deprotection of the
CbZ group in 188 was then achieved using a 33 % solution ofHBr in acetic acid to leave
the corresponding amine as its hydrobromide salt 189. This bromide was then coupled
with the thiazole acid 190 to give the linear hexapeptide 191. Saponification and Boc-
deprotection of 191 led to the macrocyclic precursor 192 in good yield. Finally
exposure of 192 to FDPP, and DIPEA in anhydrous acetonitrile led to the isolation of
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nostacyclamide in a 62 % yield. The synthetic material had chiroptical and
spectroscopic data which were found to be identical to those reported for the natural
product isolated from Nostoc sp. (Scheme 44).
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Reagents: i, EDC, HOBt, NMM, DCM, O°C; ii, 33 % HBr in acetic acid; iii, NaOH, THF,
H20, rt; iv, 4M HCl, dioxane, rt; v, FDPP, DIPEA, CH3CN.
Scheme 44
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2.8.1 Cyc/ooligomerisation Reactions towards Nostacyclamide
A 1:1:1 mixture of 185,91, and 186 was then stirred in acetonitrile with DIPEA and
FDPP at room temperature for three days. Analysis of the crude mixture of cyclic
products obtained, by hplc, revealed the presence of six cyclic trimers and no cyclic
tetramers. The cyclic products were composed of nostacyclamide 16 (21 %), the
structural isomer of nostacyclamide 194 (23 %), the cyclic trimer of the valine derived
thiazole 42 (6 %), 195 (21 %), 196 (21 %), and 8 % of an unidentifiable product
(Scheme 45). The reaction showed similar selectivity to the self-assembly we had
performed towards dendroamide A 14 which was very pleasing. In a similar fashion we
now wanted to attempt to metal template the formation of one of these six products,
preferably nostacyclamide 16!
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2.8.2 Metal Templation Reactions towards Nostacyclamide
The metal salts which we employed in our dendroamide A 14 studies were used again to
attempt templation of nostacyclamide 16. Thus a 1 : 1 : 1mixture of 185,91, and 186
was stirred in anhydrous acetonitrile with DIPEA in the presence of a metal salt at room
temperature. After stirring the mixture for six hours, FDPP was added and the mixture
was again stirred for a further three days at room temperature. The crude mixture of
cyclic products was analysed by reverse phase hplc using the conditions already
described. The results that were obtained using these metals did not adhere to the clear
cut trend as was observed for dendroamide A 14. One group of metals promoted the
formation of 195, to varying extents, while to our delight the other group of metals
promoted the formation of nostacyclamide 16 (Scheme 45).
Firstly, zinc, sodium, potassium and silver were found to increase the proportion of 195
formed in the cyclic products. Using Zn(BF4h as a template the proportion of 195
produced was increased from 21 % without a metal to 36 % composition of the total
cyclic products produced. The slightly larger ion, Na" increased this proportion to 44
%, and using the even larger ion, K+ the amount of 195 formed was increased to 48 %
(Table 8). During the metal studies with dendroamide A, silver was found to be an
excellent template for one particular cyclic hexapeptide, forming 173 exclusively.
Returning to the nostacyclamide studies, when a 1 : 1 : 1 mixture of 185, 41 and 186
was stirred with DIPEA and AgBF4 in anhydrous acetonitrile and later with FDPP,
analysis of the resulting cyclic products revealed 195 as the only product of the reaction
(Table 8).
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Percentage Composition of Cyclic Products
Metal Salt Ionic Radius/ A 195 Nostacyclamide 16 Nostacyclamide
Structural Isomer
194
no metal - 21 21 23
Zn(BF4h 0.74 36 25 38
AgBF4 0.81 100 -
-
NaBF4 1.13 44 28 28
KBF4 1.51 48 26 26
Table 8
Cu2+, Li+ and Ca2+ were found to promote the formation of nostacyclamide 16. Using
copper as a template only two cyclic products were formed. The mixture comprised
nostacyclamide (66 %) and the structural isomer of nostacyclamide 194 (34 %).
Increasing the ionic radius of the metal ion slightly, moving to Li+, the ion still had a
significant effect on the distribution of products. The amount of nostacyclamide 16
formed was enhanced from 21 % composition to 45 % of the total cyclic products.
Ca2+ was also found to increase the proportion of nostacyclamide 16 produced from 21
% to 48 % (Table 9b). In this instance, however, there was not the same correlation
between the ionic radius of the template and the effectiveness of the ion as a template.
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Percentage Composition of Cyclic Products
Metal Salt Ionic Radius/ A Nostacyclamide 16 Nostacyclamide
Structural Isomer
193
Cu(BF4h 0.71 66 34
LiBF4 0.73 4S 13
Ca(BF4h 1.14 48 29
no metal - 21 23
Table 9
The templating effect we observed for copper was really quite remarkable. The ability
of the metal to selectively form a natural product, and only one other isomeric product
from a possible forty nine cyclic products provides strong evidence that metal ions may
indeed act as convenient biological templates in the formation of cyclopeptide
metabolites. The cyclooligomerisation reactions in which metal ions are used as
templates are generally slightly lower yielding than the equivalent reaction without the
metal. However, in the case of copper, the total isolable yield of cyclic products was
extremely low - just 11 %. It is possible that the metal binds the heterocyclic amino
acids quite strongly and therefore slows down the rate of the coupling reactions. Indeed
viewing a space - filling representation of a Cu2+ ion encapsulated in the macrocyclic
cavity of nostacyclamide 16 illustrates how perfectly this ion fits (Figure 13).
The nature of the starting material makes it very difficult to monitor the reactions by tic.
It is not then easy to know when the reactions have gone to completion. Indeed, any
unreacted monomeric heterocycles, or uncyclised linear precursor still present would
simply be lost in the aqueous wash during work-up. The reduction in the yield of cyclic
material obtained when metal templates are used can probably be overcome by either
finding an optimum reaction time, or by heating the reaction to increase the rate of the
reaction. These are investigations for the future!
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Figure 13 :Nostacyclamide containing a Cu2+ ion (LHS); Nostacyclamide containing a
Cu2+ ion - a space filling representation eRRS)
2.9 Summary
We have developed a high yielding cyc1ooligomerisation reaction in which analogues of
naturally occurring cyclopeptides are formed in just one step from thiazole and/or
oxazole based amino acids. Thiazole based hexa- and octa- cyclopeptides can be formed
in yields up to 80 % while the analogous reactions with oxazoles are considerably lower
yielding. In the case of the thiazole cyclooligomerisations the distribution of products
can be affected by altering the size of the alkyl side chain. When the reaction is
performed on a thiazole with a methyl side chain i.e. alanine, the cyclic trimer is the
predominant product. However, increasing the size of the side chain to an isopropyl
group, and then to a benzyl group alters the predominant product to the cyclic
tetramer. 107 Additionally metal ions can be used as templates in these reactions. In the
case of the thiazole derived from (D)-alanine the addition of Li" into the reaction results
in the formation of only the corresponding cyclic trimer. As the size of metal ion is
increased in radius this templating affect drops off. The use of metal ions as templates
has therefore provided us with a further synthetic tool with which to manipulate the
distribution of cyclic products.
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We have extended these cyclooligomerisation reactions to the self-assembly of the
natural products, dendroamide A 14 and nostacyc1amide 16. We successfully
completed the first total synthesis of dendroamide A 14 in a linear fashion and
subsequently synthesised it via a novel cyclooligomerisation from its constituent
heterocyclic amino acids.138 The cyc1ooligomerisation was highly selective, forming
just four major products from a possible forty nine cyclic trimers and tetramers.
Furthermore we were able to promote the formation of dendroamide A 14 to an even
greater extent using Ca2+ as a template. In addition it was possible to form another
cyclic product 173 exclusively from this cyclooligomerisation using silver as a template.
These studies were finally directed towards the synthesis of nostacyclamide 16. A total
synthesis of this natural product was completed via a linear method and later via a
cyclooligomerisation reaction. The selectivities of these mixed cyc1ooligomerisations
were similar to those obtained towards dendroamide A 14. This time six main products
were formed from a possible forty nine. Employing metal ions as templates, once
again, uncovered some striking results. Using Zn2+, Na+, K+, and Ag" as templates in
the self-assembly reaction towards nostacyclamide 16 we were able to tailor the reaction
to form more of the cyclic product 195. Indeed silver templated this product to
perfection, producing 195 exclusively. Another group of metals, Cu2+, Li+, and Ca2+
were found to promote the formation of nostacyclamide 16, copper being the most
effective, producing a mixture of just two products composing nostacyclamide 16 (66
0/0), and its structural isomer 194 (34 %).
During our research we have uncovered strong circumstantial evidence which suggests
that oxazole/thiazole based cyclopeptide metabolites could be produced in nature via a
self-assembly of pre-formed oxazole/thiazole amino acids. We have also demonstrated
the power of metal ions to act as templates and to promote the formation of natural
products from their constituent heterocyclic amino acids, thereby giving further
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evidence to the idea that metal ions are involved in the biological assembly of these
compounds.
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EXPERIMENTAL
General Details
All melting points were determined on a Kofler hot-stage apparatus and are uncorrected.
Optical rotations were recorded in spectroscopic grade chloroform or ethanol on a Jasco
DIP-370 polarimeter, [a]D values are recorded in units of 10-1deg ern- g-I. Ultraviolet
spectra were recorded on a Phillips PU 8700 spectrophotometer as solutions in
spectroscopic grade ethanol, E values are recorded in units of dm- mol-I em-I. Infrared
spectra were obtained using Perkin-Elmer 1600 series FT-IR instrument or a Nicolet
Magna 550 instrument as liquid films or as dilute solutions in spectroscopic grade
chloroform. Proton nmr spectra were recorded on either a Bruker DPX 360 (360
MHz), a Bruker DPX 500 (500 MHz) or a Jeol EX 270 (270 MHz) spectrometer as
dilute solutions in deuterochloroform unless otherwise stated. The chemical shifts are
quoted in parts per million (ppm) relative to residual chloroform (~ 7.27) or residual
methanol (8 3.35) as internal standard and the multiplicity of each signal is designated
by the following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; quin., quintet;
br, broad; m, multiplet; app., apparent; obs., obscured. All coupling constants are
quoted in Hertz. Carbon-13 nmr spectra were recorded on either a Bruker DPX 360
(90.5 MHz), a Bruker DPX 500 (125 MHz) or a Jeol EX 270 (67.5 MHz)
spectrometer as dilute solutions in deuterochloroform unless otherwise stated.
Chemical shifts are reported relative to internal chloroform (877.0) or residual methanol
(849.0) as standard on a broad band decoupled mode, and the multiplicities determined
using a DEPT sequence. Mass spectra were recorded on a VG Autospec, a MM-
701CF, a VG Micromass 7070E or a Micromass LCT. Microanalytical data were
obtained on a Perkin-Elmer 240B elemental analyser.
Flash chromatography was performed on Merck silica gel 60 as the stationary phase
and the solvents employed were either of analytical grade or were distilled before use.
All reactions were monitored by tlc using Merck silica gel60 F254 precoated aluminium
backed plates which were visualised with ultraviolet light and then with either acidic
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ninhydrin solution, acidic alcholic vanillin solution or a basic potassium permanganate
solution.
Routinely, dry organic solvents were stored under nitrogen and/or over sodium wire.
Other organic solvents were dried by distillation from the following: THF and benzene
(potassium benzophenone ketyl), dichloromethane (calcium hydride) and methanol
(magnesium methoxide). Other organic solvents and reagents were purified by the
accepted literature procedures. Dess-Martin periodinane was prepared according to the
modified procedure of Ireland and Liu.127 All organic extracts were dried with
magnesium sulfate unless otherwise stated. Solvent was removed on a Buchi rotary
evaporator. Where necessary, reactions requiring anhydrous conditions were performed
in a flame or oven dried apparatus under nitrogen or argon atmosphere as stated.
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2-(R)-(I-Carbamoylethyl)-carbamic acid tert-butyl ester (85a)
o
"'·-.r+NH2
BocNH
N-Methylmorpholine (3.5 ml, 31.5 mmol) and isobutyl chloroformate (4.1 ml, 31.5
mmol) were added to a stirred solution of Boc-(D)-alanine (6.0 g, 31.5 mmol) in
anhydrous THF (85 ml) at -5°C under a nitrogen atmosphere. The solution was stirred
at -5 °C for 15 min, and then ammonia was bubbled through the solution for 5 min. The
ice bath was removed and ammonia was bubbled through the solution for a further 20
min. The resulting white/opaque solution was stirred at room temperature for 20 min
and then water (ca 30 ml) was added. The separated aqueous layer was extracted with
dichloromethane (4 x 30 ml), the combined organic extracts were then washed with
saturated sodium hydrogen carbonate solution (3 x 30 ml), and brine (3 x 30 ml), dried
(MgS04) and evaporated in vacuo to leave the amide (5.5 g, 28.8 mmol, 92 %) as a
white powder; mp. 90-93 °C (from dichloromethane) (Lit.141 mp. 95-96 °C); umax
(CHC13)/cm-1 3482,3436,2981, 1704, 1369; cSH (360 MHz, CDC!) 1.33 (3H, d, J
7.1 Hz, CH3CH), 1.40 (9H, s, But), 4.22 OH, hr. m, CHCH3), 5.53 OH, hr. m,
NHBoc), 6.41 OH, br. s, NH2), 6.74 (lH, hr. s, NH2).
2-(R)-(1-Thiocarbamoylethyl)-carbamic acid tert-butyl ester (86a)
s
",,2 Jl
'r I-NH2
BocNH
Lawesson's reagent (5.82 g, 14.4 mmol) was added as one portion to a stirred solution of
the amide 85a (5.46 g, 28.8 mmol) in anhydrous THF (70 ml) at room temperature
under an atmosphere of nitrogen. The resulting solution was stirred at room
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temperature for 14 h and concentrated in vacuo to leave a green oil. The residue was
purified by chromatography on silica using 30 % ethyl acetate in light petroleum (40-60
°C) as eluant to give the thioamide (5 g, 24.4 mmol, 85 %) as a pale green/yellow solid;
mp. 83-84 °C (from dichloromethane) (Lit.142 mp. 85-87 °C); umax (CHCI3)/cm-l
3524,3437, 2978, 1697; BH (360 MHz, CDCI3) 1.33 (9H, s, But), 1.36-1.39 (3H, m,
CH3CH), 4.53 OH, br., CHCH3), 5.66 OH, br., NHBoc); Bc (90.5MHz, CDCh)
20.8 (q), 21.7 (d), 28.1 (q), 79.9 (s), 155.2 (s), 210.2 (s).
1'-(R)-2-(1-tert-Butoxycarbonylaminoethyl)-thiazole-4-carboxylic acid ethyl ester
(87a)
A solution of the thioamide 86a (1.4 g, 6.6 mmol) in DMF (9 ml) was stirred with
potassium hydrogen carbonate (5.3 g, 52.6 mmol) at room temperature for 10 min. The
solution was cooled to -15°C and then ethyl bromopyruvate (2.5 ml, 19.7 mmol) was
added dropwise over 5 min. The resulting yellow solution was stirred at -15°C for 10
min and a precooled mixture of collidine (7.4 ml, 55.9 mmol) and trifluoroacetic
anhydride (3.7 ml, 26.3 mmol) in dry DME (9 ml) was then added dropwise over 15
min. This solution was stirred at -15°C for a further 15 min and then poured onto ice
cold water (40 ml). The separated aqueous layer was extracted with dichloromethane (3
x 20 ml) and the combined organic extracts were then washed with 10% aqueous citric
acid solution (3 x 30 ml), copper sulfate solution (3 x 30 ml), and brine (3 x 30 ml), were
dried (MgS04) and evaporated in vacuo to leave a brown residue. This residue was
purified by chromatography on silica using 30 % ethyl acetate in light petroleum (40-60
°C) as eluant to give the thiazole (1.41 g, 4.7 mmol, 71 %) as a pale yellow solid; mp.
88-90 °C (from petroleum ether/diethyl ether) (Lit.143 mp. 89.5 °C); [a]o295 +34.4 (c
= 1.20, CHCh); umax (CHCI3)/cm-l 3440,2980,2935, 1715, 1488, 1454, 1369, 1155;
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()H (360 MHz, CDCl3) 1.28 (3H, t, J 7.1Hz, CH3CH2), 1.33 (9H, S, But), 1.51 (3H, d,
J 7.1 Hz, CH3CH), 4.29 (2H, q, J 7.1 Hz, CH2CH3), 4.99-5.01 (lH, rn, CHCH3),
5.47 (lH, d, J 7.2 Hz, NHBoc), 7.99 OH, s, CHS); ()e (90.5MHz, CDCb) 14.0 (q),
21.3 (q), 27.9 (q), 48.7 (d), 61.1 (t), 79.8 (s), 126.9 (d), 146.8 (s), 154.7 (s), 161.0
(s), 174.9 (s); mlz (FAB) Found: 323.1046 (MH++Na+, C13H2004N2SNa requires
323.1041).
l' -(R)-2-(I-tert-Butoxycarbonylaminoethyl)-thiazole-4-carboxylic acid (197)
Sodium hydroxide (416 mg, 10.4 mmol) was added in one portion to a stirred solution of
the thiazole 87a (390 mg, 1.3 mmol) in a THF:H20 (9: 1) mixture (7 ml) at room
temperature, and the resulting mixture was then stirred for a further 2.5 h. The
separated aqueous layer was acidified to pH 4 with citric acid and then extracted with
dichloromethane (3 x 30 ml). The combined organic extracts were washed with water (3
x 20 ml) and brine (3 x 20 ml), then dried (MgS04) and the solvent was removed under
reduced pressure to leave the acid (291 mg, 1.07 mmol, 82 %) as a white solid; mp.
127-129 °C (from ethyl acetate/petroleum ether) (Lit.143 mp. 128-129 QC); [a]o29S
+36.0 (c = 1.0, CHCI3); Found: C, 48.3; H,6.1; N, 9.8%; calc. for CIIH1604N2S:
C,48.5; H,5.9; N, 10.3%. Umax (CHCl)/cm-1 3440, 2934,2614,1711,1491,1368,
1160; OH (360 MHz, CDCI3) 1.46 (9H, S, But), 1.64 (3H, d, J 6.7 Hz, CH3CH),
5.10-5.12 (IH, m, CHCH3 and NHBoc), OH, s, CHS); oe (90.5 MHz, CDC}3) 21.5
(q), 28.3 (q), 48.7 (d), 80.4 (s), 128.5 (d), 146.4 (s), 155.0 (s), 164.2 (s).
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1'-(R)-2-(1 '-Amino-ethyl)-thiazole-4-carboxylic acid (88a)
A 4M solution of hydrochloric acid in dioxane (2 ml) was added to the thiazole 197
(291 mg, 1.07 mmol) at room temperature under an atmosphere of nitrogen, and the
mixture was then stirred for 2 h. The dioxane was removed in vacuo by azeotroping
with toluene to leave the amine hydrochloride (190 mg, 0.92 mmol, 86 %) as a
hygroscopic cream solid; mp. 262-264 °C (from ethanol/diethyl ether) (Lit.144 mp.
265-267°C); [a]D293+0.4 (c = 1, EtOH); Found: C, 34.1; H,4.2; N, 13.1 %; calc.
for C6H902N2SCl: C, 34.6; H,4.4; N, 13.5 %; BH (360 MHz, CD30D) 1.79 (3H, d,
J 6.9 Hz, CH3CH), 4.94 (1H, app. q, J 6.9 Hz, CHCH3), 8.52 (1H, s, CHS); Be (125
MHz, CD30D); 20.2 (q), 48-50 (d) (obscured by CD30D), 130.9 (d), 148.4 (s), 163.9
(s) ; mlz (FAB) Found: 485.0512 (MH++Na+,ClsHlS03N6S3Na requires 485.0500).
Cyclic-tris-(R),(R),(R)-alanine-thiazole (93) and cyclic-tetra-(R),(R),(R),(R)-
alanine-thiazole (94)
o :
........ll : SS'Y-N~-/;
"....(=N H N'}:O
o={:N H N'··'"
~~N~S
= 0
Diisopropylethylamine (0.48 mI, 2.76 mmol) was added dropwise over 5 min to a
stirred solution of the thiazole 88a (190 mg, 0.92 mmol) in anhydrous acetonitrile (18
ml) at room temperature under a nitrogen atmosphere. The solution was stirred at room
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temperature for 5 min, FDPP (530 mg, 1.38 mmol) was added in one portion and the
resulting solution was then stirred at room temperature for 3 days. The solvent was
removed in vacuo to leave a yellow residue which was taken up in dichloromethane (ca
30 ml), washed with 2M hydrochloric acid solution (4 x 20 ml), 2M sodium hydroxide
solution (3 x 20 ml), and brine (2 x 20 ml), dried (MgS04) and evaporated in vacuo.
The white residue was purified by chromatography on silica using 70 % ethyl acetate in
light petroleum (40-60 QC) to 90 % ethyl acetate in light petroleum (40-60 QC) as
eluants to give, i) the cyclic peptide 93 (58 mg, 0.38 mmol, 41%) as a white powder;
mp. 298-300 °C (from dichloromethane); [a]o302 +48.1 (c = 1, CHCI3); Found: C,
46.8; H, 4.1 %; CigHIg03N6S3 requires: C,46.8; H, 3.9 %; Amax (EtOH)/nm 228
(s/dm ' mol+crrr ' 1916); umax (CHCI3)/cm-l 3402,2977, 1663, 1544, 1498, 1350,
1047, 878; OH (360 MHz, CDCI3) 1.74 (3H, d, J 6.8 Hz, CH3CH), 5.64 (lH, app.
quintet, J 6.8 Hz, CHCH3), 8.17 (lH, s, CHS), 8.68 (lH, d, J 6.8 Hz, NHCO); Oc
(125 MHz, CDCI3); 25.0 (q), 47.4 (d), 124.0 (d), 148.8 (s), 159.5 (s), 171.2 (s); mlz
(FAB) Found: 485.0512 (MH++Na+, ClsH1903N6S3Na requires 485.0500), and ii) the
cyclic peptide 94 (18 mg, 0.09 mmol, 10 %) as a white powder; mp. 268-271 °C (from
dichloromethane); [a]o293 = +17.l (c = 0.7, CHCI3); Amax (EtOH)/run 225 (E/dm3 mol-
lem-I 55593); umax (CHCI3)/cm-1 3632, 3402, 2928, 2856, 1715, 1665, 1543, 1462,
1297, 1016; OH (360 MHz, CDCI3) 1.86 (3H, d, J 6.9 Hz, CH3CH), 5.61 (lH, app.
quintet, J 6.9 Hz, CHCH3), 7.99 (lH, d, J 8.1 Hz, NHCO), 8.12 OH, s, CHS); 8c
(125 MHz, CDCI3) 21.2 (q), 46.0 (d), 124.8 (d), 148.2 (s), 159.9 (s), 170.8 (s); m/:
(FAB) Found: 639.0666 (MH+,+ Na+, C24H2S04NgS4Na requires 639.0701).
2-(R)-(1-Carbomoyl-2-phenyl-etbyl)-carbamic acid teFt-butyl ester (85b)
Ph 0
1""'~NH2
BocNH
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N-Methylmorpholine (3.2 ml, 28.8 mmol) and isobutyl chloroformate (3.7 ml, 28.8
mmol) were added to a solution of Boc-(D)-phenylalanine (8.0 g, 28.8 mmol) in
anhydrous THF (7 ml) at -10 QC under an atmosphere of nitrogen. The resulting
solution was stirred at -10 QC for 15 min, ammonia was then bubbled through the
solution for 5 min at -10 QC, and at room temperature for a further 20 min. Water (ca
50 ml) was added, the aqueous layer was then separated and extracted with chloroform
(4 x 30 ml). The combined organic extracts were washed with saturated sodium
hydrogen carbonate solution (3 x 30 ml) and brine (3 x 30 ml), dried (MgS04) and
evaporated in vacuo to leave the amide (7.27 g, 26.2 mmol, 91 %) as a white solid; mp.
87-89 QC (from ethyl acetate/petroleum ether) (Lit.145 mp. 92-93 QC); bH (360 MHz,
CDCl3) 1.41 (9H, s, But), 3.07 (2H, app. d, J 5.8 Hz, CH2Ph), 4.40 (1H, br. s, J 5.2
Hz, NHBoc), 5.13-5.16 (lH, br. m, CHCH2), 5.71 (1H, br. s, NH2), 5.97 (1H, br. s,
NH2), 7.22-7.33 (5H, m, ArH); be (90.5 MHz, CDC13) 28.2 (q), 38.4 (t), 55.3 (d), 80.1
(s), 126.9 (d), 128.6 (d), 129.3 (d), 136.5 (s), 189.1 (s).
2-(R)-(2-Phenyl-l-thiocarbornyl-etbyl)-carbarnic acid tert-butyl ester (86b)
Ph S
1".2Jl
• .( I-NH2
BocNH
Lawesson's reagent (5.3 g, 13.65 mmol) was added as one portion to a solution of the
amide (7.6 g, 27.3 mmol) in anhydrous THF (13 ml) and the solution was stirred at
room temperature for 15 h under an atmosphere of nitrogen. The solution was
concentrated in vacuo, the green residue taken up in dichloromethane (40 ml), washed
with 2M sodium hydroxide solution (3 x 30 ml), brine (2 x 30 ml), dried (MgS04) and
evaporated in vacuo to leave the thioamide (7.4 g, 25.1 mmol, 92 %) as a green solid;
mp. 97-99 QC (from ethyl acetate/petroleum ether) (Lit.146 mp. 97-99 QC); bH (360
MHz, CDCI3) 1.41 (9H, s, (Bu), 3.15-3.18 (2H, br. m, CH2Ph), 4.62 (1H, app. quintet,
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J 7.5 Hz, CHCH2Ph), 7.25-7.39 (5H, m, ArH)~ Be (90.5 MHz, CDCI3) 28.1 (q), 60.5
(d), 7104 (t), 80.1 (s), 126.6 (d), 128.3 (d), 129.1 (d), 155.3 (s), 208.1 (s).
l' (R)-2-(1 "-tert-Butoxycarbonylamino-2' -phenyl-ethyl)-thiazole-4-carboxylic acid
ethyl ester (87b)
A solution of the thioamide 86b (3.5 g, 12.5 mmol) in DMF (15 ml) was stirred
vigorously with potassium hydrogen carbonate (l0.0 g, 100 mmol) at 0 °C for 5 min
under an atmosphere of nitrogen. Ethyl bromopyruvate (4.7 ml, 37.5 mmol) was added
dropwise over 5 min. The resulting yellow solution was stirred at -15°C for 5 min, and
a precooled solution of collidine (14 ml, 106 mmol) and trifluoroacetic anhydride (7.1
ml, 50 mmol) in DMF (15 ml) was added dropwise over 10 min, the reaction was
allowed to warm to room temperature and stirred for a further 20 min. The volatiles
were removed under reduced pressure, water (40 ml) was added and the separated
aqueous layer extracted with chloroform (3 x 40 ml). The combined organic extracts
were washed with copper sulfate solution (3 x 30 ml), water (3 x 30 ml), and brine (2 x
30 ml), were dried (MgS04) and evaporated in vacuo to leave a brown residue. The
residue was purified by chromatography on silica using 30% ethyl acetate in light petrol
(40-60 CC) as eluant to leave the thiazole (3.9 g, lOA mmol, 83 %) as a cream solid; mp.
111-114 °C (from dichloromethane) (Lit.146 mp III CC); [a]o294 = +10.6 (c = 1.0,
CHCh); Umax (CHCI3)/cm-1 3432,3125,2982, 1715, 1489, 1455, 1393, 1369, 1300,
1154,; OH (360 MHz, CDCh) 1.38 (9H, br. s, But), 1.33-1.44 (3H, m, CH3CH20),
3.28-3.35 (2H, m, CH2Ph), 4.45 (2H, q, J 7.0 Hz, CH2CH3), 5.28 (2H, hr. s,
CHCH2Ph), 5.28 (2H, br. s, NHBoc), 7.10-7.12 (2H, m, ArH), 7.23-7.26 (3H, m, ArH),
8.05 (lH, s, CHS); Be (90.5 MHz, CDCh) 14.1 (q), 28.0 (q), 41.2 (t), 53.7 (d), 61.3
(t), 80.0 (s), 126.7 (d), 127.1 (d), 128.4 (d), 129.2 (d), 136.0 (s), 146.9 (s), 154.8 (s),
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161.1 (s), 173.0 (s); mlz (FAB) Found: 399.1343 (M++Na+, Cl9H2404N2SNa
requires 399.1354).
1'(R)-2-(1 '-tert-Butoxycarbonylamino-2'-phenyl-ethyl)-thiazole-4-carboxylic acid
ethyl ester (198)
The thiazole 87b (1.0 g, 2.7 mmol) was stirred in a THF:H20 (9:1) mixture (14 ml) with
sodium hydroxide (0.9 g, 21.3 mmol) for 12 h at room temperature. The solution was
extracted with ethyl acetate (30 ml) and the separated aqueous layer was acidified to
pH4 by the addition of citric acid. The acidified aqueous layer was extracted with ethyl
acetate (4 x 30 ml), and these combined organic extracts were washed with brine (2 x 30
ml), dried (MgS04) and condensed in vacuo to leave the thiazole (670 mg, 1.9 mmol, 71
%) as a pale yellow solid; mp. 159-161 "C (from dichloromethane) (Lit.86 describes an
oil); [a]D298 = + 12.2 (c = 1.0, CHC13); umax (CHC13)/cm-1 3435, 3125, 2981, 1714,
1490,1456,1394,1369,1155; eSH(360 MHz, COC13) 1.41 (9H, s, But), 3.33-3.39
(2H, br. m, CH2Ph), 5.28 (lH, br., CHCH2Ph), 5.29 (lH, br. s, NHBoc), 7.12-7.15
(2H, m, ArH), 7.22-7.39 (3H, m, ArH), 8.18 (lH, s, CHS); eSc(90.5 MHz, CDCh)
28.0 (q), 41.2 (t), 53.7 (d), 80.1 (s), 126.8 (d), 128.1 (d), 128.4 (d), 128.7 (d), 146.7 (s),
154.9 (s), 163.7 (s), 173.1 (s); mlz (FAB) Found: 371.1021 (MH+ +Na+,
C17H2004N2SNa requires 371.1040).
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1'(R)-2-(I-Amino-2-phenyl-ethyl)-thiazole-4-carboxylic acid (88b)
The thiazole 198 (900 mg, 2.7 mmol) was stirred with a 4M solution of hydrochloric
acid in dioxane (2 rnl) at room temperature under an atmosphere of nitrogen for 2.5 h.
The dioxane was removed by azeotroping with toluene to leave the thiazole (701 mg,
2.5 mmol, 91 %) as a cream/white solid; mp. 232°C (decomp.) (Lit.148 mp. 250-252
CC); Found; H, 4.9, N, 9.4 %; calc. for CJ2HI302N2SCI: H, 4.6, N, 9.9 %; OH (360
MHz, CD30D) 3.34-3.39 (lH, br. m, CH2Ph), 3.46-3.52 (lH, br. m, CH2Ph), 5.11-
5.15 (lH, br. m, CHCH2Ph), 7.23-7.29 (2H, m, ArH), 7.30-7.38 (3H, rn, ArH), 8.40
(lH, s, CHS); Oc (90.5 MHz, CD30D) 54.4 (d), 68.1 (t), 128.9 (d), 130.1 (d), 130.8
(d), 135.6 (d), 148.5 (s), 163.8 (s), 165.5 (s).
Cyclic-tr;s-(R),(R),(S)-phenylalanine-thiazole (95) and Cyclic-tetra-(R),(R),(R),(R)-
phenylalanine-tbiazole (96).107
Ph
o !'
r-=?N~
~N H Ni
Ph-\\.,. NH RN 0
O~N~
'Ls Ph
Diisopropylethylamine (0.09 ml, 0.52 mmol) and FDPP (lOO mg, 0.26 mmol) were
added to a suspension of the thiazole 88b (50 mg, 0.18 mmol) in anhydrous acetonitrile
(4 ml) at room temperature under an atmosphere of nitrogen, the solution was stirred
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for 3 days before being evaporated to dryness in vacuo. The residue was taken up in
dichloromethane (20 ml) and partitioned with 2M hydrochloric acid solution (15 ml) the
separated organic layer was then washed with 2M hydrochloric acid solution (3 x 20
ml). The combined aqueous solutions were re-extracted with dichloromethane (2 x 20
ml) and the combined organic extracts were washed successively with 2M sodium
hydroxide solution (3 x 20 ml), water (3 x 20 ml) and brine (2 x 20 ml). The organic
solution was dried (MgS04) and the solvent removed under reduced pressure to leave a
white residue. The cyclic peptide containing residue was separated by chromatography
on silica using 70 % ethyl acetate in light petroleum (40-60 QC)as eluant to give, i) the
cyclic trimer (4 mg, 0.017 mmol, 10 %) as a white powder; mp. 248-249 QC(from
dichloromethane); [a]o303 = -0.40 (c = 1.00, CHC13); Found: C, 62.4; H,4.7%;
C36H3003N6S3requires; C, 62.6; H,4.4%); A.max (CH2CI2)/nm 231 (e/dm3 mol-)cm-}
519003); Umax (CHCh)/cm-) 3400, 2927, 1667, 1550, 1492, 1464, 1360, 1306, 1140,
1061, 997, 900; OH (360 MHz, CDC13) 2.89 (lH, dd, J 9.1, 12.8 Hz, CH2Ph), 2.90
(lH, dd, J 9.1, 12.8 Hz, CH2Ph), 3.21 (lH, dd, J 8.4, 13.7 Hz, CH2Ph), 3.55 (IH, dd, J
4.2, 12.9 Hz, CH2Ph), 3.57 (lH, dd, J 4.2, 12.9 Hz, CH2Ph), 3.74 (lH, dd, J 4.2, 12.9
Hz, CH2Ph), 5.46-5.48 (lH, m, CHCH2Ph), 5.65-5.66 (IH, m, CHNH), 5.86-5.87 (IH,
m, CHNH), 7.02-7.05 (6H, m, ArH), 7.18-7.31 (9H, m, ArH), 8.01 (IH, s, CHS), 8.04
(lH, s, CHS), 8.14 (lH, s, CHS); oe (90.5 MHz, CDC13) 43.1 (t), 43.3 (t), 43.6 (t),
52.9 (d), 53.8 (d), 54.1 (d), 120.3 (d), 123.5 (d), 123.9 (d), 124.9 (d), 127.2 (d), 127.3
(d), 127.5 (d), 128.7 (d), 129.3 (d), 129.7 (d), 129.9 (d), 130.1 (d), 148.3 (s), 148.5 (s),
149.1 (s), 159.5 (s), 159.9 (s), 160.0 (s), 168.1 (s), 168.1 (s), 169.1(s); mlz (FAB)
Found: 713.1450 (M+ +Na"; C36H3003N6S3Narequires 713.1439), and ii) the cyclic
tetramer (48 mg, 0.05 mmol, 41 %) as a white powder; mp. 250-254 QC (from
dichloromethane); [a]o302 = -5.79 (c = 1.50, CHCh); umax (CHCl)/cm-) 3400, 2927,
1667, 1550, 1492, 1464, l360, 1306, 1140, 1061, 997, 900; OH (360 MHz, CDCh)
3.49-3.57 (2H, m, CH2Ph), 5.68-5.74 (lH, m, CHCH2Ph), 7.15-7.30 (5H, m, ArH),
7.95-7.98 (lH, d, J 8.5 Hz, NHCO), 7.99 (lH, s, CHS); oe (90.5 MHz, CDCh) 43.9
(t), 52.7 (d), 123.9 (d), 127.2 (d), 129.6 (d), 130.0 (d), 135.9 (s), 148.6 (s), 159.4 (s).
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1'(S)-2-(1 '-tert-Butoxycarbonylamino-2'-phenyl-ethyl)-thiazole-4-carboxylic acid
ethyl ester (199)
EtO~~N
!(,NNHBOC
S 2 l
Ph
The thioamide (3.0 g, 10.2 mmol), was stirred vigorously with potassium hydrogen
carbonate (S.2 g, S1.6 mmol) in DMF (12 ml) for 5 min. Ethyl bromopyruvate (3.9 ml,
30.7 mmol) was added dropwise over 5 min and the solution cooled to 0 "C. A
precooled mixture of trifluoroacetic anhydride (5.S ml, 40.S mmol) and collidine (11.5
ml, 86.7 mmol) in DMF (12 ml) was added dropwise over 10 min, the reaction was
allowed to warm to room temperature and was stirred for a further 30 min. The
volatiles were removed in vacuo, water (ca 50 ml) was added and the aqueous extracted
with dichloromethane (4 x 30 ml). The combined organic extracts were washed with
10% aqueous citric acid solution (3 x 30 ml), dried (MgS04) and evaporated in vacuo to
leave a brown residue which was purified by chromatography on silica using 30 % ethyl
acetate in light petroleum (40-60 QC)to leave the thiazole (2.8 g, 7.4 mmol, 73 %) as a
cream solid; mp. 140-142 °C (from dichloromethane) (Lit.146a no mp. given); Umax
(CHCI3)/cm-l 36S9, 3434,2982, 1717, 1603, 1490; aH (360 MHz, CDCI3) 1.31 (9H,
s, But), 1.29-1.33 (3H, br. m, CH3CH2), 3.19-3.28 (lH, br. m, CH2Ph), 3.29-3.33 (IH,
br. m, CH2Ph), 4.34 (2H, q, J7.l Hz, CH2CH3), 5.20-5.23 (lH, br. rn, CHCH2), 5.49
(1H, d,J7.8 Hz, NHBoc), 7.04-7.19 (SH, m, ArH), 7.97 (lH, s, CHS); oc(90.5 MHz,
CDCb) 14.0 (q), 27.9 (q), 41.0 (t), 61.0 (t), 79.7 (s), 126.6 (d), 127.0 (d), 128.2 (d),
129.0 (d), 146.8 (s), 154.7 (s), 161.0(s), 172.9 (s).
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l'(S)-2-(1 '-leTI-Butoxycarbonylamino-2' -phenyl-ethyl)-thiazole-4-carboxylic acid
(200)
H02~
I£.._~NHBOC
S 2 l
Ph
Sodium hydroxide (0.9 g, 21.3 mmol) was added to a solution of the thiazole 199 (1.0 g,
2.7 mmol) in a THF:HzO (4:3) mixture (6 ml) at room temperature. The resulting
solution was then stirred at room temperature for 13 h, and the separated aqueous
extracted with dichloromethane (2 x 30 ml) to remove any impurities. The aqueous was
then acidified to pH4 by the addition of citric acid and was re-extracted with
dichloromethane (4 x 30 ml). These combined organic extracts were then washed with
brine (3 x 30 ml), dried (MgS04) and evaporated in vacuo to leave the thiazole 200
(670 mg, 1.9 mmol, 71 %) as a pale yellow solid; mp. 140-142 °C (from
dichloromethane) (Lit.86 no mp. given); [a.]D30Z = -8.0 (c = 1.0, CHCh); 'Umax
(CHC13)/cm-13434, 3124, 2979, 293, 1760, 1708, 1489, 1455, 1394, 1369, 1344, 1294,
1156, 1049; BH (360 MHz, CDC13) 1.30 (9H, s, But), 3.01-3.03 (lH, br. m, CH2Ph),
3.29-3.31 (lH, br. m, CH2Ph), 4.99-5.09 (lH, br. m, CHCH2Ph), 7.09-7.27 (5H, m,
ArH), 8.11 (IH, d, J8.6 Hz, NHBoc), 8.16 (IH, s, CHS); Be (90.5 MHz, CDCl]) 28.1
(q), 41.3 (t), 53.8 (d), 80.4 (s), 126.9 (d), 128.6 (d), 129.3 (d), 136.1 (s), 146.4 (s), 164.7
(s), 177.1 (s).
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l' (S)-2-(1-{[2-(I-tert- Butoxycarbonylamino-2-phenyl-ethyl)-thiazole-4-carbony1]-
amino}-l '-(S)-2-phenyl-ethyl)-thiazole-4-carboxylic acid ethyl ester (101)
BOCHN_rPh
S "N
'==!Yo
HNrPh
~N
'==J..
4 C02Et
N -Methylmorpholine (0.21 ml, 1.9 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (364 mg, 1.9 mmol) and N-hydroxybenzotriazole (260
mg, 1.9 mmol) were added to a solution of the thiazole acid 200 (600 mg, 1.7 mmol) in
anhydrous dichloromethane (20 ml) at 0 "C. The solution was stirred at 0 °C for 15
min, and a precooled solution of the thiazole ethyl ester hydrochloride (540 mg, 1.7
mmol) in DMF (3 ml) deprotonated with N-methylmorpholine (0.21 ml, 1.9 mmol) was
added dropwise over 10 min. The resulting solution was stirred at 0 °C for 1 h, then at
room temperature for 12 h. The solution was evaporated in vacuo to leave a residue
which was taken up in ethyl acetate (30 ml) and washed with 10% aqueous citric acid
solution (3 x 15 ml), saturated aqueous sodium bicarbonate solution (3 x 20 ml), and
water (3 x 20 ml), was dried (MgS04) and evaporated in vacuo to leave a residue.
Purification by chromatography on silica using 30 % ethyl acetate in light petroleum
(40-60 CC)as eluant gave the dimer (360 mg, 0.6 mmol, 35 %) as a cream foam; [a]D302
= -12.9 (c = 1.0, CHCh); Found: C, 61.29; H,5.71; N, 8.82 %; C3lH340SN4S2
requires: C,61.37; H,5.65; N,9.24%; vmax (CHCh)/cm-1 3393,3124,2981,2933,
1716, 1672; OH (360 MHz, CDCh) 1.15-1.46 (3H, m, CH3CH2), 1.31 (9H, br. s, tBu),
2.95-3.04 (IH, m, CH2Ph), 3.17-3.26 (IH, m, CH2Ph), 3.42-3.44 (2H, m, CH2Ph), 5.13-
5.20 (lH, m, CHNHBoc), 5.65-5.71 (lH, rn, CHCH2), 5.77-5.79 (lH, m, CHCH2),
7.01-7.26 (lOH, m, ArH), 7.81 (lH, s, CHS), 7.84 (lH, s, CHS), 8.23 (IH, d, J7.1Hz,
NHCO); Oc(90.5 MHz, CDCh) 13.9 (q), 27.8 (q), 27.8 (q), 40.3 (t), 52.0 (d), 53.3
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(d), 60.9 (t), 79.5 (s), 122.7 (d), 123.6 (d), 126.3 (d), 126.4 (d), 126.5 (d), 127.1 (d),
128.0 (d), 128.1 (d), 135.8 (s), 136.1 (s), 146.8 (s), 148.4 (s), 154.6 (s), 160.2 (s), 160.7
(s).
l' (S)-( -{ [-(1-Methyl-2-phenyl-ethyl)-thiazole-4-carbonyl]-amino} 1'(S)-2-phenyl-
ethyl)-thiazole-4-carboxylic acid ethyl ester (102)
The dimer 101 (600 mg, 0.99 mmol) was stirred with a 4M solution of hydrochloric acid
in dioxane (2 ml) for 1.5 h at room temperature under a nitrogen atmosphere. The
dioxane was removed in vacuo by azeotroping with toluene to leave the amine (515 mg,
0.95 mmol, 96 %) as a yellow viscous oil; OH(360 MHz, CD30D) 1.38 (3H, t, J 7.0
Hz, CH3CH2), 3.41-3.52 (2H, m, CH2Ph), 3.41-3.52 (2H, m, CH2Ph), 4.38 (2H, q, J
7.0, Hz, CH2CH3), 5.24-5.27 (lH, m, CHCH2), 5.77-5.81 (IH, m, CHCH2), 7.19-
7.41 (lOH, m, ArH), 8.21 (lH, s, CHS), 8.36 (lH, s, CHS); Oc (90.5 MHz, CD30D)
14.6 (q), 40.8 (t), 41.3 (t), 54.3 (d), 54.4 (d), 62.5 (t), 126.5 (d), 127.3 (d), 127.8 (d),
128.6 (d), 129.4 (d), 129.7 (d), 129.8 (d), 130.4 (d), 130.5 (s), 138.1 (s), 147.0 (s),
149.4 (s), 162.1 (s), 162.3 (s).
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l'(S)-2-(1-{ [2-(1-tert- Butoxycarbonylamino-2-phenyl-ethyl)-thiazole-4-carbony1]-
amino }-1'(S)-2-phenyl-ethyl)-thiazole-4-carbonyl]-amino }-1' (S)-2-phenyl-ethyl)-
thiazole-4-carboxylic acid ethyl ester (103)
N-Methylmorpholine (0.11 ml, 1.01 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (I94 mg, 1.01 mmol) and N-hydroxybenzotriazole
(140 mg, 1.01 mmol) were added to a solution of the thiazole acid 99 (321 mg,0.92
mmol) in anhydrous dichloromethane (20 ml) at 0 °C, the solution was stirred for 15
min and a precooled solution of the dimer amine hydrochloride 102 (500 mg, 0.92 mmol)
in DMF (3 ml) deprotonated with N-methylmorpholine (0.11 ml, 1.01 mmol) was
added dropwise over 5 min. The resulting solution was stirred at 0 °C for 1h, and at
room temperature for 14 h. The solution was evaporated in vacuo to leave a residue
which was taken up in ethyl acetate (30 ml) and washed with 10 % aqueous citric acid
solution (3 x 15 ml), saturated aqueous sodium hydrogen carbonate solution (3 x 20 ml)
and water (3 x 20 ml), dried (MgS04) and evaporated in vacuo to leave a residue.
Purification by chromatography using 30 % ethyl acetate in light petroleum (40-60 °C)
as eluant gave the hexapeptide (500 mg, 0.6 mmol, 65 %) as a cream foam; [a]o301 =
-28.6 (c = 1.0, CHC13); umax (CHCh)/cm-1 3393,3123,2932,1716,1673; OH (360
MHz, CDCh) 1.16-1.35 (3H, m, CH3CH2), 1.16-1.35 (9H, m, But), 3.16-3.56 (6H, m,
CH2Ph), 4.26-4.41 (2H, m, CH2CH3), 5.21-5.24 (IH, m, NHBoc), 5.53-5.79 (3H, m,
CHCH2Ph), 7.04-7.21 (ISH, m, ArH), 7.90-7.98 (lH, m, CHS), 7.90-7.98 (lH, m,
CHS), 7.90-7.98 (lH, m, CHS), 7.90-7.98 (IH, m, NHCO), 8.20 (IH, d, J 8.3 Hz,
NHCO); Oc(90.5 MHz, CDCh) 14.0 (q), 27.9 (q), 40.3 (t), 40.6 (t), 51.7 (d), 52.1 (d),
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53.4 (d), 61.1 (t), 79.9 (s), 123.8 (d), 123.9 (d), 126.6 (d), 128.3 (d), 128.3 (d), 129.1
(d), 129.9 (d), 130.6 (d), 135.8 (s), 135.9 (s), 136.0 (s), 146.9 (s), 148.5 (s), 148.7 (s),
160.2 (s), 160.9 (s), 170.9 (s), 171.3 (s).
2' (R)-2-(2' -tert-Butoxycarbonylamino-3 '-phenylpropionylamino )-3-
hydroxypropionic acid methyl ester (147)102, 146
Ph ° 3 OH
" 2,Jlll
3' "'r I ,-1';l 2 C02Me
BocNH H
Triethylamine (1.0 ml, 7.4 mmol) was added dropwise over 2 min to a stirred solution
of Boc-(D)-phenylalanine (1.0 g, 3.54 mmol) in THF (20 ml) at -30°C. Isobutyl
chloroformate (0.5 ml, 3.9 mmol) was added, the solution stirred for a further 2 min at
-30°C and (D, L)-serine methyl ester hydrochloride salt (0.6 g, 3.9 mmol) was added in
one portion to the white suspension. The resulting solution was allowed to warm to
room temperature over 15 h, the volatiles were removed in vacuo, and water (50 ml)
was added. The solution was extracted with ethyl acetate (4 x 30 ml), the combined
organic extracts were then washed with sodium bicarbonate solution (3 x 30 ml), dried
(MgS04) and evaporated in vacuo to leave a white residue. Purification by
chromatography on silica using 20 % ethyl acetate in light petroleum (40-60 QC)to 70
% ethyl acetate in light petroleum (40-60 QC)as eluants gave the dipeptide (1.3 g, 3.4
mmol, 97 %) as a sticky white foam; umax (CHCI3)/cm-1 3428,2957,2539,2358, 1744,
1679, 1603, 1456, 1394; OH (360 MHz, CDCI3) 1.39 (9H, S, But), 3.01-3.07 (lH, m,
CH2Ph), 3.12-3.17 (IH, hr. m, CH2Ph), 3.72 (3H, s, CH30), 4.02 (lH, br. s, CH20H),
4.46-4.48 (lH, m, CHNHBoc), 4.58-4.61 (IH, hr. m, CHC02Me), 5.02 (lH, d, J 7.4
Hz, NHBoc), 7.10-7.31 (SH, m, ArH); Oc(90.5 MHz, CDCh) 28.2 (q), 38.5 (t), 52.3
(q), 54.0 (d), 55.8 (d), 63.2 (t), 80.2 (s), 126.9 (d), 129.3 (d), 136.7 (s), 155.7 (s), 170.5
(s), 170.9 (s);
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1'(R)-2-(I-tert-Butoxycarbonylamino-2-phenyl-ethyl)-4,5-dihydro-oxazole-4-
carboxylic acid methyl ester (148)147
Me02~N
(_~NHBoc
o 2 ~
<,
Ph
DAST (0.2 ml, 1.5 mmol) was added dropwise over 3 min to a solution of the dipeptide
147 (500 mg, 1.4 mmol) in anhydrous dichloromethane (9 ml) at -70 QCunder an
atmosphere of nitrogen. The resulting pale yellow solution was stirred at -70 QCfor a
further 2 h 40 min, aqueous ammonia (15 ml) was added in one portion and the mixture
was allowed to warm to room temperature. The separated aqueous layer was extracted
with dichloromethane (3 x 30 ml). The combined organic extracts were washed with
water (3 x 30 ml) and brine (2 x 30 ml), dried (MgS04) and concentrated in vacuo to
give a yellow residue which was purified by chromatography on silica using 30 % ethyl
acetate in light petroleum (40-60 QC)as eluant to give the oxazoline (370 mg, 1.1 mmol,
76 %) as a pale yellow oil; umax (CHCh)/crn-1 3684,3430,2957, 1744, 1713, 1456,
1369, 1158, 1057~ OH (360 MHz, CDCl) 1.34 (9H, s, But), 2.93-3.11 (2H, m,
CH2Ph), 3.67 (3H, s, OCH3), 4.31-4.37 (lH, rn, CHCH2Ph), 4.48 (IH, t, J 8.2 Hz,
CHC02Me), 4.57-4.66 (2H, m, CH20CN), 5.21 (lH, d, J 8.2 Hz, NHBoc), 7.06-7.22
(5H, m, ArH)~ Oc (90.5 MHz, CDCh) 27.8 (q), 38.4 (t), 49.5 (d), 52.3 (q), 67.3 (d),
70.8 (t), 79.2 (s), 127.2 (d), 128.2 (d), 128.9 (d), 154.5 (s), 168.9 (s), 170.6 (s);
l' (R)-2-( I-tert- Butoxycarbonylamino-2-phenyl-ethyl)-oxazole-4-carboxylic acid
methyl ester (149)
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Bromotrichloromethane (0.16 ml, 1.6 mmol) was added dropwise over 5 min to a stirred
solution of the oxazoline 148 (500 mg, 1.4 mmol) in anhydrous dichloromethane (7 ml)
at -5°C under an atmosphere of nitrogen. The solution was stirred for 5 min at 0 °C
and 1, 8-diazobicyclo[5.4.0] undec-7-ene (0.24 ml, 1.6 mmol) was added dropwise over
5 min, the resulting mixture was allowed to warm to room temperature over 1 h, and
saturated ammonium chloride solution (15 ml) was added in a single portion. After
stirring for 10 min the organic layer was separated and washed with water (2 x 10 ml),
dried (MgS04) and evaporated in vacuo to leave a pale yellow solid residue. The
residue was purified by chromatography on silica using 30% ethyl acetate in light
petroleum (40-60 °C) as eluants to give the oxazole (370 mg, 1.07 mmol, 76 %) as a
cream solid; mp. 108-110 °C (dichloromethane) (Lit.146a no mp. given); [a]o301 =
+9.8 Cc = 1.0, CHCI3); Umax (CHCI3)/cm-1 3437, 2980, 2933, 1714, 1586, 1369, 1347,
1325, 1141, 1112, 1002; eSH (360 MHz, CDCl3) 1.36 (9H, s, But), 3.14-3.21 (2H, br.
m, CH2Ph), 3.87 (3H, s, CH30), 5.17-5.26 (lH, br. m, CHCH2Ph), 5.28 (lH, d, J
8.2Hz, NHBoc), 7.00-7.15 (2H, m, ArH), 7.17-7.23 (3H, m, ArH), 8.11 (IH, s, CHO);
eSc (90.5 MHz, CDCh) 27.7 (q), 39.5 (t), 49.6 (d), 51.5 (q), 79.3 (s), 126.4 (d), 127.9
(d), 128.7 (d), 135.3 (s), 143.6 (d), 154.4 (s), 160.9 (s), 164.3 (s).
1'(R)-2-(tert-Butoxycarbonylamino-2-phenyl-ethyl)-oxazole-4-carboxylic acid
(150)
Sodium hydroxide (1.1 g, 26.1 mmol) was added in one portion to a solution of the
oxazole (1.1 g, 3.3 mmol) in a THF:H20 (9: 1) mixture (17 ml) at room temperature.
The solution was stirred for 14 h and acidified to pH4 by the addition of citric acid, the
acidified aqueous layer was then extracted with dichloromethane (3 x 40 ml). The
combined organic extracts were washed with water (2 x 30 ml) and brine (2 x 30 ml),
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dried (MgS04) and evaporated in vacuo to leave the acid (1.0 g, 5.16 mmol, 96 %) as a
yellow foam; [a]D301= +12.6 (c = 0.4, CHC13); Vmax (CHC13)/cm-l 3696,3437,2930,
1713,1601,1494,1455,1368,1158,1109, 984; ~H (360 MHz, CDC13) 1.39 (9H, S,
But), 3.24 (2H, d, J 6.9 Hz, CH2Ph), 5.10-5.29 (lH, m, CHCH2Ph), 5.94 (IH, d, J 8.2
Hz, NHBoc), 7.08-7.27 (SH, m, ArH), 8.21 (lH, s, CHO); ~c (90.5 MHz, CDCI3)
28.2 (q), 40.3 (t), 50.3 (d), 80.2 (s), 127.1 (d), 128.6 (d), 129.2 (d), 133.0 (s), 135.2 (s),
144.7 (d), 164.1 (s), 182.1 (s).
1'(R)-2-(1-Amino-2-phenyl-ethyl)-oxazole-4-carboxylic acid (151)
A 4M solution of hydrochloric acid in dioxane (16 ml) was added to the oxazole 150
(500 mg, 1.5 mmol) at room temperature under an atmosphere of nitrogen. The solution
was stirred for 2 h and the dioxane was then removed under reduced pressure using
toluene as an azeotrope. The crude amine was triturated with acetonitrile, filtered and
dried by suction to give the amine (350 mg, 1.3 mmol, 87 %) as a cream/white solid;
mp. 78-90 QC(from methanol); 8H (360 MHz, CD30D) 3.34-3.45 (2H, m, CH2Ph),
4.88-4.90 (lH, m, CHCH2Ph), 7.21-7.23 (2H, m, ArH), 7.31-7.38 (3H, m, ArH), 8.58
(lH, s, CHO); 8c (90.5 MHz, CD30D) 39.l (t), 51.1 (d), 128.9 (d), 130.1 (d), 130.4
(d), 135.l (s), 147.1 (d), 161.5 (s), 163.6 (s).
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Cyclic-tris-(R),(R),(R)-phenylalanine-oxazole (163) and cyclic-tetra-(R), (R),(R),(R)-
phenylalanine-oxazole (164)
Diisopropylethylamine (0.35 ml, 2 mmol) and FDPP (392 mg, 1.02 mmol) were added
to a suspension of the oxazole 151 (180 mg, 0.68 mmol) in anhydrous acetonitrile (15
ml) the solution was then stirred at room temperature for 3 days before being
evaporated to dryness in vacuo. The residue was partitioned between dichloromethane
(30 ml) and 2M hydrochloric acid solution (30 ml) the separated organic layer was then
washed with 2M hydrochloric acid solution (3 x 30 ml). The combined aqueous
solutions were re-extracted with dichloromethane (2 x 30 ml) and the combined organic
solutions were washed successively with 2M sodium hydroxide solution (3 x 30 ml),
water (3 x 30 ml) and brine (2 x 30 ml). The organic solution was dried (MgS04) and
the solvent removed under reduced pressure to leave the cyclic peptide 163 as a mixture
with 164 (0.21 mmol, 31 %). The cyclic peptide containing residue was separated by
chromatography on silica using 70 % ethyl acetate in light petroleum (40-60 QC) as
eluant to give, i) the cyclic trimer (6 mg, 0.026 mmol, 15 %) as a white powder; mp.
239-241 °C (from dichloromethane); [a]o296 = -0.80 (c = 0.50, CHC13); umax
(CHCh)/cm-1 3697, 3604, 2926, 2855, 1721, 1673, 1600, 1490, 1456, 1295, 1162,
1052, 1010, 966, 903; OH(360 MHz, CDC13) 3.30-3.44 (2H, rn, CH2Ph), 5.37-5.41
(1H, m, CHCH2Ph), 6.95-6.97 (2H, rn, ArH), 7.24-7.30 (3H, rn, ArH), 8.16-8.18 (lH,
m, NHCO), 8.16-8.18 (lH, rn, CH=O); Oc(90.5 MHz, CDCI3) 28.9 (t), 60.4 (d), 120.1
(d), 125.3 (s), 125.6 (d), 129.8 (s), 129.9 (d), 157.4 (s), 167.1 (s), and ii) the cyclic
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tetramer (9 mg, 0.028 mmol, 16 %) as a white powder; mp. 241-244 °C (from
dichloromethane); [a]D301 = -21.6 (c = 1.50, CHCl3); Amax (EtOH)/nm 271 (c/dm3
mol+crrr ' 64409); Umax (CHCl3)/cm-13385,2958,2928,2857, 1719, 1678, 1600, 1494,
1456, 1377, 1297, 1102, 1078,863; OH (360 MHz, CDCl3) 3.30-3.49 (2H, m, CH2Ph),
5.37-5.47 (IH, m, CHCH2Ph), 6.95-6.97 (2H, m, ArH), 7.22-7.32 (3H, m, ArH)' 8.12
(IH, s, CHO), 8.17 (IH, d, J 6.3 Hz, NHCO); Oc (90.5 MHz, CDCh) 40.1 (t),49.7
(d), 127.1 (d), 128.4 (d), 129.3 (d), 135.0 (s), 141.5 (d), 159.2 (s), 162.8 (s).
l' (R)-2-( I-Ierl-Butoxycarbony lamino-2-methylpropyl)-4,5-dihydro-oxazole-4-
carboxylic acid methyl ester (202)143a
Me02~
( ~NHBOC
o ~
A
DAST (0.55 ml, 4.2 mmol) was added dropwise over 2 min to a stirred solution of the
dipeptide (1.2 g, 3.7 mmol) in anhydrous dichloromethane (20 ml) at -78°C under an
atmosphere of nitrogen. The reaction was stirred at -78°C for I h, and aqueous
ammonia (ca. 40 ml) was then added, and the solution allowed to warm to room
temperature. The separated aqueous layer was extracted with dichloromethane (4 x 30
ml), and the combined organic extracts were then washed with brine (3 x 20 ml), dried
(MgS04) and evaporated in vacuo to leave a yellow oil. Chromatography on silica
using 50 % ethyl acetate in light petroleum (40-60 °C) as eluant gave the oxazoline (550
mg, 1.9 mmol, 50 %) as a colourless oil; OH (360 MHz, CDCh) 0.72 (6H, t, J7.5 Hz,
(CH3hCH), 1.21 (9H, s, But), 1.83-1.88 (lH, hr. m, CH(CH3h), 3.54 (3H, s, CH30),
4.10 (lH, dd, J 5.6, 8.9 Hz, CHNH), 4.28 (lH, dd, J 8.1 Hz, CH20), 4.34 (lH, dd, J
8.1 Hz, CH20), 4.54 (IH, dd, J8.1, 10.4 Hz, CHC02Me), 5.07 (lH, d, J9.2 Hz,
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NHBoc); Be (90.5 MHz, CDC13) 17.2 (q), 18.2 (q), 27.7 (q), 31.2 (d), 52.0 (d), 53.5
(q), 67.2 (d), 69.3 (t), 79.5 (s), 154.9 (s), 168.9 (s), 170.7 (s).
1'(R)-2-(1-tert-Butoxycarbonylamino-2-methylpropyl)-oxazole-4-carboxylic acid
methyl ester (203)
Me02~
~.~NHBOC
o 2 ~
A
Bromotrichloromethane (0.21 ml, 2.1 mmol) was added dropwise over 5 min to a stirred
solution of the oxazoline 202 (550 mg, 1.9mmol) in anhydrous dichloromethane (10 ml)
at 0 °C under an atmosphere of nitrogen. The solution was stirred at 0 °C for 15 min,
and then 1,8-diazabicyc10[5.4.0]undec-7-ene (0.31 ml, 2.1 mmol) was added dropwise
over 10 min. The resulting solution was stirred at room temperature for a further 2 h
and then ammonium chloride solution (ca 20 ml) was added. The separated aqueous
layer was extracted with dichloromethane (3 x 20 ml) and the combined organic extracts
were washed with brine (2 x 20 ml), dried (MgS04) and evaporated in vacuo. The
residue was purified by chromatography on silica using 30 % ethyl acetate in light
petroleum (40-60 °C) as eluant to give the oxazole 203 (432 mg, 1.5 mmol, 76 %) as a
white solid; mp. 125-127 °C (from dichloromethane) (Lit.146a mp. 120-123 °C);
[a]o302 + 5.6 (c = 1.0, CHCh); Found: C, 56.1; H, 7.4; N, 9.2 %; calc. for
C14H220SN2: C,56.4; H,7.4; N, 9.4 %; BH (360 MHz, CDCI3) 0.70 (6H, t, J 6.9
Hz, CH(CH3h), 1.19 (9H, s, But), 1.94-2.03 (IH, br. m, CH(CH3h), 3.68 (3H, s,
CH30), 4.58 (lH, dd, J 6.3, 9.2 Hz, CHNHBoc), 5.32 (lH, d, J 9.2 Hz, NHBoc), 8.07
(lH, s, CHO); Oc(90.5 MHz, CDCh) 17.4 (q), 18.2 (q), 27.7 (q), 32.3 (d), 51.6 (q),
53.8 (d), 79.2 (s), 132.6 (s), 143.6 (d), 154.9 (S), 161.0 (s), 164.6 (s); m/z (FAB)
Found: 321.3279 (MH++Na+, C14H220sN2Na requires 321.3288).
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1'(R)-2-(1-tert-Butoxycarbonylamino-2-methyl-propyl)-oxazole-4-carboxylic acid
(204)
Sodium hydroxide (410 mg, 0.22 mmol) was added to a stirred solution of the oxazole
(381 mg, 1.28 mmol) in a 5:4 mixture of THF:H20 (5:4) mixture (7 ml) at room
temperature and this mixture was stirred at room temperaure for 14 h. The separated
aqueous layer was acidified to pH4 with citric acid and then extracted with ethyl acetate
(4 x 20 ml). The combined organic extracts were dried (MgS04) and evaporated in
vacuo to leave the acid (349 mg, 1.22 mmol, 96 %) as a white foam which crystallised to
give a white powder; mp. 141-142 °C (from dichloromethane) (Lit.1SO mp. 145-147
QC); Umax (CHC13)/cm-1 3682,3439,2974,2398, 1714, 1601, 1498, 1368, 1326, 1160,
1111, 1001; &H (360 MHz, CDC13) 0.90 (3H, d, J 6.7 Hz, (CH3hCH), 0.99 (3H, d, J
6.7 Hz, But), 1.44 (9H, s, But), 2.17-2.25 (IH, m, CR(CH3h), 4.65 (lH, d, J 6.7 Hz,
CHNHBoc), 7.12 (lH, d, J 8.8 Hz, NHBoc), 8.49 (IH, c, CRO); 8c (90.5 MHz,
CDCI3) 18.8 (q), 19.3 (q), 28.6 (q), 43.7 (d), 55.9 (d), 80.6 (s), 134.2 (s), 145.7 (d),
163.7 (s), 166.5 (s), 176.6 (s); mlz (FAB) Found: 307.1306 (MH++Na+,
C13H200sN2Na requires 307.1270)
1'(R)-2-(1-Amino-2-methylpropyl)-oxazole-4-carboxylic acid (165)
H02C 4 N
Ito%f NH2·HCI
A
The oxazole 204 (440 mg, 1.6 mmol) was stirred with a 4M solution of hydrochloric
acid in dioxane (5 ml) at room temperature for 3 h under an atmosphere of nitrogen. The
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dioxane was removed under reduced pressure by azeotroping with toluene to leave the
amine (250 mg, 1.04 mmol, 65%) as a sticky pale yellow solid; OH (360 MHz, CD30D)
1.03 (3H, d, J 6.9 Hz, (CR3hCH), 1.15 (3H, d, J 7.2 Hz, (CR3hCH), 2.45-2.53 (IH,
br. m, CR(CH3h), 4.50 (lH, d, J 7.2 Hz, CHNH2.HCI), 8.75 (lH, s, CRO), 8.85-8.96
(lH, br. s, NH); OC (90.5 MHz, CD30D) 18.0 (q), 18.9 (q), 32.3 (d), 55.2 (d), 134.7
(s), 147.2 (d), 163.6 (s), 173.4 (s); rnlz (FAB) Found: 185.0930 (MH+-Cl-,
C8H1303N2requires 185.0926)
Cyclic-tris-(R),(R),(R)-valine-thiazole (166)
Diisopropylethylamine (0.53 ml, 3 mmol) was added to a stirred suspension of the
oxazole 165 (220 mg, 1 mmol) in anhydrous acetonitrile (20 ml) at room temperature
under an atmosphere of nitrogen. The mixture was stirred for 5 min and FDPP (576 mg,
1.5 mmol) was added in one portion, the resulting solution was then stirred for 3 days at
room temperature. The mixture was concentrated in vacuo to leave a brown residue
which was taken up in dichloromethane (ca 30 ml) and washed with 2M hydrochloric
acid solution (2 x 20 ml), 2M sodium hydroxide solution (2 x 30 ml), and brine (30 ml).
The separated organic layer was dried (MgS04) and evaporated in vacuo to leave a
white residue which was purified by chromatography on silica using 70 % ethyl acetate
in light petroleum (40-60 QC)as eluant to give the cyclic peptide (8 mg, 0.05 mmol, 5 %)
as a white powder; mp. 176-179 QC(from dichloromethane); [a]D301 = -57.1 (c = 0.7,
CHC13); "'max (EtOH)/nm 215 (e/dm! mol+crrr! 152678); Umax (CHCh)/cm-1 3389,
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2968,2934, 1681, 1600, 1575, 1373, l304, 1129, 1097,882; 8H (360 MHz, CDCh)
1.05 (3H, d, J 6.9 Hz, (CH3hCH), 1.09 (3H, d, J 6.9 Hz, (CH3hCH), 2.34-2.41 (1H,
m, CH(CH3h), 5.15 (lH, dd, J4.9,7.9 Hz, CHNH), 8.20 (tH, s, CHO), 8.25 (lH, d, J
7.9 Hz, NHCO); 8c (125 MHz, CDCI3) 18.3 (q), 33.6 (d), 53.3 (d), 135.4 (s), 141.4
(d), 159.6 (s), 163.6 (s); mlz (FAB) Found: 521.2189 (MH++Na+, C24H3006N6Na
requires 521.2125).
2'(R)-2-(2-Benzyloxycarbonylamino-propionylamino )-3-hydroxy-butyric acid
methyl ester (157)149
yOH
"" 2'~ 1_~
"r 1'-N C02Me
CbZNH H
N-Methylmorpholine (2.6 ml, 23.7 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (4.5 g, 23.7 mmol) and N - hydroxybenzotriazole (3.2
g, 23.7 mmol) were added to a stirred solution ofCbZ-protected (D)-alanine (4.8 g, 21.5
mmol) at 0 °C under an atmosphere of nitrogen. The resulting mixture was stirred for
20 min and a precooled solution of (D, L) - threonine methyl ester hydrochloride (3.6 g,
21.5 mmol) deprotonated with N-Methylmorpholine (2.6 ml, 23.7 mmol) in DMF (5
ml) was added dropwise over 5 min. The mixture was stirred at 0 °C for 1 h and at
room temperature for 14 h. Water (ca 50 ml) was added, the aqueous layer separated
and extracted with ethyl acetate (6 x 50 ml). The combined organic extracts were
washed with sodium hydrogen carbonate solution (3 x 40 ml), 10 % aqueous citric acid
solution (3 x 40 ml), and brine (3 x 40 ml), were dried (MgS04) and evaporated in
vacuo. The yellow residue was purified by chromatography on silica using 70 % ethyl
acetate in light petroleum (40-60 CC) as eluant to give the dipeptide (5.75 g, 17.0 mmol,
79 %) as a viscous oil; Urnax (CHCh)/cm-1 3429,2954,1730,1682, 1494, 1455, 1321,
1069, 908; 8H (360 MHz, CDCl3) 1.20 (3H, d, J 6.4 Hz, CH3CHOH), 1.44 (3H, d, J
7.1 Hz, CH3CH), 3.76 (3H, s, CH30), 4.34-4.37 (lH, br. m, CH(OH)CH3), 4.34-4.37
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(IH, m, CHCH3), 4.58 (IH, dd, J2.4, 8.9 Hz, CHC02Me), 5.13 (2H, s, CH2Ph), 5.40-
5.47 (lH, br. s, NHCbZ), 6.83 (lH, d, J 8.9 Hz, NHCO), 7.30-7.39 (5H, m, ArH); Be
(90.5 MHz, CD30D) 18.7 (q), 19.5 (q), 50.5 (d), 52.3 (q), 57.3 (d), 66.6 (t), 67.3 (d),
127.7 (d), 127.9 (d), 128.1 (d), 155.8 (s), 171.3 (s), 173.5 (s); mlz (FAB) Found:
2' (R)-2-(2- Benzyloxycarbonylamino-propionylamino )-3-oxo-butyric acid methyl
ester (158)
Ox° 3
",2' JlI
"'r 1'- N 2 C02Me
CbZNH H
Dess Martin Periodinane (17.6 g, 41.5 mmol) was added in one portion to a solution of
the dipeptide 157 (l0.8 g, 31.9 mmol) in anhydrous dichloromethane (lOOml) at room
temperature under an atmosphere of nitrogen. The resulting brown solution was stirred
for 4 h at room temperature, the volatiles were then removed in vacuo leaving a solid
yellow residue. The residue was purified by chromatography on silica using 70 % ethyl
acetate in light petroleum (40-60 CC)as eluant to give the dipeptide (9.2 g, 27.5 mmol,
86 %) as a white solid; mp. 117-118 °C (from dichloromethane); Umax (CHCI3)/cm-1
3422,2957, 1757, 1729, 1682, 1492, 1454, 1359, 1069,973; 8H (360 MHz, CDCh)
1.42 (3H, d, J 7.1 Hz, CH3CH), 2.38 (3H, s, CH3COCH), 3.81 (3H, s, CH30CO), 4.36-
4.40 (lH, m, CHCH3), 5.13 (2H, s, CH2Ph), 5.24 (lH, d, J 6.3 Hz, CHC02Me), 5.36
(lH, d,J6.9 Hz, NHCbZ), 7.15-7.20 (IH, br. s, NHCO), 7.31-7.36 (5H, m, ArH); Be
(90.5 MHz, CD30D) 18.2 (q), 27.5 (q), 50.0 (d), 52.1 (q), 62.6 (d), 66.6 (t), 127.7 (d),
127.8 (d), 128.2 (d), 155.8 (s), 166.3 (s), 172.6 (s), 198.4 (s); mlz (FAB) Found:
359.1219 (M++Na+, CI6H2006N2Na requires 359.1219);
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l' (R)-2-( 1-Benzyloxycarbonylamino-ethyl)-5-methyl-oxazole-4-carboxylic acid
methyl ester (159)
A solution of the dipeptide 158 (1.2 g, 3.6 mmol) in anhydrous THF (3.5 ml) at -78 QC
under an atmosphere of nitrogen was added dropwise, over 5 min, to ~ solution of
triphenylphosphine (2.1 g, 7.85 mmol), iodine (0.9 g, 7.14 mmol) and triethylamine (1.8
ml, 12.96 mmol) in anhydrous THF (12 ml) at -78 QC. The resulting yellow solution
was allowed to stir at -78 QCfor 4 h and at room temperature for a further 14 h.
Water (ca 50 ml) was added and the separated aqueous layer was extracted with
dichloromethane (4 x 40 ml). The combined organic extracts were washed with sodium
hydrogen carbonate solution (2 x 40 ml), 2M hydrochloric acid solution (2 x 40 ml) and
brine (2 x 40 ml), dried (MgS04) and evaporated in vacuo. The solid yellow residue
was purified by chromatography on silica using 70 % ethyl acetate in light petroleum
(40-60 CC) as eluant to leave the oxazole (960 mg, 3.02 mmol, 84 %) as a white solid;
mp. 126-128 cc (from dichloromethane); [a]D295 = +29.4 (c = 1.0, CHCI3); Umax
(CHCI3)/cm-l 3433,2954, 1722, 1624, 1454, 1353, 1101, 1066,980; OH (360 MHz,
CDCh) 1.57 (3H, d, J 6.9 Hz, CH3CH), 2.62 (3H, s, CH3CO), 3.91 (3H, s, CH30),
5.03-5.09 (1H, m, CHCH3), 5.12-5.13 (2H, m, CH2Ar), 5.31 (IH, br. s, NHCbZ), 7.30-
7.35 (5H, m, ArH); Oc (90.5 MHz, CDCI3); 11.9 (q), 20.0 (q), 45.0 (d), 51.9 (q), 67.0
(t), 128.0 (d), 128.1 (d), 128.4 (d), 136.1 (s), 155.4 (s), 156.6 (s), 162.5 (s), 167.1 (s);
mlz (FAS) Found: 341.1086 (M++Na+, C16HIsOsN2Na requires 341.1113).
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l' (R)-2-( 1-Benzy loxycarbonylamino-ethyl)-5-methy l-oxazole-4-carboxylic acid
(205)
A solution of sodium hydroxide (201 mg, 5 mmol) in water (2 ml) was added to a
solution of the oxazole 159 (200 mg, 0.63 mmol) in ethanol (6 ml) at room temperature.
The solution was stirred for 3 h, the volatiles were removed in vacuo and the resulting
oil was flooded with 2M hydrochloric acid solution. The oxazo1e acid was collected by
suction filtration (176 mg, 0.58 mmol, 92 %) as a white solid; mp. 248-250 "C (from
diethyl ether); umax(CHCh)/cm-1 3437,2980,1721,1632,1454,1362,1120,1066;
bH (360 MHz, CDCh) 1.56 (3H, d, J 6.9 Hz, CH3CH), 2.53 (3H, s, CH3CO), 5.02-
5.12 (lH, m, CHCH3), 5.02-5.12 (2H, m, CH2Ar), 6.48-6.55 (lH, br. s, NHCbZ) 7.20-
7.35 (5H, m, ArH); be (90.5 MHz, CDCI3); 11.7 (q), 20.0 (q), 45.0 (d), 66.9 (t), 128.0
(d), 128.3 (d), 128.6 (d), 136.2 (s), 155.5 (s), 156.0 (s), 163.8 (s), 165.0 (s); m/z (FAB)
Found: 327.0953 (M++Na+,ClsHl60sN2Na requires 327.0957).
1'(R)-2-(1-Amino-ethyl)-5-methyl-oxazole-4-carboxylic acid hydrobromide (160)
A 33% solution of hydrobromic acid in acetic acid (1.5 ml) and glacial acetic acid (1 ml)
were added to the oxazole 205 (250 mg, 0.84 mmol) at room temperature under an
atmosphere of nitrogen. The brown solution was stirred for 2 h and the volatiles
removed in vacuo to leave the amine (193 mg, 0.76 mmol, 91 %) as an orange
hygroscopic solid; [a]o295 = +7.4 (c = 1.0, EtOH); bH (360 MHz, CD30D) l.73
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(3H, d, J 7.0 Hz, CH3CH), 2.69 (3H, s, CH3CO), 4.68-4.74 (lH, m, CHCH3); Be (90.5
MHz, CD30D); 13.2 (q), 18.5 (q), 46.8 (d), 134.9 (s), 160.1 (s), 160.8 (s), 165.8 (s).
2'(S)-2-(2-Benzyloxycarbonylamino-propionylamino)-3-hydroxy-butyric acid
methyl ester (206)
N -Methylmorpholine (3.4 ml, 31.2 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (6.0 g, 31.2 mmol) and N - hydroxybenzotriazole (4.2
g, 31.2 mmol) were added to a stirred solution of CbZ-protected (L)-alanine (6.3 g, 28.4
mmol) at 0 QCunder an atmosphere of nitrogen. The resulting mixture was stirred for
20 min at 0 QCand a precooled solution of (D, L) - threonine methyl ester hydrochloride
(4.8 g, 28.4 mmol) deprotonated with N-Methylmorpholine (3.4 ml, 31.2 mmol) in
DMF (4 ml) was added dropwise over 5 min. The mixture was stirred at 0 QCfor 1 h
and at room temperature for 14 h. Water (ca 40 ml) was added, the aqueous layer
separated and extracted with ethyl acetate (4 x 40 ml). The combined organic extracts
were washed with sodium hydrogen carbonate solution (3 x 40 ml), water ( 3 x 40 ml),
and brine (3 x 40 ml), dried (MgS04) and evaporated in vacuo. The yellow residue was
purified by chromatography on silica using 70 % ethyl acetate in light petroleum (40-60
QC) as eluant to give the dipeptide (7.88 g, 23.3 mmol, 82 %) as a viscous oil; Umax
(CHCI3)/cm-l 3428,2541, 1715, 1682, 1497, 1455, 1356, 1072; OH (360 MHz, CDCh)
1.16 (3H, d, J 6.4 Hz, CH3CHOH), 1.40 (3H, d, J 7.1 Hz, CH3CH), 3.73 (3H, s,
CH30), 4.31-4.41 (lH, br. m, CH(OH)CH3), 4.31-4.41 (lH, m, CHCH3), 4.58-4.61
(lH, m, CHC02Me), 5.03-5.08 (2H, m, CH2Ph), 5.84 (IH, d, J 7.8 Hz, NHCbZ), 7.22
(tH, d, J 8.9 Hz, NHCO), 7.29-7.40 (5H, m, ArH); Oc (90.5 MHz, CD30D) 16.3 (q),
18.2 (q), 49.8 (q), 50.8 (d), 56.9 (d), 65.5 (t), 66.3 (d), 126.7 (d), 126.8 (d), 127.3 (d),
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155.8 (s), 171.3 (s), 173.5 (s); mlz (FAB) Found: 361.1336 (M+ + Na",
2' (S)-2-(2- Benzyloxycarbonylamino-propionylamino )-3-oxo-butyric acid methyl
ester (207)
Dess Martin Periodinane (7.8 g, 18.4 mmol) was added in one portion to a solution of
the dipeptide 206 (5.0 g, 14.2 mmol) in anhydrous dichloromethane (80 ml) at room
temperature under an atmosphere of nitrogen. The resulting yellow solution was stirred
for 4 h at room temperature, the volatiles were then removed in vacuo leaving a solid
orange residue. The residue was purified by chromatography on silica using 50 % ethyl
acetate in light petroleum (40-60 QC)as eluant to give the dipeptide (3.1 g, 9.1 mmol, 64
%) as a white solid; mp. 118-119 °C (from dichloromethane) (Lit.lSl mp. 122-123 QC);
Umax (CHCI3)/cm-1 3423, 2957, 1757, 1729, 1685, 1493, 1455, 1358, 1070; OH (360
MHz, CDC13) 1.42 (3H, d, J 7.1 Hz, CH3CH), 2.39 (3H, s, CH3COCH), 3.82 (3H, s,
CH30CO), 4.35-4.40 (lH, m, CHCH3), 5.14 (2H, s, CH2Ph), 5.24 (IH, d, J 6.5 Hz,
CHC02Me), 5.31 (IH, d, J 7.6 Hz, NHCbZ), 7.15-7.21 (lH, br. s, NHCO), 7.32-7.46
(5H, m, ArH); Oc (90.5 MHz, CDCI3) 18.3 (q), 27.7 (q), 50.1 (d), 53.1 (q), 62.7 (d),
66.8 (t), 127.8 (d), 127.9 (d), 128.3 (d), 155.8 (s), 166.3 (s), 172.6 (s), 198.3 (s); mlz
(FAB) Found: 359.1219 (M++Na+, Cl6H2006N2Na requires 359.1219);
l' (S)-2-(1-Benzyloxycarbonylamino-ethyl)-5-methyl-oxazole-4-carboxylic acid
methyl ester (208)
Me02~
.s.~ NHCbZ
5 0 2 I
122
A solution of the dipeptide 207 (3.1 g, 9.3 mmol) in anhydrous THF (9 ml) at -78 QC
was added dropwise over 5 min to a solution of triphenylphosphine (5.4 g, 20.5 mmol),
iodine (2.4 g, 18.6 mmol) and triethylamine (4.7 ml, 33.5 mmol) in anhydrous THF (32
ml) at -78 QCunder an atmosphere of nitrogen. The resulting yellow solution was
allowed to stir at -78 QCfor 5 h and at room temperature for 15 h. Water (ca. 50 ml)
was added and the separated aqueous layer was then extracted with dichloromethane (4
x 40 ml). The combined organic extracts were washed with sodium hydrogen carbonate
solution (2 x 40 ml), 2M hydrochloric acid solution (2 x 40 ml) and brine (2 x 40 ml),
dried (MgS04) and evaporated in vacuo. The solid yellow residue was purified by
chromatography on silica using 70 % ethyl acetate in light petroleum (40-60 QC)as
eluant to leave the oxazole (2.2 g, 7.0 mmol, 75 %) as a white solid; mp. 126-128 QC
(from dichloromethane) (Lit.1St mp. 125.5-126 QC); [a]D29S= -33.6 (c = 1.0, CHCI));
Umax (CHCI3)/cm-l 3433, 2954, 1722, 1624, 1454, 1353, 1101, 1066, 9803436,2954,
1722, 1623, 1499, 1454, 1353, 1101, 1066; 8H (360 MHz, CDCI)) 1.57 (3H, d, J 7.0
Hz, CH)CH), 2.61 (3H, s, CH3CO), 3.91 (3H, s, CH30), 5.02 (IH, dq, J 5.5, 7.9 Hz,
CHCH)), 5.12-5.13 (2H, m, CH2Ar), 5.42 (IH, d, J 7.9 Hz, NHCbZ), 7.29-7.37 (5H,
m, ArH); 8c (90.5 MHz, CDCI)); 11.9 (q), 19.7(q), 44.8 (d), 51.7 (q), 66.7 (t), 127.8
(d), 127.9 (d), 128.2 (d), 135.9 (s), 155.3 (s), 156.3 (s), 162.3 (s), 162.3 (s); mlz (FAB)
Found: 341.1118 (M++Na+,C16HlsOSN2Narequires 341.1113).
l' (S}-2-(1- Benzyloxycarbonylamino-ethyl)-5-methyl-oxazole-4-carboxylic acid
(209)
H02C 4
~'7i-LNHCbZ
"fo 2 I
A solution of sodium hydroxide (900 mg, 22.6 mmol) in water (9 ml) was added to a
solution of the oxazole 208 (0.9 g, 2.83 mmol) in ethanol (27 ml) at room temperature.
The solution was stirred for 3 h, the volatiles were removed in vacuo and the resulting
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oil was flooded with 2M hydrochloric acid solution. The oxazole acid was collected by
suction filtration (792 mg, 2.6 mmol, 92 %) as a white solid; mp. 166-168 "C (from
diethylether); [alo295=-68.7(c= 1.0,CHCI3); 'Umax(CHC13)/cm-13441,2998,1723,
1454,1361, 1064; 8H (360 MHz, CD30D) 1.55 (3H, d, J 7.1 Hz, CH3CH), 2.61 (3H,
s, CH3CO), 4.91-4.97 (IH, m, CHCH3), 5.12 (2H, br. s, CH2Ar), 6.48-6.55 (IH, br. s,
NHCbZ) 7.31-7.39 (SH, m, ArH); 8c(125 MHz, CD30D); 13.0 (q), 20.2 (q), 47.3 (d),
68.7 (t), 129.9 (d), 130.1 (d), 130.2 (d), 139.2 (s), 158.3 (s), 159.1 (s), 165.3 (s), 166.5
(s); mlz (FAB) Found: 327.0952 (M++Na+,C15H1605N2Narequires 327.0957).
1'(R)-(I-{[I '(R)-(-tert-Butoxycarbonylaminoethyl)-thiazole-4-carbonyl]-amino}-
ethyl)-5-methyl-oxazole carboxylic acid methyl ester (179)
N -Methylmorpholine (0.19 ml, 1.76 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (338 mg, 1.76 mmol) and N-hydroxybenzotriazole
(238 mg, 1.76 mmol) were added to a stirred solution of the alanine thiazole acid 177
(436 mg, 1.6 mmol) in anhydrous dichloromethane (20 ml) at 0 QCunder an atmosphere
of nitrogen. The resulting solution was stirred at 0 QCfor a further 15 min and a
precooled solution of the oxazole amine 178 (353 mg, 1.6 mmol) deprotonated with N-
methylmorpholine (0.19 ml, 1.76 mmol) in DMF (3 ml) was added dropwise over 5
min. The orange/opaque solution was stirred at 0 °C for 1 h and at room temperature
for 15 h. 10 % aqueous citric acid solution (30 ml) was added and the separated
aqueous layer was extracted with dichloromethane (5 x 30 ml), the combined organic
extracts were then washed with sodium hydrogen carbonate solution (3 x 30 ml), water
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(3 x 30 ml), and brine (3 x 30 ml), were dried (MgS04) and evaporated in vacuo. The
brown residue was purified by chromatography on silica using 60 % ethyl actetate in
light petroleum (40-60 QC) as eluant to leave the tetrapeptide (560 mg, 1.28 mmol, 80
%) as a white foam; [a]D299 = +29.6 (c = 1.0, CHC13); umax (CHCI3)/cm-1 3688,
3872,3606,3441,3402,2981,2955,2934,1716,1672, 1622,1545,1490,1454,1389,
1369, 1353, 1299, 1153, 1099, 1059,984,908; 8H (360 MHz, CDCh) 1.46 (9H, s,
But), 1.60 (3H, d, J 6.8 Hz, CH3CH), 1.68 (3H, d, J 7.1 Hz, CH3CH), 2.62 (3H, S,
CH3CCO), 3.90 (3H, s, CH3CO), 5.06-5.14 (IH, br. m. CHCH3), 5.06-5.14 (lH, br. m.
NHBoc), 5.41-5.50 (lH, m, CHCH3), 7.74 (IH, d, J 8.5 Hz, NHCO), 8.03 (lH, s,
CHS); Be (90.5 MHz, CDCI3) 11.3 (q), 18.7 (q), 20.4 (q), 27.7 (d), 30.7 (d), 42.5 (q),
51.1 (q), 79.6 (s), 124.3 (d), 126.7 (s), 148.3 (s), 155.1 (s), 160.1 (s), 161.8 (s), 161.9
(s), 162.2 (s), 162.3 (s).
1'(R)-2-1 '(R)-2-(I-{[2-(-tert-Butoxycarbonylaminoethyl)-thiazole-4-carbonyl]-
amino}-ethyl)-5-methyl-oxazole carboxylic acid (180)
Sodium hydroxide (365 mg, 9.12 mmol) was added to a stirred solution of 179 (500 mg,
1.14 mmol) in a THF:H20 (5:4) mixture (11 ml) at room temperature and the resulting
solution was stirred at room temperature for 14 h. The separated aqueous layer was
acidified to pH4 by the addition of citric acid and was extracted with ethyl acetate (5 x
20 ml). The combined organic extracts were then washed with brine (3 x 20 ml), dried
(MgS04) and evaporated in vacuo to leave the acid (470 mg, 1.11 mmol, 97%) as a
cream foam which crystallised to give a cream powder; mp 76-78 QC (from diethyl
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ether); [a]D298 +36.4 (c = l.0, CHCI3); 'Umax (CHCh)/cm-1 3441, 3399, 3206, 2980,
2933,2629, 1706, 1668, 1622, 1549, 1490, 1454, 1393, 1369, 1323, 1152, 1101, 1058,
984, 897; SH (360 MHz, CDCI3) 1.45 (9H, s, But), 1.57 (3H, d, J 6.9 Hz, CH3CH),
1.70 (3H, d, J 6.9 Hz, CH3CH), 2.63 (3H, s, CH3CO), 5.06-5.13 (lH, hr. s, CHCH3),
S.lS-S.33 (lH, hr. s, NHBoc), 5.42-5.50 (lH, m, CHCH3), 7.95-7.98 (lH, hr. s,
NHCO), 8.06 (lH, s, CHS); Se (90.5 MHz, CDCI3) 11.6 (q), 18.7 (q), 20.S (q), 27.9
(q), 42.7 (d), 48.2 (d), 79.7 (s), 124.0 (d), 126.9 (s), 148.1 (s), 154.9 (s), 156.0 (s), 160.6
(s), 162.4 (s), 164.0 (s), 172.7 (s); mlz (FAB) Found: 447.1275 (MH++Na+,
1'(R)-2-(1-{[1 '(R)-2-(I-tert-Butoxycarbonylaminoethyl)-thiazole-4-carbonyl)-
amino }-ethyl)-5-rnethyl-oxazole-4-carbonyl)-amino }-1'(R)-2-rnethylpropyl)-
thiazole-4-carboxylic acid ethyl ester (182)
aV
~N~SU
o~;.N H N-:i(CO Et
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N -Methylmorpholine (0.14 ml, 1.26 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (242 mg, 1.26 mmol) and N-hydroxybenzotriazole
(170 mg, 1.26 mmol) were added to a stirred solution of the dimer 180 in anhydrous
dichloromethane (12 ml) at 0 °C under an atmosphere of nitrogen. The cream/opaque
solution was stirred at 0 °C for a further 15 min and a precooled solution of the thiazole
hydrochloride 181 (304 mg, 1.15 mmol) deprotonated with N-methylmorpholine (0.14
ml, 1.26 mmol) in DMF (3 ml) was added dropwise over 5 min. The resulting orange
solution was stirred at 0 °C for 1 h and at room temperature for 16 h. 10% aqueous
126
citric acid solution (20 ml) was added, and the separated aqueous layer was extracted
with dichloromethane (4 x 30 ml), the combined organic extracts were washed with
sodium hydrogen carbonate solution (3 x 20 ml), water (3 x 20 ml), and brine (3 x 20
ml), were dried (MgS04) and evaporated in vacuo. The orange residue was purified by
chromatography on silica using 50 % ethyl actetate in light petroleum (40-60 CC)as
eluant to leave the hexapeptide (497 mg, 0.8 mmol, 70 %) as a white foam; [a]D296
+46.4(c= 1.0,CHC13); umax(CHCl)/cm-1 3400,2979,1714,1668,1635,1544,1494,
1369, 1059, 908; OH (360 MHz, CDCI3) 0.99 (3H, d, J 6.8 Hz, (CH3hCH), 1.02 (3H,
d, J 6.8 Hz, (CH3hCH), 1.39 (3H, t, J 7.0 Hz, CH3CH2), 1.45 (9H, s, But), 1.63 (3H, d,
J 6.9 Hz, CH3CH), 1.68 (3H, d, J 7.0 Hz, CH)CH), 2.55-2.64 (lH, m, CH(CH3h), 2.62
(3H, s, CH)CO), 4.41 (2H, q, J7.0 Hz, CH2CH3), 5.01-5.11 (lH, br. s, CHCH3), 5.11-
5.26 (lH, br. s, NHBoc), 5.29 (lH, dd, J 6.7, 9.2 Hz, CHCHCH3), 5.42 (lH, dt, J 7.1,
15.4 Hz, CHCH3), 7.57 (IH, d, J9.2 Hz, NHCO), 7.76 (lH, d, J 8.4 Hz, NHCO), 8.06
(lH, s, CHS), 8.06 (lH, s, CHS); Oc(90.5 MHz, CDCI3) 11.1 (q), 13.8 (q), 17.4 (q),
18.7 (q), 19.1 (q), 20.2 (q), 27.7 (t), 32.4 (d), 42.4 (d), 48.2 (d), 55.4 (d), 60.7 (q), 79.2
(s), 123.4 (d), 126.6 (s), 127.9 (d), 146.7 (s), 148.3 (s), 153.3 (s), 154.2 (s), 159.9 (s),
160.6 (s), 160.8 (s), 160.9 (s), 171.2 (s), 174.5 (s); mlz (FAB) Found: 657.2186
(MH++Na+, C28H3407N6S2Narequires 657.2141).
l' (R)-2-(I- {[I' (R)-2-(I-tert- Butoxycarbonylamino-ethyl)-thiazole-4-carbonyl]-
amino} -ethyl)-5-methyl-oxazole-4-carbonyl] -amino }-I '(R)-2-methy l-propyl)-
thiazole-4-carboxylic acid (210)
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Sodium hydroxide (247 mg, 6.2 mmol) was added to a solution of the trimer 182 (480
mg, 0.77 mmol) in a THF:H20 (5:4) mixture (8 ml) at room temperature and the
reaction was stirred for 15 h. The separated aqueous layer was acidified to pH4 with
citric acid and the aqueous layer was extracted with dichloromethane (5 x 20 ml), the
combined organic extracts were dried (MgS04) and evaporated in vacuo to leave the acid
(446 mg, 0.75 mmol, 97 %) as a white foam which crystallised to give a white powder;
mp. 108-110 QC (from dichloromethane); [a]D296 = +42.8 (c = 1.0, CHCl3); umax
(CHCl3)/cm-l 3401,3246,2970,2933, 1714, 1667, 1634, 1546, 1490, 1454, 1394,
1369, 1154, 1059, 952, 908; OH (360 MHz, CDCh) 0.96-1.06 (6H, m, (CH3hCH),
1.47 (9H, s, But), 1.60-1.62 (3H, m, CH3CH), 1.68 (3H, d, J7.1 Hz, CH3CH), 2.51-
2.55 (lH, m, CH(CH3h), 2.62 (3H, s, CH3CO), 5.02-5.10 (IH, br. m, CHCH3), 5.22-
5.28 (lH, br. m, CHCH(CH3h), 5.22-5.28 (IH, br. m, NHBoc), 5.44-5.47 (lH, m,
CHCH3), 7.70-7.79 (IH, br. s, NHCO), 7.87-7.91 (lH, br. s, NHCO), 8.07 (lH, s,
CHS), 8.09 (IH, CHS); Oc (90.5 MHz, CDCI3) 11.6 (q), 18.1 (q), 19.2 (q), 19.5 (q),
21.1 (q), 28.1 (q), 32 .7 (d), 43.0 (d), 48.7 (d), 55.9 (d), 80.2 (s), 121.1 (s), 124.6 (d),
128.3 (d), 146.7 (s), 148.4 (s), 154.2 (s), 155.2 (s), 160.8 (s), 161.2 (s), 161.6 (s), 163.5
(s), 173.2 (s), 175.9 (s); mlz (FAB) Found: 629.1823 (MH++Na+, C26H3407N6S2Na
requires 629.1828).
1'(R)-2-(I-{[I'(R)-2-(I-{[2-(I-Amino-ethyl)-thiazole-4-carbonyl)-amino}-ethyl)-5-
methyl-oxazole-4-carbonyl) -amino }-1'(R)-2-methylpropy 1)-thiazole-4-carboxylic
acid hydrochloride (183)
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The linear trimer 210 (400 mg, 0.67 mmol) was stirred with a 4M soluti-
hydrochloric acid in dioxane (3 ml) at room temperature for 2 h under an atmosphere ot
nitrogen. The reaction was flooded with diethyl ether and the precipitate collected by
suction filtration to leave the amine (348 mg, 0.64 mmol, 96 %) as a white solid; mp.
72-74 QC(from dichloromethane); [a]D299+24.4 (c = 1.0, EtOH); OH (360 MHz,
CD30D) 0.99 (3H, d, J 6.7 Hz, (CH3)2CH), 1.10 (3H, d, J 6.7 Hz, (CH3)2CH), 1.74
(3H, d, J 7.0 Hz, CH3CH), 1.82 (3H, d, J 6.9 Hz, CH3CH), 2.46-2.52 (lH, m,
CH(CH3)2), 2.62 (3H, s, CH3CO), 4.93-4.98 (lH, m, CHCH3), 5.24 (lH, d, J 7.8 Hz,
CHCH(CH3)2), 5.42 (lH, q, J7.0 Hz, CHCH3), 8.36 (lH, s, CHS), 8.42 (lH, s, CHS);
Oc (90.5 MHz, CD30D) 18.3 (q), 19.0 (q), 19.9 (q), 20.5 (q), 33.9 (q), 44.4 (d), 49.1
(d), 57.5 (d), 58.1 (d)127.5 (d), 129.3 (s), 129.6 (d), 147.4 (s), 149.6 (s), 153.3 (s),
161.7 (s), 162.6 (s), 163.1 (s), 163.3 (s), 168.6 (s), 173.7 (s); mlz (FAB) Found:
507.1451 (MH+-CI-, C21H2705N6S2requires 507.1484).
Dendroamide (14)
Diisopropylethylamine (0.15 ml, 0.84 mmol) was added to a stirred suspension of the
linear trimer 183 (150 mg, 0.28 mmol) in anhydrous acetonitrile (6 ml) at room
temperature under a nitrogen atmosphere. The resulting solution was stirred for 5 min,
FDPP (160 mg, 0.42 mmol) was added and the reaction stirred at room temperature for
a further 2 h. Water (ca. 20 ml) was added and the separated aqueous layer was
extracted with dichloromethane (5 x 20 ml). The combined organic extracts were washed
with 2M sodium hydroxide solution (3 x 20 ml), 2M hydrochloric acid solution (3 x 20
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ml), and brine (2 x 20 ml), were dried (MgS04) and evaporated in vacuo to leave an
orange residue which was purified by chromatography on silica using 80 % ethyl acetate
in light petroleum (40-60 QC)as eluant to give dendroamide A (125 mg, 0.26 mmol, 91
%) as a white solid; mp. 146-148 QC(from dichloromethane) (Lit.23 no mp. given);
[a]o296 +66.9 (c = 0.7, CHC13) (Lit.23 [a]D296 +40.5 (c = 3.5, CH2C12); "'max
(MeOH)/nm 224 (s/dm! mol+crrr! 279136); Umax (CHCh)/cm-1 3396, 2963, 2929,
1716,1666,1639,1600,1546,1497,1450,1363,1300,1129, 1065,976,895; oH(360
MHz, CDCI3) 0.99 (3H, d, J 6.8 Hz, (CH3)2CH), 1.08 (3H, d, J 6.8 Hz, (CH3hCH),
1.71 (3H, d, J 6.8 Hz, CH3CH), 1.74 (3H, d. J 6.8 Hz. CH3CH). 2.28-2.37 OH, m,
CH(CH3h), 2.68 (3H, s, CH3CO), 5.21 OH, app. quintet, J6.4 Hz, CHCH3), 5.32 (1H,
dd, J 4.8, 8.2 Hz, CHCH(CH3h), 5.72 (1H, dq, J 6.8, 8.2 Hz, CHCH3), 8.14 (IH, s,
CHS), 8.15 (lH, s, CHS), 8.49 (lH, d, J 8.2 Hz, NHCO), 8.56 (IH, d, J 8.2 Hz,
NHCO), 8.65 (1H, d, J 6.4 Hz, NHCO); oe (125 MHz, CD2Ch); 11.7 (q), 18.3 (q),
18.5 (q), 21.1 (q), 25.1 (q), 35.6 (d), 44.6 (d), 47.4 (d), 56.2 (d), 123.8 (d), 124.1 (d),
128.9 (s), 149.2 (s), 149.3 (s), 154.0 (s), 159.7 (s), 160.0 (s), 160.7 (s), 162.2 (s), 168.9
(s), 171.8 (s); m/z (FAB) Found: 511.1169 (MH++Na+, C21H2404N6S2Na requires
511.1198).
I' (R)-2-(I-{ [I '(R)-2-(I-tert-Butoxycarbonylamino-2-methyl-propyl)-thiazole-4-
carbonyl]-amino}-ethyl)-5-methyl-oxazole-4-carboxylic acid methyl ester (211)
"'f=:4(e02Me
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N-Methylmorpholine (0.1 ml, 0.9 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (173 mg, 0.9 mmol) and N-hydroxybenzotriazole (122
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mg, 0.9 mmol) were added to a solution of the valine thiazole acid (235 mg, 0.82 mmol)
in anhydrous dichloromethane (10 ml) at 0 QCunder an atmosphere of nitrogen. The
resulting solution was stirred at 0 QCfor 15min, and a precooled solution of the oxazole
amine hydrobromide 178 (218 mg, 0.82 mmol) deprotonated with N-methylmorpholine
(0.1 ml, 0.9 mmol) in DMF (2 ml) was added dropwise over 5 min. The resulting
solution was stirred at 0 QCfor 1 h, and at room temperature for 16 h. Water (ca 30 ml)
was added and the separated aqueous layer was extracted with dichloromethane (4 x 20
ml), the combined organic extracts were washed with 10% aqueous citric acid solution (3
x 20 ml), saturated aqueous sodium bicarbonate solution (3 x 20 ml), were dried
(MgS04) and evaporated in vacuo. Purification by chromatography on silica using 30
% ethyl acetate in light petroleum (40-60 CC)as eluant gave the tetrapeptide (244 mg,
0.52 mmol, 64 %) as a white foam; [a]o295 = +19.6 (c = 1.0, CHCI3); 'Umax
(CHCI3)/cm-1 3696,3605,3442,3401,2967,2933,2874,1715,1669, 1622, 1544,
1490, 1455, 1392, 1369, 1332, 1158, 1100,983,908,870; OH (500 MHz, CDCI3) 0.94
(3H, d, J 6.9 Hz, (CH3)2CH), 1.00 (3H, d, J 6.9 Hz, (CH3)2CH), 1.47 (9H, s, But), 1.70
(3H, d, J 7.1 Hz, CH3CH), 2.34-2.41 (1H, m, (CH(CH3h), 2.63 (3H, s, CH3CO), 3.91
(3H, s, CH30CO), 4.84-4.88 (lH, m, CHCH(CH3h), 5.16 (lH, d, J 8.4 Hz, NHBoc),
5.46 (1H, dq, J 7.1,8.6 Hz, CHCH3), 7.69 (IH, d, J 8.6 Hz, NHCO), 8.04 (lH, s,
CHS); Oc(125 MHz, CDCl)) 11.8 (q), 17.5 (q), 19.3 (q), 19.4 (q), 28.1 (q), 32.7 (d),
42.8 (q), 51.7 (d), 57.7 (d), 79.9 (s), 123.3 (d), 127.2 (s), 149.1 (s), 155.2 (s), 156.3 (s),
160.3 (s), 162.3 (s), 162.4 (s), 172.4 (s); mlz (FAB) Found: 489.1759 (MH++ Na",
C21H3106N4SNarequires 489.1784);.
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l' (R)-2-(1-{ [1'(R)-2-(1-Amino-2-methyl-propyl)-thiazole-4-carbonyl]-amino )-5-
methyl-oxazole-4-carboxylic acid methyl ester hydrochloride (212)
A 4M solution of hydrochloric acid in dioxane (2 ml) was added to the dimer 211 at
room temperature under an atmosphere of nitrogen. The orange solution was stirred for
1 h and the dioxane removed in vacuo using toluene as an azeotrope to give the amine
(225 mg, 0.5 mmol, 98 %) as a pale yellow foam: [a]0299 = +2.4 (c = 0.5, EtOH); OH
(360 MHz, CD30D) 1.07 (3H, d, J 6.4 Hz, (CH3hCH), 1.18 (3H, d, J 6.4 Hz,
(CH3hCH), 1.73 (3H, d, J 6.9 Hz, CH3CH), 2.45-2,48 (IH' m, CH(CH3h), 2.64 (3H, s,
CH3CO), 3.91 (3H, s, CH30CO), 4.77-4.79 (lH, m, CHCH3), 5.38-5.40 (IH, rn,
CH(CH3)2), 8.41 (lH, s, CHS), 8.75 (lH, hr. s, NHCO); Oc (90.5 MHz, CD30D) 10.1
(q), 16.5 (q), 16.7 (q), 16.9 (q), 31.5 (q), 42.6 (d), 50.4 (d), 56.8 (d), 125.3 (d), 126.1 (s),
147.7 (s), 156.0 (s), 160.1 (s), 161.7 (s), 162.0 (s), 164.1 (s); mlz (FAB) Found:
367.1459 (MH++Na+, C16H2304N4Srequires 367.1440).
1'(R)-2-(I-{[1 '(R)-2-(I-{[1 '(R)-2-(I-tert-Butoxycarbonylamino-ethyl)-thiazole-4-
carbonyl]-amino}-2-methyl-propyl)-thiazole-4-carbonyl]-amino}-ethyl)-5-
methyl-oxazole-4-carboxylic acid methyl ester (213)
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N -Methylmorpholine (0.06 ml, 0.57 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (110 mg, 0.57 mmol) and N-hydroxybenzotriazole (77
mg, 0.57 mmol) were added to a stirred solution of the thiazole acid 197 (142 mg, 0.52
mmol) in anhydrous dichloromethane (5 ml) at 0 QCunder an atmosphere of nitrogen.
The resulting solution was stirred for a further 20 min at 0 QC,and a precooled solution
of the dimer 212 (210 mg, 0.52 mmol) deprotonated with N-methylmorpholine (0.06 ml,
0.57 mmol) in DMF (2 ml) was added dropwise over 5 min. The resulting solution was
stirred for 1 hat 0 QC,and then at room temperature for 16 h. Water (ca 20 ml) was
added and the separated aqueous layer extracted with dichloromethane (4 x 20 ml). The
combined organic extracts were washed with 10% aqueous citric acid solution (3 x 10
ml), saturated aqueous sodium bicarbonate solution (3 x 10 ml), were dried (MgS04) and
evaporated in vacuo. Purification by chromatography on silica using 60 % ethyl
acetate in light petroleum (40-60 QC)as eluant gave the hexapeptide (207 mg, 0.32
mmol, 62 %) as a white foam which crystallised to give a white powder; mp. 78-84 QC
(from dichloromethane); [a]D297 = +6.4 (c = 0.5, CHCh); '\)max (CHCI3)/cm-t 3401,
2970,1716, 1672, 1622, 1544, 1391, 1369, 1352, 1153, 1099, 1057; 8H (360 MHz,
CDC13) 1.05 (6H, d, J 6.4 Hz, (CH3hCH), 1.46 (9H, s, But), 1.63 (3H, d, J 6.5 Hz,
CH3CH), 1.70 (3H, d, J7.1 Hz, CH3CH), 2.52-2.62 (1H, m, CH(CH3h), 2.62 (3H, s,
CH3CO), 3.90 (3H, s, CH30CO), 5.11 (lH, hr. s, NHBoc), 5.11 (IH, hr. s, CHCH3),
5.33 (lH, dd, J 6.4, 9.l Hz, CHCH(CH3)2), 5.41-5.49 (lH, m, CHCH3), 7.71 (IH, d, J
8.3 Hz, NHCO), 7.83 (tH, d, J9.1 Hz, NHCO), 8.04 (lH, s, CHS), 8.06 (lH, s, CHS);
8c (90.5 MHz, CDCh) 11.8 (q), 17.7 (q), 19.4 (q), 19.5 (q), 28.l (d), 32.6 (d), 42.8 (d),
51.7 (q), 56.l (d), 79.9 (s), 123.5 (d), 123.7 (d), 127.2 (s), 148.8 (s), 149.1 (s), 154.8 (s),
154.9 (s), 156.3 (s), 160.2 (s), 160.6 (s), 162.3 (s), 171.4 (s), 175.0 (s); m/z (FAB)
Found: 643.1958 (MH++Na+, C27H3607N6S2Narequires 643.1985);
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1'(R)-2-(1-{[1 '(R)-2-(1-{[1 '(R)-(1-Amino-ethyl)-thiazole-4-carbonyl]-amino}-2-
methyl-propyl)-thiazole-4-carbonyl]-amino}-ethyl)-5-methyl-oxazole-4-
carboxylic acid hydrochloride (214)
Sodium hydroxide (51 mg, 1.28 mmol) was added to a solution of the trimer 213 (207
mg, 0.32 mmol) in a THF:H20 (5:4) mixture (4 ml) at room temperature. The solution
was stirred for 5 h, the separated aqueous layer was acidified to pH4 by the addition of
citric acid and extracted with dichloromethane (4 x 15 rnl). The combined organic
extracts were washed with water (2 x 10 rnl) and brine (2 x 10 ml), were dried (MgS04)
and evaporated in vacuo to leave a yellow oil. This yellow oil was subsequently stirred
with a 4M solution of hydrochloric acid in dioxane (4 ml) for 2 h at room temperature
under an atmosphere of nitrogen. The dioxane was removed in vacuo using toluene as
an azeotrope to give the hexapeptide (115mg, 0.26 mmol, 82 %) as a hygroscopic cream
solid; [a]D297 = -129.1 (c = 0.37, EtOH); 8H (360 MHz, CD30D) 1.05 (3H, d, J 6.5
Hz, (CH3)2CH), 1.14 (3H, d, J 6.5 Hz, (CH3hCH), 1.72 (3H, d, J 6.9 Hz, CH3CH),
1.84 (3H, d, J 6.8 Hz, CH3CH), 2.46-2.60 (lH, m, CH(CH3h), 2.65 (3H, s, CH3CO),
4.95-5.03 (lH, m, CHCH3), 5.22-5.25 (lH, m, CHCH(CH3h), 5.38-5,42 (lH, m,
CHCH3), 8.25 (lH, s, CHS), 8,41 (IH, s, CBS); mlz (FAB) Found: 507.1455 (M+-Cl-,
C21H270sN6S2requires 507.1484).
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Structural isomer of dendroamide A (171)
Diisopropylethylamine (0.1 ml, 0.6 mmol) and FDPP (lIS mg, 0.3 mmol) were added
to a suspension of 214 (100 mg, 0.3 mmol) in anhydrous acetonitrile (3 ml) at room
temperature under an atmosphere of nitrogen. The solution was stirred for 14 h at room
temperature and water (ca 20 ml) was added, the separated aqueous layer was extracted
with dichloromethane (5 x 10 ml), the combined organic extracts were then washed with
2M hydrochloric acid solution (3 x 10 ml) and aqueous sodium hydrogen carbonate
solution (3 x 10 ml), were dried (MgS04), and evaporated in vacuo to leave a white
solid residue. The residue was chromatographed using 70 % ethyl acetate in light
petroleum (40-60 °C) as eluant to give the cyclic peptide (68 mg, 0.14 mmol, 76 %) as a
white powder; mp. 145-147 °C (from dichloromethane); [a]D295 = +61.1 (c = 0.7,
CHC13); timax (CHCh)/cm-1 3395, 2969, 1687, 1640, 1546, 1495, 1449, 1360, 1131,
1044, 883; 8H (360 MHz, CDCI3) 1.02 (3H, d, J 6.8 Hz, (CH3hCH), 1.09 (3H, d, J
6.8 Hz, (CH3hCH), 1.69 (3H, d, J 6.8 Hz, CH3CH), 1.73 (3H, d, J 6.8 Hz, CH3CH),
2.29 (lH, dq, J 6.8, 13.5 Hz, CH(CH3)z), 2.69 (3H, s, CH3CO), 5.24-5.31 (lH, m,
CHCH3), 5.39-5.49 (lH, m, CHCH3), 5.39-5.49 OH, m, CHCH(CH3h), 8.11 (lH, s,
CHS), 8.15 (lH, s, CHS), 8.44 (lH, d, J 9.1 Hz, NHCO), 8.60-8.65 OH, m, NHCO);
8c (90.5 MHz, CDCh) 11.6 (q), 18.5 (q), 18.8 (q), 20.8 (q), 24.9 (q), 35.5 (d), 43.9 (d),
47.5 (d), 55.7 (d), 123.2 (d), 124.2 (d), 131.6 (s), 148.6 (s), 149.2 (s), 153.9 (s), 159.6
(s), 159.8 (s), 160.5 (s), 161.6 (s), 168.3 (s), 171.3 (s); mlz (FAB) Found: 511.1231
13S
1'(R)-2-(1-{[l '(R)-2-(1 '-tert-Butoxycarbonylamino-ethyl)-thiazole-4-carbonyl]-
arnino}-ethyl)-thiazole-4-carboxylic acid ethyl ester (215)
N-Methylmorpholine (0.07 ml, 0.66 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (127 mg, 0.66 mmol) and N-hydroxybenzotriazole (89
mg, 0.66 mmol) were added to a stirred solution of the alanine thiazole acid 197 (163
mg, 0.6 mmol) in anhydrous dichloromethane (7 ml) at 0 °C under an atmosphere of
nitrogen. The mixture was stirred at 0 °C for 20 min and a precooled solution of the
alanine thiazole amine 89a (142 mg, 0.6 mmol) deprotonated with N-methylmorpholine
(0.07 ml, 0.66 mmol) in DMF (1 ml) was added dropwise over 5 min. The solution was
stirred at 0 °C for 1 h, and at room temperature for 17 h. 10 % aqueous citric acid
solution (20 ml) was added, and the separated aqueous layer was extracted with ethyl
acetate (5 x 20 ml). The combined organic extracts were washed with sodium hydrogen
carbonate solution (3 x 15 ml), 10% aqueous citric acid solution (3 x 15 ml), and brine
(2 x 15 ml), were dried (MgS04) and evaporated in vacuo to leave a yellow residue.
Purification by chromatography on silica using 50 % ethyl acetate in light petroleum
(40-60 CC)as eluant gave the tetrapeptide (119 mg, 0.3 mmol, 50 %) as a pale yellow
foam; [a]o296 +30.0 (c = 1.0, CHCh); Umax (CHCI3)/cm-l 3442, 3398, 2981, 2935,
1716, 1668, 1543, 1489, 1453, 1369, 1322, 1154, 1098, 1060,908,877; OH (360 MHz,
CDCh) 1.41 (3H, t, J 7.1 Hz, CH3CH2C02), 1.47 (9H, s, But), 1.62 (3H, d, J 6.6 Hz,
CH3CH), 1.81 (3H, d, J 7.0 Hz, CH3CH), 4.43 (2H, q, J 7.1 Hz, CH3CH2C02), 5.61
(IH, hr. s, NHBoc), 5.61 OH, hr. s, CHCH3), 5.62 (lH, dq, J7.0, 7.0 Hz, CHCH3),
7.85 (lH, d, J 7.9 Hz, NHCO), 8.05 (IH, s, CHS), 8.10 (lH, s, CHS); Oc (90.5 MHz,
CDCh) 14.2 (q), 20.8 (q), 21.2 (q), 28.2 (q), 47.0 (d), 48.6 (d), 61.3 (t), 80.1 (s), 123.8
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(d), 127.3 (d), 146.9 (s), 148.8 (s), 154.8 (s), 160.4 (s), 161.1 (s), 172.9 (s), 174.6 (s);
mlz (FAB) Found: 477.1200 (MH++Na+, C19H260sN4S2Na requires 477.1242).
l' (R)-2-(I- {[ 1'(R)-2-( 1'-tert-Butoxycarbonylamino-ethyl)-thiazole-4-carbonyl)-
amino} -ethyl)-thiazole-4-carboxylic acid (216)
Sodium hydroxide (96 mg, 2.4 mmol) was added in one portion to a solution of the
dimer 215 (119 mg, 0.3 mmol) in a THF:H20 (6:3) mixture (5 ml) at room temperature.
The solution was stirred at room temperature for 6 h, the separated aqueous layer was
then acidified to pH4 by the addition of citric acid. The separated aqueous layer was
extracted with dichloromethane (5 x 20 ml) and the combined organic extracts were
washed with water (3 x 20 ml), and brine (3 x 20 ml), were dried (MgS04) and
evaporated in vacuo to give the acid (100 mg, 0.25 mmol, 84 %) as a pale yellow foam;
[a]D294+30.4 (c = 1.0, CHCh); Umax (CHCI3)/cm-l 3440, 3398, 3125, 2933, 2873,
1758, 1712, 1668, 1544, 1489, 1454,1369,1295,1061,997,897; OH (360 MHz,
CDCI3) 1.46 (9H, s, But), 1.62 (3H, d, J 6.9 Hz, CH3CH), 1.81 (3H, d, J 6.9 Hz,
CH3CH), 5.09 (2H, br. d, J 6.9, CHCH3 and CHCH3), 7.87 (IH, br. s, NHCO), 8.09
(lH, s, CHS), 8.10 (lH, s, CHS); Oc (90.5 MHz, CDCh) 20.7 (q), 21.4 (q), 28.2 (q),
46.9 (d), 47.1 (d), 80.3 (s), 124.2 (d), 128.7 (d), 146.5 (s), 148.6 (s), 160.7 (s), 164.0 (s),
173.1 (s), 174.2 (s),176.4 (s); mlz (FAB) Found: 449.0915 (MH+ + Na+,
C17H220SN4S2Na requires 449.0929).
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1'(R)-2-(1-{[1 '(R)-2-(1-{[1' -(1' -tert-Butoxycarbonylamino-ethyl)-thiazole-4-
carbonyl]-amino }-ethyl)-thiazole-4-carbonyl] -amino }-1'(R)-2-methylpropyl)-
thiazole-4-carboxylic acid ethyl ester (217)
oV
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N -Methylmorpholine (0.03 ml, 0.27 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (52 mg, 0.27 mmol) and N-hydroxybenzotriazole (37
mg, 0.27 mmol) were added to a solution of the dimer acid 216 (94 mg, 0.24 mmol) in
anhydrous dichloromethane (4 ml) at 0 QCunder an atmosphere of nitrogen. The
mixture was stirred at 0 QCfor 20 min and a precooled solution of the valine thiazole
amine (64 mg, 0.24 mmol) deprotonated with N-methylmorpholine (0.03 ml, 0.27
mmol) in DMF (1ml) was added dropwise over 5 min. The solution was stirred at 0 QC
for 1 h, and then at room temperature for 15 h. 10 % aqueous citric acid solution (20
ml) was added, and the separated aqueous layer was extracted with ethyl acetate (5 x 20
ml), the combined organic extracts were washed with sodium bicarbonate solution (3 x
20 ml), 10% aqueous citric acid solution (3 x 20 ml), and brine (2 x 20 ml), were dried
(MgS04) and evaporated in vacuo to leave a residue. Purification by chromatography
on silica using 50 % ethyl acetate in light petroleum (40-60 QC) as eluant gave the
hexapeptide (97 mg, 0.15 mmol, 63 %) as a pale yellow foam; [a]D293 = +28.0 (c =
2.0, CHCh); umax (CHCl)/cm-1 3399, 2987, 2939, 2838, 1716, 1668, 1542, 1489,
1370, 1322, 1161, 1098, 1016; OH (360 MHz, CDCh) 1.01 (3H, d, J 6.8 Hz,
(CH3hCH), 1.05 (3H, d, J 6.8 Hz, (CH3hCH), 1.40 (3H, t, J 7.1 Hz, CH3CH2), 1.45
(9H, s, But), 1.62 (3H, d, J 6.8 Hz, CH)CH), 1.80 (3H, d, J 6.9 Hz, CH3CH), 2.65 (lH,
app. quintet, J 6.8Hz, CH(CH3)2), 4.42 (2H, q, J 7.1 Hz, CH2CH3), 5.06-5.10 (lH, m,
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CHCH3), 5.10-5.18 (lH, br. s, NHBoc), 5.34 (lH, dd, J 6.8,9.2 Hz, CHCH(CH3h),
5.59 (IH, dq, J 6.9,6.9 Hz, CHCH3), 7.79 (lH, d, J 8.4 Hz, NHCO), 7.97 (IH, d, J 9.3
Hz, NHCO), 8.06 (lH, s, CHS), 8.07 (IH, s, CHS), 8.08 (lH, s, CHS); Oc(90.5 MHz,
CDC}3) 14.2 (q), 17.9 (q), 19.6 (q), 21.0 (q), 21.2 (q), 28.2 (q), 32.9 (d), 47.0 (d), 56.4
(d), 61.3 (t), 80.2 (s), 123.9 (d), 124.0 (d), 126.9 (d), 147.3 (s), 148.9 (s), 149.0 (s),
160.4 (s), 160.6 (s), 161.2 (s), 171.6 (s), 172.9 (s), 175.0 (s), 179.8 (s); mlz (FAB)
Found: 659.1773 (MH++ Na+, C27H3606N6S3Narequires 659.1756).
1'(R)-2-(1-{[1 '(R)-2-(1-{[2-(1' -Amino-ethyl)-thiazole-4-carbonyl]-amino }-ethyl)-
thiazole-4-carbonyl] -amin 0}-l '(R)- 2-m ethyl-propyl)-thiazole-4-carboxylic
acid hydrochloride (218)
aY
~N~~
SyN H N 4 ca2H
...l1'
"... NH
N r NH2·HC1
a ~h ....S ~
Sodium hydroxide (48 mg, 1.2 mmol) was added in one portion to a solution of 217 (97
mg, 0.15 mmol) in a THF:H20 (5:4) mixture (3 ml) at room temperature. The solution
was stirred for 5 h, and the separated aqueous layer was acidified to pH4 by the
addition of citric acid, and extracted with ethyl acetate (6 x 15 ml). The combined
organic extracts were washed with water (3 x 10 ml) and brine (3 x 10 ml), were dried
(MgS04) and evaporated in vacuo. The yellow oil was subsequently stirred with a 4M
solution of hydrochloric acid in dioxane (1 ml) for 4 h at room temperature under an
atmosphere of nitrogen. The solvent was removed in vacuo by azeotroping with
toluene to leave the hexapeptide (63 mg, 0.11 mmol, 73 %) as a viscous oil; [a]D295 =
+2.0 (c = 0.8, EtOH); OH (360 MHz, CD30D) 1.01 (3H, d, J 7.7 Hz, CH3CH), 1.13
(3H, d, J 6.7 Hz, CH3CH), 1.83 (3H, d, J 6.9 Hz, (CH3hCH), 1.84 (3H, d, J 6.9 Hz,
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(CH3hCH), 2.50-2.60 (lH, m, CH(CH3)2), 4.99-5.l3 (lH, m, CHCH3), 5.28 (lH, d, J
8.0 Hz, CHCH(CH3h), 5.62-5.65 (IH, m, CHCH3), 8.25 (lH, s, CHS), 8.37 (lH, s,
CHS), 8043 (lH, s, CHS); Dc (90.5 MHz, CD30D) 19.1 (q), 20.0 (q), 20.3 (q), 2l.1
(q), 34.3 (d), 43.8 (d), 58.3 (d), 74.1 (d), 125.9 (d), 127.4 (d), 12904 (d), 148.0 (s), 149.8
(s), 149.9 (s), 162.3 (s), 162.9 (s), 163.9 (s), 168.9 (s), 17304 (s), 176.8 (s); mlz (FAB)
Found: 509.1102 (MH+-Cl-, C2oH2s04N6S3requires 509.1099).
Cyclic-bis-(R)-Alanine-thiazole-(R)-valine-thiazole (172)
aV
r!N~S~( H Ni
",.., NH HN a
~/N. J.
a 'LT "'1
Diisopropylethylamine (0.03 ml, 0.17 mmol) was added to a solution of 218 (30 mg,
0.055 mmol) in anhydrous acetonitrile (3 ml) at room temperature under an atmosphere
of nitrogen. The solution was stirred for 5 min and FDPP (32 mg, 0.08 mmol) was
added in one portion. The resulting mixture was stirred for 3 days at room temperature,
water (ca 10 ml) was added and the separated aqueous layer extracted with
dichloromethane (5 x 15 ml). The combined organic extracts were washed with 2M
hydrochloric acid solution (3 x 10 ml), 2M sodium hydroxide solution (3 x 10 ml) and
brine (2 x 10 ml), were dried (MgS04) and evaporated in vacuo to leave a yellow
residue. The residue was purified by chromatography on silica using 80 % ethyl acetate
in light petroleum (40-60 QC)as eluant to give the cyclic peptide (22 mg, 0.041 mmol, 82
%) as a white powder; mp. 254-256 °C (from dichloromethane); [a]D295 = +36.0 (c =
004, CHCI3); "'max (MeOH)/nm 231 (e/dm! mol-tcrn-t 19510); 'Umax (CHC13)/crn-t
3403,2930, 1665, 1544, 1496, 1298, 1047,974; OH (360 MHz, CDCh) 1.04 (3H, d, J
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6.8 Hz, (CH3)2CH), 1.09 (3H, d, J 6.8 Hz, (CH3)2CH), 1.75 (3H, d, J 6.8 Hz, CH3CH),
1.75 (3H, d, J 6.7 Hz, CH3CH), 2.26-2.35 (lH, m, CH(CH3h), 5.46 (lH, dd, J 5.6, 9.1
Hz, CHCH(CH3h), 5.58-5.71 (2H, m, CHCH3 and CHCH3), 8.13 (lH, s, CHS), 8.13
(lH, s, CHS), 8.17 (lH, s, CHS), 8.53 (lH, d, J9.1 Hz, NHCO), 8.64 (2H, d, J7.8 Hz,
NHCO and NHCO); 8c (125 MHz, CDCl3); 18.4 (q), 18.8 (q), 24.9 (q), 29.7 (q), 35.5
(d), 47.2 (d), 47.3 (d), 55.8 (d), 123.6 (d), 123.8 (d), 124.1 (d), 148.7 (s), 149.0 (s),
149.1 (s), 159.5 (s), 159.6 (s), 159.7 (s), 168.6 (s), 171.0 (s), 171.4 (s); mlz (FAB)
Found: 513.0890 (MH++ Nat, C2oH2203N6S3Narequires 513.0813).
l' (R)-2-( 1'-{[1'(R)-2-(1 ,2-Dimethylpropyl)-thiazole-4-carbonyl]-amino- }-2-
methylpropyl)-thiazole-4-carboxylic acid ethyl ester (219)
A 4M solution of hydrochloric acid in dioxane (l ml) was added to the dimer (117 mg,
0.26 mmol) at room temperature and the solution was stirred for 8 h under an
atmosphere of nitrogen. The solvent was removed in vacuo using toluene as an
azeotrope to leave the amine (93 mg, 0.24 mmol, 93 %) as a viscous oil; [a]D296+5.6 (c
= 1.5, EtOH); 8H (360 MHz, CD30D) 1.02-1.04 (3H, m, CH(CH3h), 1.06-1.10 (3H,
m, CH(CH3)2), 1.12 (3H, d, J6.8 Hz, CH(CH3h), 1.16-1.19 (3H, m, CH(CH3)2), 1.43
(3H, t, J7.1 Hz, CH3CH2C02), 2.41-2.49 (IH, m, CH(CH3h), 2.41-2.49 (IH, m,
CH(CH3h), 4.43 (2H, q, J 7.1 Hz, C02CH2CH3), 4.78 (lH, dd, J 2.4, 6.2 Hz,
CHCH(CH3h), 5.33 (tH, dd, J 4.7, 7.5 Hz, CHCH(CH3h, 8.42 (2H, S, CHS and
CHS); 8c(90.5 MHz, CD)OD) 14.6 (q), 18.4 (q), 18.6 (q), 19.1 (q), 19.8 (q), 33.6 (d),
34.4 (d), 58.3 (d), 58.6 (d), 62.8 (t), 127.4 (d), 129.8 (d), 146.4 (s), 149.7 (s), 162.0 (s),
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162.4 (s), 166.3 (s), 174.4 (s); mlz (FAB) Found: 411.155 (MH+ + Na+,
CI8H270N4S2N requires 411.1525).
I '(R)-2-(I '-{[I '(R)-2-(1-{[I '(R)-2-(I-tert-Butoxycarbonylamino-ethyl)-thiazole-4-
carbonyl]-amino}-2-methylpropyl)-thiazole-4-carbonyl]-amino}-2-methylpropyl)-
thiazole-4-carboxylic acid ethyl ester (220)
° Y )
~N~S)
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N -Methylmorpholine (0.03 ml, 0.22 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride 942 mg, 0.22 mmol) and N-hydroxybenzotriazole (30
mg, 0.22 mmol) were added to a stirred solution of the alanine thiazole acid 197 (55 mg,
0.2 mmol) in anhydrous dichloromethane (4 ml) at 0 °C under an atmosphere of
nitrogen. The resulting mixture was stirred at 0 °C for 20 min and a precooled solution
of the valine thiazole dimer 219 (77 mg, 0.2 mmol) deprotected with N-
methylmorpholine (0.024 ml, 0.22 mmol) in DMF (l mI) was added dropwise over 5
min. The mixture was stirred at 0 °C for 1 h, and at room temperature for 14 h. 10 %
aqueous citric acid solution (20 ml) was added, and the separated aqueous layer was
extracted with ethyl acetate (5 x 20 ml). The combined organic extracts were washed
with sodium bicarbonate solution (3 x 20 ml), 10 % aqueous citric acid solution (3 x 20
ml), and brine (2 x 20 ml), dried (MgS04) and evaporated in vacuo to leave a residue.
Purification by chromatography on silica using 50 % ethyl acetate in light petroleum
(40-60 CC) as eluant gave the hexapeptide (97 mg, 0.15 mmol, 63 %) as a pale yellow
foam; [a]D294 +3l.3 (c ::: 0.6, CHCh); umax (CHCI3)/cm-1 3398, 3124, 2967, 2992,
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2874,1721,1682,1666,1545,1488,1462,1392,1370,1321, 1153, 1098,1057,908,
878; BH (360 MHz, CDCl3) 1.02 (3H, d, J 6.8 Hz, (CH3hCH), 1.05 (3H, d, J 6.8 Hz,
(CH3)zCH), 1.06 (3H, d, J 6.8 Hz, (CH3)zCH), 1.08 (3H, d, J 6.8 Hz, (CH3hCH), 1.40
(3H, t, J 7.1 Hz, CH3CH2C02), 1.47 (9H, s, But), 1.64 (3H, d, J 6.7 Hz, CH3CH),
2.53-2.69 (2H, m, CH(CH3h, and CH(CH3h) 4.42 (2H, q, J 7.1 Hz, CH2CH3), 5.02-
5.12 (1H, rn, CHCH3), 5.13-5.18 (lH, br. s, NHBoc), 5.35 (lH, dd, J 6.0, 11.8 Hz,
CHCH(CH3h), 5.37 (lH, dd, J 6.0, 11.8 Hz, CHCH(CH3)z), 7.89 (lH, d, J 8.9 Hz,
NHCO), 7.94 (lH, d, J 9.2 Hz, NHCO), 8.05 (lH, s, CHS), 8.07 (lH, s, CHS), 8.07
(lH, s, CHS); Be (90.5 MHz, CDCh) 14.3 (q), 17.7 (q), 17.9 (q), 19.4 (q), 19.6 (q),
21.0 (q), 28.2 (q), 29.6 (d), 32.9 (d), 33.1 (d), 56.1 (d), 56.4 (d), 61.3 (t), 80.3 (s),
123.6(d), 123.8 (d), 126.9 (d), 147.4 (s), 149.1 (s), 149.3 (s), 154.9 (s), 160.7 (s), 160.8
(s), 161.2 (s), 171.6 (s), 171.7 (s), 175.1 (s); mlz (FAB) Found: 687.2012 (MH+ +
Na+, C29H4006N6S3Narequires 687.2069).
I '(R)-2-(I '-{[I '(R)-2-(I-{[2-(I-Amino-etbyl)-tbiazole-4-carbonyl)-amino}2-
methylpropyl)-thiazole-4-carbonyl]-amino }-1'(R)-2-metbylpropyl)-thiazole-4-
carboxylic acid (221)
Sodium hydroxide (51 mg, 1.28 mmol) was added in one portion to a stirred solution of
220 (105 mg, 0.16 mmol) in a THF:H20 (5:4) mixture (3 ml) at room temperature. The
solution was stirred for 9 h, and the separated aqueous layer acidified to pH4 by the
addition of citric acid, the acidified aqueous layer was then extracted with ethyl acetate
(5 x 20 ml). The combined organic extracts were washed with water (3 x 10 ml) and
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brine (3 x 10 ml), were dried (MgS04) and evaporated in vacuo. The yellow oil was
subsequently stirred with a 4M solution of hydrochloric acid in dioxane (1 ml) at room
temperature under an atmosphere of nitrogen for 3 h. The solvent was removed in
vacuo by azeotroping with toluene to leave the amine (52 mg, 0.09 mmol, 56 %) as a
viscous oil; [a]o295 +8.4 (c = 1.0, EtOH); OH (360 MHz, CD30D) 1.0I (3H, d, J 6.7
Hz, (CH3hCH), 1.08 (3H, d, J6.7 Hz, (CH3hCH), 1.12-1.15 (6H, m, (CH3hCH),
1.82 (3H, d, J 6.9 Hz, CH3CH), 2.50-2.63 (lH, m, CH(CH3h), 2.50-2.63 (lH, m,
CH(CH3h), 5.00-5.06 (lH, m, CHCH3), 5.28-5.39 (IH, m, CHCH(CH3h), 5.28-5.39
(lH, m, CHCH(CH3h), 8.27 (lH, s, CHS), 8.27 (lH, s, CHS), 8.36 (1H, s, CHS); be
(90.5 MHz, CD30D) 18.8(q), 19.1 (q), 19.9 (q), 19.9 (q), 20.3 (q), 34.4 (d), 34.5 (d),
34.5 (d), 58.1 (d), 58.3 (d), 125.8 (d), 127.5 (d), 129.5 (d), 147.2 (s), 149.9 (s), 150.0
(s), 162.4 (s), 162.8 (s), 167.2 (s), 169.1 (s), 172.4 (s), 172.6 (s).
Cyclic-bis-(R)- Valine-thiazole-(R)-alanine-thiazole (173)
Diisopropylethylamine (0.04 ml, 0.26 mmol) and FDPP (50 mg, 0.13 mmol) were added
to a suspension of 221 (50 mg, 0.09 mmol) in anhydrous acetonitrile (3 ml) at room
temperature under an atmosphere of nitrogen. This solution was stirred at room
temperature for 2 days, water (ca 10 ml) was added and the separated aqueous layer
was then extracted with dichloromethane (4 x 20 ml). The combined organic extracts
were washed successively with 2M hydrochloric acid solution (2 x 10 ml), sodium
hydrogen carbonate solution (2 x 10 ml) and brine (2 x 10 ml), then dried (MgS04) and
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evaporated in vacuo to leave a solid residue. The residue was purified by
chromatography using 80 % ethyl acetate in light petroleum (40-60 °C) as eluant to give
the cyclic peptide (37 mg, 0.07 mmol, 79 %) as a white powder; [a]D294+34.0 (c = 0.2,
CHCI3); Umax (CHCI3)/cm-l 32928,2926, 1666, 1544, 1045; eSH(360 MHz, CDCI3)
1.04 (3H, d, J6.8 Hz, (CH3hCH), 1.06 (3H, d,J6.8 Hz, (CH3hCH), 1.12 (3H, d, J6.8
Hz, (CH3hCH), 1.75 (3H, d, J 6.8 Hz, (CH3CH), 2.24-2.37 (lH, m, CH(CH3h), 2.24-
2.37 (lH, m, CH(CH3h), 5.38-5.42 (lH, m, CH(CH3h), 5.40 (IH, dd, J 6.1,8.9 Hz,
CHCH(CH3h), 5.51 (lH, dd, J 5.3, 9.4 Hz, CHCH(CH3h), 5.61-5.69 (lH, m,
CHCH3), 8.10 (IH, s, CHS), 8.13 (lH, s, CHS), 8.l3 (lH, s, CHS), 8.47 (lH, d, J 8.9
Hz, NHCO), 8.51 (lH, d, J 9.4 Hz, NHCO), 8.59 (lH, d, J 7.6 Hz, NHCO); eSc(90.5
MHz, CDCh) 20.3 (q), 27.3 (q), 28.6 (q), 28.8 (q), 29.7 (q), 30.3 (d), 30.7 (d), 35.2 (d),
35.3 (d), 36.0 (d), 123.4 (d), 128.6 (d), 130.5 (d), l36.3 (s), 144.2 (s), 149.5 (s), 155.7
(s), 159.8 (s), 159.9 (s), 169.1 (s), 177.0 (s), 180.9 (s); mlz (FAB) Found: 541.111
(MH++ Na+, C22H2603N6S3Na requires 541.1126).
1'(R)-2-(1-{[l '(R)-2-(1-Benzyloxycarbonylamino-etbyl)-5-metbyl-oxazole-4-
carbonyl]-amino}-2-methyl-propyl)-thiazole-4-carboxylic acid ethyl ester (222)
N -Methylmorpholine (0.08 ml, 0.73 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (139 mg, 0.73 mmol) and N-hydroxybenzotriazole (99
mg, 0.73 rnrnol) were added to a solution of the oxazole acid (200 mg, 0.66 mmol) in
anhydrous dichloromethane (7 ml) at 0 °C under an atmosphere of nitrogen. This
solution was stirred at 0 °C for 20 min and a precooled solution of the valine thiazole
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amine (175 mg, 0.66 mmol) deprotonated with N-methylmorpholine (0.08 m1, 0.73
mmo1) in anhydrous DMF (3 ml) was added dropwise over 5 min. The resulting
solution was stirred at 0 QCfor 1 h and at room temperature for 15 h.
Water (ca 30 ml) was added and the separated aqueous layer was extracted with
dichloromethane (4 x 25 ml). The combined organic extracts were washed with 10%
aqueous citric acid solution (3 x 20 ml), saturated sodium hydrogen carbonate solution
(3 x 20 ml) and brine (2 x 20 ml), were dried (MgS04) and evaporated in vacuo. The
yellow residue was purified by chromatography on silica using 60 % ethyl acetate in
light petroleum (40-60 QC)as eluant to give the tetrapeptide (260 mg, 0.51 mrnol, 77 %)
as a cream foam which crystallised to give a white powder; [a]o294 +32.8 (c = 1.0,
CHCI3); Umax (CHCh)/crn-1 3438,2966,1723,1668,1635,1498,1454,1371,1341,
1323, 1098, 1066,908; BH (360 MHz, CDCh) 1.00 (3H, d, J 6.8 Hz, (CH3hCH), 1.03
(3H, d, J 6.8 Hz, (CH3)zCH), 1.40 (3H, t, J 7.1 Hz, CH3CH20), 1.57 (3H, d, J 7.0 Hz,
CH3CH), 2.59-2.66 (lH, rn, CH(CH3h), 2.61 (3H, s, CH3CO), 4.42 (2H, q, J 7.1 Hz,
CH2CH3), 4.99-5.09 (lH, m, CHCH3), 5.16 (2H, m, CH2Ph), 5.29 (IH, dd, J 6.7,9.2
Hz, CHNH), 5.34-5.36 (IH, br. m, NHCbZ), 7.35-7.38 (5H, rn, ArH), 7.52 (lH, d, J
8.9 Hz, NHCO), 8.07 (IH, s, CHS); Be (90.S MHz, CDCl3) 11.4 (q), 14.1 (q), 17.8
(q), 19.4 (q), 19.6 (q), 32.7 (d), 44.9 (d), 55.7 (d), 61.1 (t), 66.8 (t), 126.7 (d), 127.8 (d),
127.9 (d), 128.2 (d), 136.0 (s), 147.2 (s), 153.5 (s), 155.5 (s), 161.0 (s), 161.2 (s), 161.3
(s), 171.7 (s); mlz (FAB) Found: S37.1725 (M+ + Na+, C2sH3006N4SNa requires
537.1784).
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l' (R)-2-(1-{ [1'(R)-2-(1- Benzyloxycarbonylamino-ethyl)-5-methyl-oxazole-4-
carbonyl]-amino}-2-methyl-propyl)-thiazole-4-carboxylic acid ethyl ester (223)
Sodium hydroxide (82 mg, 2.07 mmol) was added to a solution of the dimer 222 (260
mg, 0.51 mmol) in a THF:H20 (5:3) mixture (5 ml) at room temperature. The solution
was stirred for 14 h and the separated aqueous layer acidified to pH 4 with citric acid.
The aqueous layer was then extracted with ethyl acetate (5 x 20 ml) and the combined
organic extracts washed with brine (2 x 20 ml), were dried (MgS04) and evaporated in
vacuo to leave the acid (2.06 mg, 0.42 mmol, 83 %) as a pale yellow foam: mp. 70-73
°C (from dichloromethane); [a]D294+50.4 (c = 1.0, EtOH); umax (CHCl3)/cm-t 3437,
1723, 1667, 1452, 1343, 1063; OH (360 MHz, CD30D) 1.00 (3H, d, J 6.7 Hz,
(CH3hCH), 1.08 (3H, d, J 6.7 Hz, (CH3hCH), 1.58 (3H, d, J 7.2 Hz, CH3CH), 2.47-
2.57 (IH, rn, CH(CH3h), 2.60 (3H, s, CH3CO), 4.91-4.95 (IH, m, CHCH3), 5.14 (2H,
br. s, CH2Ph), 5.21-5.26 (lH, m, CHCH(CH3h), 7.28-7.38 (5H, m, ArH), 8.34 (IH, s,
CHS); Se (90.5 MHz, CDCh) 11.7 (q), 18.8 (q), 19.2 (q), 19.9 (q), 34.1 (d), 43.8 (t),
46.2 (d), 57.8 (d), 128.8 (d), 129.0 (d), 129.1 (d), 129.4 (d), 138.0 (s), 148.3 (s), 155.4
(s), 158.0 (s), 163.6 (s), 163.9 (s), 176.7 (s); m/z (FAB) Found: 509.1509 (M+ + Na+,
C23H2606N4SNa requires 509.1471).
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1'(R)-2-(1-{[ 1'(R)-2-(1-{[1 '(R)-2-(1-Benzyloxycarbonylamino-ethyl)-5-methyl-
oxazole-4-carbonyl]-amino}-2-methyl-propyl)-thiazole-4-carbonyl]-amino}-2-
methyl-propyl)-thiazole-4-carboxylic acid ethyl ester (224)
oV
~N~S?
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N-Methylmorpholine (0.03 ml, 0.23 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (44 mg, 0.23 mmol) and N-hydroxybenzotriazole (31
mg, 0.23 mmol) were added to a solution of the dimer acid (100 mg, 0.21 mmol) in
anhydrous dichloromethane (5 ml) at 0 °C under an atmosphere of nitrogen. This
solution was stirred for 20 min at 0 °C and a precooled solution of the thiazole amine
deprotonated with N-methylmorpholine (0.03 ml, 0.23 mmol) in DMF (1 ml) was
added dropwise over 5 min. The resulting solution was stirred at 0 °C for 1 h and at
room temperature for 17 h.
Water (ca 20 ml) was added and the separated aqueous layer was extracted with
dichloromethane (4 x 20 ml). The combined organic extracts were washed with 10 %
aqueous citric acid solution (3 x 20 ml) and brine (2 x 20 ml), were dried (MgS04) and
evaporated in vacuo. The residue was purified by chromatography on silica using 50 %
ethyl acetate in light petroleum (40-60 °C) as eluant to leave the hexapeptide (96 mg,
0.4 mmol, 66 %) as a cream foam; [a]0294 +34.6 (c = 0.9, CHCl)); 'Umax (CHCh)/cm-1
3399,2966,1722,1668,1635,1543,1489,1455,1372, 1322, 1069; OH(360 MHz,
CDCh) 1.00-1.06 (6H, m, (CH3hCH), 1.00-1.06 (6H, m, (CH3hCH), 1.37 (3H, t, J
7.1 Hz, CH3CH20), 1.59 (3H, d, J 7.0 Hz, CH3CH), 2.48-2.55 (lH, rn, CH(CH3h),
2.57-2.66 (lH, m, CH(CH3h), 2.62 (3H, s, CH3CO), 4.39 (2H, q, J 7.1 Hz, CH2CH3),
5.02-5.09 (lH, m, CHCH3), 5.12-5.14 (2H, m, CH2Ph), 5.30-5.36 (lH, rn,
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CHCH(CH3h), 5.30-5.36 (lH, m, CHCH(CH3h), 5.48 (lH, d, J 8.3 Hz, NHCbZ),
7.35-7.39 (5H, m, ArH), 7.48 (lH, d, J9.4 Hz, NHCO), 7.98 (lH, d, J9.3 Hz, NHCO),
8.03 (lH, s, CHS), 8.04 (lH, s, CHS); Be (90.5 MHz, CDCh) 11.6 (q), 14.3 (q), 17.8
(q), 17.9 (q), 19.4 (q), 19.6 (q), 19.7 (q), 33.0 (d), 33.1 (d), 45.0 (d), 55.8 (d), 56.4 (d),
61.3 (t), 67.1 (t), 123.5 (d), 126.9 (d), 128.1 (d), 128.2 (d), 128.5 (d), 136.1 (s), 147.4
(s), 149.3 (s), 153.9 (s), 160.7 (s), 161.2 (s), 161.4 (s), 161.5 (s), 171.6 (s), 171.7 (s);
mlz (FAB) Found: 719.2368 (M++ Na+, C33H4007N6S2Na requires 719.2297).
l' (R)-2-(I-{[ 1'(R)-2-(I- {[1'(R)-2-(I-Amino-ethyl)-S-methyl-oxazole-4-carbonyl)-
amino}-2-methyl-propyl)-thiazole-4-carhonyl]-amino}-2-methyl-propyl)-
thiazole-4-carboxylic acid (225)
aV
t-0N~S#
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A solution of sodium hydroxide (20 mg, 0.5 mmol) in water (0.5 ml) was added to a
solution of the trimer 224 (88 mg, 0.13 mmol) in ethanol (2 ml) and this solution was
stirred for 4 h. The ethanol was removed in vacuo and the residue acidified with 2M
hydrochloric acid solution (30 ml), the amine was then collected by suction filtration as
a white solid. This solid was stirred with a 33 % solution of hydrobromic acid in acetic
acid (1 ml) and glacial acetic acid (0.6 ml) for 3 h at room temperature under an
atmosphere of nitrogen. The volatiles were removed in vacuo to leave the amine (65 mg,
0.1 mmol, 77 %) as a brown foam; [a]o295 +4.0 (c = 0.7, EtOH); BH (360 MHz,
CD30D) 1.00-1.04 (3H, m, (CH3hCH), 1.00-1.04 (3R, m, (CH3hCR), 1.09-1.13 (3H,
m, (CH3h)CH), 1.09-1.13 (3H, m, (CH3hCH), 1.76 (3H, d, J 7.0 Hz, CH3CH), 2.51-
2.60 (lH, m, CH(CH3h), 2.51-2.60 (IH, m, CH(CH3h), 2.67 (3H, s, CH3CO), 4.76-
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4.80 (lH, m, CHCH3), 5.15-5.28 (lH, m, CHCH(CH3h), 5.15-5.28 (lH, m,
CHCH(CH3h), 8.26 (lH, s, CHS), 8.41 (lH, s, CHS); Be (90.5 MHz, CD30D) 14.9
(q), 15.1 (q), 20.7 (q), 21.5 (q), 21.7 (q), 22.3 (q), 35.6 (q), 48.4 (d), 59.3 (d), 60.0 (d),
60.7 (d), 128.8 (d), 131.5 (d), 133.2 (s), 147.6 (s), 147.8 (s), 158.1 (s), 158.2 (s), 160.4
(s), 164.2 (s), 164.3 (s), 164.4 (s), 176.2 (s); mlz (FAB) Found: 552.1777 (M+- HBr
+ H20, C23H3206N6S2 requires 552.1825).
Cyclic-bis-(R)-valine-thiazole-(R)-alanine-oxazole (176)
oV
~N~)0-:( H Nf
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Diisopropylethylamine (0.4 ml, 0.3 mmol) and FDPP (576 mg, 0.15 mmol) were added
to a suspension of225 (65 mg, 0.1 mmol) in anhydrous acetonitrile at room temperature
under an atmosphere of nitrogen. This solution was stirred for 1 day, water (ca 10 m1)
was added and the separated aqueous layer was extracted with dichloromethane (4 x 15
ml). The combined organic extracts were washed with 2M hydrochloric acid solution (3
x 10 ml), sodium hydrogen carbonate solution (3 x 10 ml), were dried (MgS04) and
evaporated in vacuo to leave a solid white residue. This residue was purified by
chromatography on silica using 70 % ethyl acetate in light petroleum (40-60 CC) as
eluant to give the cyclic peptide (35 mg, 0.068 mmol, 68 %) as a white foam; [a]D297
+46.0 (c = 0.3, CHCI3); Vmax (CHCi])/cm-1 3396,2928, 1668, 1545, 1494, 1372, 1066;
OH (360 MHz, CDCl3) 1.00 (3H, d, J 6.8 Hz, (CH3hCH), 1.06 (3H, d, J 6.8 Hz,
(CH3hCH), 1.08 (3H, d, J 7.2 Hz, (CH3hCH), 1.10 (3H, d, J 7.2 Hz, (CH3hCH), l.70
(3H, d, J 6.8 Hz, CH3CH), 2.28-2.38 (tH, rn, CH(CH3h), 2.28-2.38 (tH, m,
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CH(CH3h), 2.67 (3H, s, CH30), 5.21-5.31 (lH, m, CHCH3), 5.21-5.31 (lH, m,
CHCH(CH3h), 5.52 (lH, dd, J 5.7,9.5 Hz, CHCH(CH3h), 8.11 (1H, s, CHS), 8.11
(lH, s, CHS), 8.44 (lH, d, J 5.7 Hz, NHCO), 8.45 (lH, d, J 9.0 Hz, NHCO), 8.60 (1H,
d,J6.6 Hz, NHCO); Bc (90.5 MHz, CDCI3) 11.7 (q), 18.3 (q), 18.6 (q), 19.0 (q), 21.0
(q), 34.9 (q), 35.6 (d), 44.1 (d), 55.4 (d), 55.9 (d), 77.3 (d), 123.4 (d), 123.7 (d), 128.4
(s), 128.5 (s), 148.9 (s), 149.0 (s), 153.8 (s), 159.9 (s), 160.6 (s), 161.7 (s), 168.1 (s),
168.7 (s); m/z (FAB) Found: 517.1703 (M++ H+, C23H2904N6S2requires 517.1692).
l' (R)-2-( {[ 1'(R)-2-(1- Benzyloxycarbonylamino-ethyl)-5-methyl-oxazole-4-
carbonyIJ-amino}-methyl)-thiazole-4-carboxylic acid ethyl ester (188)
N-Methylmorpholine (0.08 ml, 0.76 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (146 mg, 0.76 mmol) and N-hydroxybenzotriazole
(103 mg, 0.76 mmol) were added to a solution of the oxazole acid 186 (210 mg, 0.7
mmol) in anhydrous dichloromethane (8 ml) at 0 °C under an atmosphere of nitrogen.
The resulting solution was stirred for 20 min and a precooled solution of the glycine
thiazole amine hydrochloride 187 (183 mg, 0.82 mmol) deprotonated with N-
methylmorpholine (0.08 ml, 0.76 mmol) in DMF (1 ml) was added dropwise over 5
mm. This solution was stirred at 0 °C for a further 1 h and at room temperature for 18
h.
Water (ca 20 ml) was added and the separated aqueous layer was extracted with
dichloromethane (3 x 20 ml). The combined organic extracts were washed with 10 %
aqueous citric acid solution (3 x 10ml), sodium hydrogen carbonate solution (3 x 10 ml)
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and brine (3 x 10 ml), were dried (MgS04) and evaporated in vacuo. Purification of the
residue by chromatography on silica using 40 % ethyl acetate in light petroleum (40-60
DC)yielded the tetrapeptide (208 mg, 0044 mmol, 60 %) as a cream foam; [a]o298
-231.7 (c = 0.53, CH3Cl); umax (CHC13): 3422, 2983, 2938, 1715, 1668, 1635, 1493,
1454, 1387, 1371, 1343, 1322, 1096, 1065, 972, 908, 878; BH (360 MHz, CHC13) 1.36
(3H, t,) 7.1 Hz, CH3CH20), 1.49 (3H, d, J 7.0 Hz, CH3CH), 2.57 (3H, s, CH3CO),
4.38 (2H, q,) 7.1 Hz, CH2CH3), 4.85 (2H, d, ) 6.5 Hz, CH2NH), 4.86-4.95 (lH, m,
CHCH3), 5.08 (2H, s, CH2Ph), 5.62 (lH, br. s, NHCbZ), 7.28-7.31 (5H, m, ArH), 8.09
(lH, s, CHS); Be (90.5 MHz, CHCh) 11.1 (q), 13.8 (q), 18.9 (q), 30.8 (d), 39.9 (t),
60.9 (t), 66.3 (d), 127.5 (d), 127.6 (d), 127.6 (d), 127.9 (d), 135.9 (s), 146.3 (s), 153.3
(s), 155.3 (s), 160.7 (s), 161.3 (s), 161.6 (s), 168.7 (s); mlz (FAB) Found: 473.1517
1'(R)-2-( {[I '(R)-2-(I-Amino-ethyl)-5-methyl-oxazole-4-carbonyl]-amino }-methyl)-
thiazole-4-carboxylic acid ethyl ester (189)
The tetrapeptide 188 (208 mg, 0.44 mmol) was stirred in a 33 % solution of
hydrobromic acid in acetic acid (1 ml) and glacial acetic acid (0.6 ml) for 3 h at room
temperature under an atmosphere of nitrogen. The volatiles were removed in vacuo to
leave the hydrobromide (168 mg, 0.4 mmol, 91 %) as a brown, highly hygroscopic
powder; [a]o302 -18.0 (c = 004, EtOH); BH(360 MHz, CD30D) 1.44 (3H, t,)7.1 Hz,
CH3CH20), 1.77 (3H, d,) 6.9 Hz, CH3CH), 2.69 (3H, s, CH3CO), 4.45 (2H, q, J 7.1
Hz, CH2CH3), 4.69-4.87 (lH, m, CHCH3), 4.97-5.01 (2H, m, CH2NH), 8.51 (lH, s,
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CHS); 8c (90.5 MHz, CD30D) 12.1 (q), 14.5 (q), 17.8 (q), 40.0 (t), 45.5 (d), 63.9 (t),
129.1 (s), 131.8 (d), 140.0 (s), 156.4 (s), 158.5 (s), 158.6 (s), 163.3 (s), 177.2 (s); mlz
(FAB) Found: 361.0948 (M+- HBr + Na+, C14HlS04N4SNa requires 361.0946).
I' (R)-2-( {[ I' (R)-2-(I- {[I '(R)-2-(I-tert- Butoxycarbonylamino-2-methyl-propyl)-
thiazole-4-carbonyl]-amino}-etbyl)-5-metbyl-oxazole-4-carhonyl]-amino}-
methyl)-thiazole-4-carboxylic acid ethyl ester (191)
N-Methylmorpholine (0.06 ml, 0.53 mmol), I-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (102 mg, 0.53 mmol) and N-hydroxybenzotriazole (72
mg, 0.53 mmol) were added to a solution of the valine thiazole 190 (143 mg, 0.48 mmol)
in anhydrous dichloromethane (5 ml) at 0 °C under an atmosphere of nitrogen. This
solution was stirred for 20 min at 0 °C and a precooled solution of the dimer 189 (200
mg, 0.48 mmol) deprotonated with N-methylmorpholine (0.06 ml, 0.53 mmol) in DMF
(1 ml) was added dropwise over 5 min. This solution was stirred at 0 °C for 1 h and at
room temperature for 15 h.
Water (ca 20 ml) was added and the separated aqueous layer was extracted with
dichloromethane (3 x 30 mil. The combined organic extracts were washed with 10%
aqueous citric acid solution (3 x 20 ml), sodium hydrogen carbonate solution (3 x 20 ml)
and brine (2 x 10 ml), were dried (MgS04) and evaporated in vacuo. Chromatography
on silica using 70 % ethyl acetate in light petroleum (40-60 QC) as eluant gave the
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hexapeptide (20 mg, 0.03 mmol, 26 %) as a white foam; [a]0297 +5.0 (c = 0.4, CHCI3);
umax(CHCI3)/cm-1 3408,2929,1716,1669,1635,1544,1490,1455,1369, 1096; ~H
(360 MHz, CDCI3) 0.93 (3H, d, J 6.8 Hz, (CH3hCH), 1.00 (3H, d, J 6.8 Hz,
(CH3hCH), 1.40 (3H, t, J7.l Hz, CH3CH20), 1.46 (9H, s, But), 1.66 (3H, s, CH3CO),
4.43 (2H, q, J 7.1 Hz, CH2CH3), 4.80-4.87 (lH, m, CHCH3), 4.92 (2H, d, J 6.5 Hz,
CH2NH), 5.14 (lH, d, J 8.2 Hz, NHBoc), 5.38-5.43 (IH, m, CHCH(CH3h), 7.61-7.65
OH, m, NHCO), 7.61-7.65 (IH, m, NHCO), 8.05 (IH, s, CHS), 8.13 (lH, s, CHS); Bc
(90.5 MHz, CDCI3) 11.7 (q), 14.4 (q), 17.4 (q), 19.4 (q), 28.3 (q), 33.2 (q), 40.4 (d),
42.3 (d), 58.1 (d), 61.5 (d), 123.5 (d), 128.1 (d), 128.4 (s), 134.3 (s), 138.2 (s), 146.9
(s), 154.1 (s), 155.4 (s), 160.3 (s), 161.3 (s), 162.0 (s); mlz (FAB) Found: 643.1928
(M+ + Na+, C27H3607N6S2Na requires 643.1985).
Nostacyclamide (16)
oV
t=!-N-\-)
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Sodium hydroxide (12 mg, 0.26 mmol) was added to a solution of the dimer 222 (40 mg.
0.06 mmol) in a THF:H20 (5:3) mixture (2 ml) at room temperature. The solution was
stirred for 15 h and the separated aqueous layer acidified to pH 4 with citric acid. The
aqueous layer was then extracted with ethyl acetate (5 x 20 ml) and the combined
organic extracts washed with brine (2 x 20 ml), were dried (MgS04) and evaporated in
vacuo to leave the acid as a pale yellow foam. The acid was then stirred with a 4M
solution of hydrochloric acid in dioxane (1 ml) at room temperature for 1 h under an
atmosphere of nitrogen. The dioxane was removed in vacuo using toluene as an
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azeotrope to leave a highly hygroscopic yellow solid which was immediately subjected
to the coupling conditions. Diisopropylethylamine (0.02 ml, 0.12 mmol), and FDPP
(23 mg, 0.06 mmol) were added to the chloride in anhydrous acetonitrile (1.5 ml) at
room temperature under an atmosphere of nitrogen. The solution was stirred for 14 h,
water (ca 10 ml) was added, the separated aqueous layer was extracted with
dichloromethane (4 x 10 ml) and the combined organic extracts were washed with 10 %
aqueous citric acid solution (3 x 10 ml), sodium hydrogen carbonate solution (3 x 10 ml)
and brine (2 x 10 ml), were dried (MgS04) and evaporated in vacuo to leave a white
solid residue which was purified by chromatography on silica using 80 % ethyl acetate
in light petroleum (40-60 QC)as eluant to leave nostacyclamide (3 mg, 0.006 mmol, 10
%) as a white solid; mp (255-257 QC) (Lit.140 mp. 259-260 QC); [a]o297 +28.0 (c =
0.2, CHC13) (Lit.139 [a]o296 +51.3 (0.84, CHCl))); 'Umax (CHCI3)/cm-1 3396,3125,
3006,2966, 2929, 1666, 1642, 1542, 1094; 8H (360 MHz, CDCh) 0.95 (3H, d, J 7.1
Hz, (CH3hCH), 0.97 (3H, d, J 7.1 Hz, (CH3hCH), 1.70 (3H, d, J 6.6 Hz, CH3CH),
2.31-2.35 (lH, m, CH(CH3h), 2.71 (3H, s, CH30), 4.79 (lH, d, J 17.6, CH2NH), 4.99
(lH, d, J 17.6 CH2NH), 5.10-5.14 (lH, m, CHCH3), 5.65 (lH, d, J 3.3 Hz,
CHCH(CH3h), 7.53 (IH, d, J 6.1 Hz, NHCO), 7.81 (IH, d, J 7.1 Hz, NHCO), 7.84
(lH, d, J7.1 Hz, NHCO), 8.16 OH, s, CHS), 8.19 (lH, s, CHS).
1'(R)-2-(1-{[l'(R)-2-(1-Benzyloxycarbonylamino-ethyl)-5-methyl-oxazole-4-
carbonyl]-amino}-2-methyl-propyl)-thiazole-4-carboxylic acid ethyl ester (226)
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N-Methylmorpholine (0.084 ml, 0.76 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (146 mg, 0.76 mmol) and N-hydroxybenzotriazole
(I03 rng, 0.76 mmol) were added to a solution of the oxazole 186 (210 mg, 0.7 mmol) in
anhydrous dichloromethane (8 ml) at 0 QC under an atmosphere of nitrogen. This
solution was stirred at 0 QCfor a further 20 min and a precooled solution of the valine
thiazole amine 181 (279 mg, 1.06 mmol) deprotected with N-methylmorpholine (0.084
ml, 0.76 mmol) in DMF (I ml) was added dropwise over 5 min. The resulting solution
was stirred at 0 QCfor a further 1 h and at room temperature for 16 h.
Water (ca 20 ml) was added and the separated aqueous layer was extracted with
dichloromethane (3 x 20 ml). The combined organic extracts were washed with 10 %
aqueous citric acid solution (3 x 10 ml) and sodium hydrogen carbonate solution (3 x 10
ml), were dried (MgS04) and evaporated in vacuo to leave the tetrapeptide (240 mg,
0.54 mmol, 77 %) as a white foam; [a]o298 -101.9 (c = 0.5, CHCI3); 'Umax (CHCI3)/cm-
I 3402,2965, 1723, 1668, 1634, 1497, 1454, 1371, 1323, 1098, 1066, 908; OH (360
MHz, CDC h) 0.98 (3H, d, J 6.8 Hz, (CH3hCH), 1.01 (3H, d, J 6.8 Hz, (CH3hCH),
1.39 (3H, t, J 7.1 Hz, CH3CH20), 1.55 (3H, d, J 7.0 Hz, CH3CH), 2.55-2.65 (lH, m,
CH(CH3h), 2.60 (3H, s, CH3CO), 4.41 (2H, q, J 7.1 Hz, OCH2CH3), 4.94-5.01 (IH,
m, CHCH3), 5.15 (2H, s, ArH), 5.28 (lH, dd, J 6.8,9.2 Hz, CHCH(CH3h), 5.41 (IH,
br. s, NHCbZ), 7.32-7.37 (5H, m, ArH), 7.51 (lH, d, J 9.2 Hz, NHCO), 8.07 (IH, s,
CHS); Oc (90.5 MHz, CDCh) 11.4 (q), 14.1 (q), 17.8 (q), 19.4 (q), 32.7 (d), 44.9 (d),
55.7 (d), 61.1 (t), 66.7 (t), 126.7 (d), 127.8 (d), 127.9 (d), 128.2 (d), 136.0 (s), 147.2 (s),
153.5 (s), 155.4 (s), 161.0 (s), 161.2 (s), 161.3 (s), 171.6 (s); mlz (FAB) Found:
515.1946 (M++ H+, C2SH3006N4S requires 515.1964).
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1'(R)-2-(1-{[1 '(R)-2-(1-Amino-ethyl)-5-methyl-oxazole-4-carbonyl]-amino}-2-
methyl-propyl)-thiazole-4-carboxylic acid ethyl ester hydrobromide (227)
A 33 % solution of hydrobromic acid in acetic acid (1 ml) and glacial acetic acid (0.6 ml)
were added to the tetrapeptide 226 at room temperature under an atmosphere of
nitrogen. The resulting solution was stirred for 3 h and the volatiles were removed in
vacuo to leave the bromide (250 mg, 0.54 mmol, 99 %) as a brown foam; [a]o298
+218.4 (c = 0.5, EtOH); &H(360 MHz, CD30D) 0.99 (3H, d, J 6.5 Hz, (CH3hCH),
1.09 (3H, d, J 6.4 Hz, (CH3hCH), 1.20 (3H, t, J 7.0 Hz, CH3CH20), 1.77 (3H, d, J 6.4
Hz, CH3CH), 2.50-2.58 (IH, m, CH(CH3h), 2.65 (3H, s, CH3CO), 3.64 (2H, q, J 7.0
Hz, CH2CH3), 4.79-4.81 (lH, m, CHCH3), 5.19-5.25 (IH, m, CHCH(CH3h), 8.45
(IH, s, CHS); &c(90.5 MHz, CD30D) 12.1 (q), 17.6 (q), 18.0 (q), 18.9 (q), 19.8 (q),
33.6 (q), 45.6 (d), 57.2 (d), 58.0 (t), 129.2 (d), 138.8 (s), 144.5 (s), 156.0 (s), 158.4 (s),
161.2 (s), 162.4 (s); mlz (FAB) Found: 381.1597 (M+ - Br-, C17H2S04N4S requires
381.1597).
1'(R)-2-(1-{[2-(1-{[2-(tert-Butoxycarbonylamino-methyl)-thiazole-4-carbonyl]-
amino} -ethy 1)-5-methyl)-oxazole-4-carbonyl] -amino} -2-methyl-propy I)-thiazole-
4-carboxylic acid ethyl ester (228)
BocHN
r-<C02Et 1
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N-Methylmorpholine (0.07 ml, 0.59 mmol), 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (114 mg, 0.59 mmol) and N-hydroxybenzotriazole (80
mg, 0.59 mmol) were added to a solution of the valine thiazole acid (140 mg, 0.54
mmol) in anhydrous dichloromethane (6 ml) at O°C under an atmosphere of nitrogen.
This solution was stirred for a further 20 min and a solution of the tetrapeptide 227
(250 mg, 0.54 mmol) deprotected with N-methylmorpholine (0.07 ml, 0.59 mmol) in
DMF (l ml) was added dropwise over 5 min. The resulting solution was stirred at 0 QC
for 1 h and at room temperature for 15 h.
Water (ca 30 ml) was added and the separated aqueous layer was extracted with
dichloromethane (3 x 30 ml). The combined organic extracts were washed with a 10 %
aqueous citric acid solution (2 x 30 ml) and sodium hydrogen carbonate solution (2 x 30
ml), were dried (MgS04) and evaporated in vacuo. Purification by chromatography on
silica using 70 % ethyl acetate in light petroleum (40-60 QC)led to the isolation of the
hexapeptide (235 mg, 0.38 mmol, 70 %) as a cream foam; [a]D295 +5.1 (c = 0.7,
CHCI3); OH (360 MHz, CHCI3) 1.01 (3H, d, J 6.7 Hz, (CH3hCH), 1.06 (3H, d, J 6.7
Hz, (CH3hCH), 1.50 (9H, s, But), 1.70 (3H, d, J 7.0 Hz, CH3CH), 2.65 (3H, s,
CH3CO), 4.65 (2H, d, J 5.7 Hz, CH2NH), 5.30 (IH, dd, J7.0, 9.1 Hz, CHCH(CH3h),
5.43-5.50 (lH, m, CHCH3), 7.62 (lH, d, J 8.7 Hz, NHCO), 7.77 (IH, d, J 8.2 Hz,
CHS), 8.13 (IH, s, CHS); Oc(90.5 MHz, CHCh) 11.7 (q), 18.0 (q), 19.3 (q), 19.7 (q),
29.3 (q), 29.7 (q), 31.9 (d), 43.0 (d), 56.0 (d), 124.3 (d), 127.2 (q), 128.6 (s), 147.1 (s),
149.1 (s), 154.0 (s), 155.6 (s), 160.2 (s), 161.1 (s), 161.6 (s), 161.8 (s), 169.6 (q), 172.1
(s); mlz (FAB) Found: 643.1913 (M++ Na+, C27H3607N6S2 requires 643.1985).
IS8
Structural isomer of nostacyclamide (194)
Sodium hydroxide (60 mg, 1.42 mmol) was added to a solution of the dimer 222 (215
mg, 0.38 mmol) in a THF:H20 (5:3) mixture (4 ml) at room temperature. The solution
was stirred for 15 h and the separated aqueous layer acidified to pH 4 with citric acid.
The aqueous layer was then extracted with ethyl acetate (5 x 20 ml) and the combined
organic extracts washed with brine (2 x 20 ml), were dried (MgS04) and evaporated in
vacuo to leave the acid as a pale yellow foam. The acid was then stirred with a 4M
solution of hydrochloric acid in dioxane (1 ml) at room temperature for 1 h under an
atmosphere of nitrogen. The dioxane was removed in vacuo using toluene as an
azeotrope to leave a highly hygroscopic yellow solid which was immediately subjected
to the coupling conditions. Diisopropylethylamine (0.05 ml, 0.28 mmol) and FDPP (54
mg, 0.14 mmol) were added to a suspension of228 (50 mg, 0.095 mmol) in anhydrous
acetonitrile (4 ml) at room temperature under an atmosphere of nitrogen. This solution
was stirred for 1 day and water (ca 10 ml) was added and the separated aqueous layer
was extracted with dichloromethane (5 x 10 ml). The combined organic extracts were
washed with 2M hydrochloric acid solution (2 x 10 ml), sodium hydrogen carbonate
solution (2 x 10 ml), were dried (MgS04) and evaporated in vacuo to leave a solid white
residue. This residue was purified by chromatography on silica using 70 % ethyl
acetate in light petroleum (40-60 CC)as eluant to give the cyclic peptide (23 mg, 0.049
mmol, 52 %) as a white powder; mp. 263-264 °C (from dichloromethane); [alo295
+21.1 (c = 1.0, CHCh); umax (CHCI3)/cm-l 3394,2964,2929, 1667, 1639, 1549, 1488,
1452, 1358, 1303, 1094, 1055, 997; OH (360 MHz, CDCh) 0.90 (3H, d, J 6.7 Hz,
159
(CH3hCH), 1.04 (3H, d, J 6.7 Hz, (CH3hCH), 1.68 (3H, d, J 6.7 Hz, CH3CH), 2.33-
2.38 (lH, m, CH(CH3)z), 2.70 (3H, s, CH3CO), 4.88 (lH, dd, J3.1, 18.2 Hz, CH2NH),
5.17 (lH, dd, J 5.4,18.2 Hz, CH2NH), 5.23 (lH, app. quintet, J 6.7 Hz, CHCH3), 5.32
(lH, dd, J 4.5, 7.7 Hz, CHCH(CH3h), 8.17 (lH, s, CHS), 8.18 (lH, s, CHS), 8.43 (lH,
hr. s, NHCH2), 8.52 (1H, d, J 7.7 Hz, NHCHCH(CH3h), 8.69 (lH, d, J 6.7 Hz,
NHCHCH3); Be (125 MHz, CDC}3) 11.7 (q), 17.8 (q), 18.5 (q), 19.7 (q), 34.7 (d),
41.6 (t), 44.5 (d), 56.2 (d), 123.7 (d), 123.8 (d), 128.5 (s), 148.5 (s), 149.0 (s), 154.2 (s),
159.7 (s), 160.5 (s), 160.6 (s), 161.2 (s), 165.0 (s), 167.9 (s); mlz (FAB) Found:
497.1033 (M++ Na+, C20H2204N6S2 requires 497.1042).
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DPPAI O,OSM 47%
DPPab O,OSM SS%
"NH H 6-~~ El)CC O,OSM 43%~ FDPpd O,SM 60%FDPP O,IM 62%
FDPP O,OSM 91 %
2 FDPP 0,01 M 93%
FDPP O,OOSM 60%
Abstract: Thiazole containing cyclic peptides have been synthe-
sised in high yields by cyclooligomerisation reactions of amino acid
substituted thiazole monomers,
Key words: cyclic peptides, macrocycles, cyclizations, hetero-
cycles
A large number of cyclic peptides containing 'unnatural'
p-amino acids, together with modified amino acids in the
form of azole heterocycles have been isolated from ma-
rine organisms and algae in recent years. The Lissoclinum
class of cyclic peptides e,g. raocyclamide I; lissoclina-
mide 4 2,2 ascidiacyclamide 3,3 is one such group, charac-
terised by the presence of oxazoline/oxazoleJthiazolineJ
thiazole heterocycles alternating with amino acid resi-
dues," The size and conformations of these macrocycles
and the functional groups they possess have suggested
that they have potential for metal ion chelation and trans-
port in vivo.~ This, together with the cytotoxic and anti-
neoplastic properties observed for a number of these com-
pounds," has inspired work towards their synthesis, usual-
ly via a linear approach followed by a macrocyclisation
step. I.. We now wish to report the preparation of some
3
novel thiazole-based analogues of natural cyclic peptides
using a concise high-yielding cyclooligomerisation proce-
dure from appropriate amino acid substituted thiazole pre-
cursors.
Thus. the fully protected amino acid thiazoles 4 were first
prepared using a modified Hantzsch synthesis.v' Saponi-
fication of the thiazole esters. 4 with NaOH next gave the
corresponding carboxylic acids S. which were then imme-
diately subjected to amine deprotection using a 4 M solu-
tion of Hel in dioxane. leading to the amino acids 6 as
their hydrochloride salts in essentially quantitative yield,'
Cyclooligomerisation experiments with 6 were performed
initially using the p-valine derived thiazole 6a, Cyclooli-
gomerisation of 68 was attempted using a number of pep-
tide coupling reagents (Table 1) and pentafluorophenyl
diphenylphosphinate (FDPP) was found to give remark-
ably consistent high yields (80 - 96 %) of cyclic products."
The optimum concentration for this cyclooligomerisation
reaction was found to be in the range 10 - 50 mM (Table
1), At lower concentrations (1 mM) the yield was marked-
ly lower (60 %) whilst at higher concentrations (~,S M)
the formation of insoluble polymeric products was found
to increase.
Table 1 Cyclooligornerisation reactions of 6• .
a) diphenyl phosphorazidlte; b) diphenylphosphinyl chloride;
c) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride;
d) pentitluorophenyl diphenylphosphinate,
~n~er the optimum conditions. i.e. yields> 80 %. the rna-
jor I~ol~ted cyclic products resulting from the cyclooligo-
mensatl?n of 68 were found to be the cyclic trimer 7 and
the cyclic tetramer 8 which were produced in a 5:2 ratio
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BoctIN~R NaOH BocHN~R 4 lA HC~C1.H2~R
EtOHIH:P _ N dioxane ~
• 02Et 5 OzH I OzH
(measured by IH nmr and HPLC). to Trace amounts of
higher oligomers (pentamer, hexamer, heptamer, octamer
and nonamer) were also observed by FAB mass spectrom-
etry, although these compounds were not isol~ted. The ra-
tio of the trimer 7 and the tetramer 8 did not vary
significantly when the reaction was carried out at differe~t
concentrations. The IH nmr spectra of the separated cyclic
peptides 7 and 8 in CDCl3 at 22 "C indicated that they
were C3 and C. symmetric, respectively. ~e IH n~ spec-
tra of7 and 8 were similar, although the SIgnal attnbutable
to the amide protons in 7 is 0.6 ppm further downfield
from that in 8, suggesting that intramolecular hydrogen
bonding may be stronger in 7 than in 8. The vicinal) JNHCH
values of 9.3 Hz and 9.1 Hz for 7 and 8, respectively cor-
respond to dihedral angles of 1500 < 9 < 1800 in both the
macrocycles.!'
HC1.~N~""(
~N
~
6.
Coupling reagent.
7 + 8
X-ray quality crystals of 7 were obtained by sloW.diffu-
sion of diethyl ether into a dichloromethane solution of
the cyclic peptide. The x-ray structure indicates that 7 is a
rigid molecule in which all of the nitrogen atoms point to-
wards the centre of the macrocycle and the valine side
chains all lie on the same face of the molecule and adopt
axial positions.'! The NHaCH dihedral angles of the three
amide linkages in 7 were found to be between 159 and
1670 which is consistent with the values determined by IH
nmr spectroscopy. This correlation suggests that the cy-
clic tetramer 8 is also a flat molecule in which the thiazole
units form the comers of a square with all side chains on
the same face of the molecule.'?
The successful outcome of the cyclooligomerisation of 6.
prompted us to investigate further reactions with other thi-
azole amino acid based monomers. When the racemic thi-
azole 6b was subjected to the same cyclooligomerisation
reaction, a statistical mixture of diastereomeric trimers, 7
and 9, and tetramers, 8, 10, 11 and 12 was obtained. This
mixture was separated by preparative HPLC and the rela-
tive stereochemistry of each of the pure compounds was
assigned on the basis of their symmetry as determined by
IH nmr. The overall yield of the cyclic products 7 - 12 was
75 % and the trimer:tetramer ratio was found to be I: I.
which is substantially different to that observed using the
homochiral thiazole precursor 6a. This difference may re-
flect the relative ease of cyclisation of linear precursors
containing a mixture of 0- and L-amino acid residues."
The cyclooligomerisations of the phenylalanine derived
thiazoles 6c and 6d were also studied. Interestingly. when
the homochiral precursor 6c: was subjected to the cyclo-
oligomerisation conditions, none of the expected ~ycli.c
trimer 13 was produced, although a small amount of Its di-
astereomer 14 (21 %) together with the expected tetramer
15 (ID %) and a diastereomeric tetramer 16 (23 %) were
obtained. The formation of both 14 and 16 can be attribut-
ed to the presence of the opposite enantiomer (enantio-
meric excess as determined by the formation of a
Mosher's amide derivative = 60 %)l~ in the starting mate-
rial. When the racemic phenylalanine derived thiazole 6d
was subjected to the cyclooligomerisation reaction a non-
statistical mixture of the trimer 14 and the diastereomeric
tetramers 15 - 18was isolated. The major product isolated
was the tetramer 16 where alternating phenylmethyl side
chains were positioned on opposite faces of the ma~roc~-
c1e.The overall trimer:tetramer ratio (I: I) observed ID this
cyclooligomerisation was substantially different to that
obtained for the enantiomerically enriched thiazole 6c:
(I :3), suggesting that the unsymmetrical trimer 14, in
which one of the side chains lies on the opposite face of
the macrocycle is formed more readily than its Cl sym-
metrical analogue 13, where all of the side chains must lie
on the same face of the macrocycle. This outcome may be
a result of the steric congestion imposed upon 13 by the
rigid backbone of the cyclic trimer. We are currently in-
vestigating the trimer:tetramer ratio obtained when thiaz-
ole monomers bearing different side chains are subjected
to the cyclooligomerisation reaction, to determine wheth-
er steric congestion is responsible for this difference.
The cyclooligomerisation of an oxazoline based amino
acid monomer has previously been employed in the for-
mation of the C3 symmetric natural product westelliamide
(or cyclooxazoline) together with a C. symmetric ana-
logue," and in contemporaneous studies the synthesis of
a number of thiazole containing symmetrical macrocycles
via the cyclooligomerisation of a thiazole containing tet-
rapeptide has been reported.P However, in both of these
examples the yields of cyclic oligomers obtained were
found to be less than 50 %. We have now shown that the
cyclooligomerisations or"amino acid substituted thiazole
monomers can be achieved in high yields (typically >80
%), thereby providing rapid access to large amounts of
novel and unusual cyclic peptide analogues. Applications
of this reaction to other heterocyclic monomers for the
purpose of preparing libraries of novel modified cyclic
peptides are now in progress in our laboratories. These
macrocycles will then be examined to determine their
conformations, biological activity and metal chelating
properties together with their potential applications as
templates for synthetic receptors or scaffolds for the de-
velopment of macromolecular devices.
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Abstract: Treatment of a solution containing a I: I: I mixture of the
chiral thiazoJe and oxazole-based amino acids 4. 8 and 9 with pen-
tafluorodiphenylphosphinate in diisopropyethylamine in acetoni-
trile at room temperature for 2 h resulted in the formation of
dendroarnide A 7 (23%) and its positional isomer 15 (22%). togeth-
er with symmetrical thiazole-based macrocyclic trimers in a com-
bined yield of 30%. An independent. linear. synthesis of
dendroamide A confirmed the structure and stereochemistry as-
signed to this natural cyclic hexapeptide.
Key words: self-assembly. cyclopeptides, dendroamide A.
The marine environment has delivered an amazing variety
of structurally novel and unusual peptidic alkaloids with
macrocyclic structures accommodating thiazole and ox-
azole rings in recent years; I representative examples are
lissoclinamide 4 (1).2 raocyclamide 23 and mollamide 3.4
The characteristic sequence of alternating heterocyclic
and amino acid residues present in these compounds is
clearly reminiscent of macrocyclic ligands such as aza-
crown ethers and extended porphyrins. and this has led to
speculation that this class of marine metabolite is capable
of metal complexation and transport in vivo.' It is also
possible that metal ions provide a template for the biolog-
ical assembly of these cyclopeptide metabolites. or even
the interesting biological activity observed for several of
their number. However. we know very little about the 'or-
der' of the assembly of the amino acid units and the con-
figurational and conformation requirements of acyclic
peptide precursors during cyclopeptide biosynthesis. In
the case of thiazole and oxazole based marine cyclopep-
tides we do not even know whether they are produced
from preformed oxazole/thiazole based amino acid resi-
dues, or whether these heterocyclic rings are elaborated in
vivo from substituted serine/cysteine intermediates fol-
lowing macrocyclisation to the cyclopeptide core.
It was against this background that recently we examined
the cyclooligomerisations of several valine and phenyla-
lanine-based thiazole amino acids which were found to
lead to the formation of cyclic trimers and cyclic tetramers
in remarkably high yields e.g. 4 -+ 5+6 (85%).6 We have
now extended these studies and investigated the scope for
the 'self-assembly' of thiazole and oxazole based cycle-
peptides from more than one heterocycle based amino ac-
id. In this Letter we summarise our first excursions in this
area, with a synthesis of dendroamide A (7) from the va-
oY
~NH~)CN Nf
"XNH NH 0
o~Y"'"
7
H.Nlr)
N_i
HO 0
4r N NH.o''''(_y ....,
9
line and alanine-based thiazoles, 4 and 9 and the alanine-
based oxazole 8.
Dendroamide A (7) is a bistratamide type cyclic hexapep-
tide isolated from the cyanobacterium Stigonema den-
droideum which exhibits multidrug-resistance reversing
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~NH1.HCI
o "N
)=\.C~M'
10
):NHBOC
S "N
"=='C~H
11
iii
-)NH2.HCI
S "N
')=1
Co2M.
ii
12
iv, v
_...:v~i_~ 7
13
Reagents: i. EDC. HOBt. NMM. DCM. 10h. rt, 80%; ii,NaOH. THF. Hp. 10h. n, 97%; iii. EDC. HOBt. NMM. DCM. 10h. rt, 70%; iv,
NaOH. THF. H20. 10h. rt, 98%; v, 4M HCI. dioxane. 2h. rt, 96%; vi. FDPP. D1PEA. CHlCN. 91 %.
Scheme
0 o ~ o ~YN~i '<N~i '<N~iO,.N H NA S,.N H NA S,N H NAFDPP.
,.lNH HN 0 R""INH HN 0 R""INH HN 04+8+9 DIPEA. 7 + + +CHICN o~r""\- O~r'~R O~r"R
15 16 17
a R=Me a R=Me,R'=CMez
b R=CMe2 b R=CMe2,R'=Me
activity.' Its structure is made up of the units 4 (from
D-valine and cysteine), 9 (from D-alanine and cysteine),
and 8 (from D-alanine and threonine). As a prelude to our
self-assembly investigations we first synthesised dendroa-
mide A totally. in a linear fashion. from the methyl ester
10, the BOC amine 11, and the methyl ester 13 and pro-
ceeding via the oxazole-thiazole 12 and the oxazole his-
thiazole 14 as shown in the Scheme. The synthetic mate-
rial had chiroptical and NMR * spectroscopic data which
were found to be identical to those reported for the natural
product isolated from S. dendroideum.:
When a solution containing a 1:1: I mixture of the hetero-
cyclic amino acids 4, 8, and 9 in acetonitrile was treated
with pentafluorodiphenylphosphinate (FDPP) and diiso-
propylethylamine (DIPEA), chromatography led to the
isolation of dendroamide A 7 (23%) together with its po-
sitional isomer (15, 22%) accompanied by the products 16
and 17 resulting from homo-coupling of the thiazole ami-
no acids 4 and 9 in a combined yield of 30%.9 The struc-
tures of these compounds followed from their
independent synthesis, using a linear approach similar to
that shown in Scheme for dendroamide A, and also from
NMR and X-ray cyrstallographic analysis.'? Investiga-
tions are now in progress to optimise and discipline the
self-assembly of the amino-acids 4, 8 and 9 alongside re-
lated systems, to produce alternative novel heterocyclic-
based cyclic peptides, and to evaluate certain of their
number in asymmetric synthesis and in the construction of
novel molecular arrays. These results will be published in
due course.
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